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ABSTRACT 
The widespread acceptance of topical formulations intended for local and/or regional activity has 
prompted renewed interest in developing a model to determine the bioavailability of drugs in order to 
establish bioequivalence as a means of evaluating formulation performance of multisource products 
and also for use during formulation development. 
 
Current in vivo techniques such as blister suction and skin biopsy amongst others used to determine 
the bioavailability and/or bioequivalence of topical formulations are either too invasive to generate 
appropriate concentration-time profiles or require large numbers of study subjects thereby making the 
study expensive and time-consuming. Moreover, there are currently no sampling techniques that can 
demonstrate dermal bioavailability and/or bioequivalence of topical formulations intended for local 
and/or regional activity. 
 
Dermal microdialysis is a relatively new application of microdialysis that permits continuous 
monitoring of endogenous and/or exogenous solutes in the interstitial fluid. The technique is involves 
the implantation of semi-permeable membranes which are perfused with an isotonic medium at 
extremely slow flow rates and collection of microlitre sample volumes containing diffused drugs. 
 
Tape stripping, a relatively older technique, has been extensively used in comparative bioavailability 
studies of various topical formulations. However, due to shortcomings arising from reproducibility 
and inter-subject variation amongst others, the published FDA guidance outlining the initial protocol 
was subsequently withdrawn. The incorporation of transepidermal water loss with tape stripping has 
garnered renewed interest and has been used for the determination of drug bioavailability from a 
number of topical formulations. 
 
Hence the primary objective of this research is to develop and evaluate microdialysis sampling and 
tape stripping techniques, including the incorporation of the determination of transepidermal water 
loss, to assess the dermal bioavailability of ketoprofen from topical gel formulations and to develop 
models for bioequivalence assessment. 
 
A rapid UPLC-MS/MS method with requisite sensitivity for the analysis of samples generated from 
dermal microdialysis was developed and validated which accommodated the microlitre sample 
volumes collected. An HPLC-UV method was developed and validated for the analysis of samples 
generated from the in vitro microdialysis and in vivo tape stripping studies. 
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The work presented herein contributes to a growing body of scientific knowledge seeking to develop a 
model for the determination of bioequivalence of pharmaceutically equivalent topical formulations 
intended for local and/or regional activity in human subjects. 
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CHAPTER ONE 
BIOAVAILABILITY AND BIOEQUIVALENCE OF TOPICAL FORMULATIONS 
 
1.1. Introduction 
The skin, despite its function as an efficient barrier, has beneficial properties which permits it to be 
considered as an alternate route for drug application. The merits of topical application have been well 
documented (1). These benefits include the ability of the skin to control the rate at which drugs reach 
the target site within the body, i.e., if the drug is intended for a systemic effect. For local and/or 
regional effects, topical application permits localised and/or regionalised drug delivery to the site of 
interest which results in a local therapeutic effect, while such application avoids or minimises 
systemic side effects. Problems related to extensive first pass effects, primarily due to metabolism by 
the liver but also to a lesser extent the by the gastrointestinal tract (GIT), encountered by most orally 
administered drugs, may be avoided. The main drawback of using the skin as an alternate route of 
drug delivery is that not all drugs are suitable candidates for topical administration (either local or 
systemic use) due to their physico-chemical properties amongst others (2). Ideally, a suitable drug 
candidate should have a low molecular mass (< 500 Da), high lipophilicity (log P in the range of 1-3), 
low melting point (< 200°C) and high potency (< 50 mg/day). Nevertheless, the relative ease of use 
and increased patient acceptance of topical formulations have made their use widespread (3,4) and 
many products for topical administration are currently available in a number of countries. Topical 
products available on the South African market include anti-bacterials, anti-fungals, anti-virals, anti-
inflammatories, analgesics, corticosteroids, and also anaesthetics (5). 
 
Topical formulations applied to the skin can be subdivided into 3 categories: 
i. dermatological formulations (creams, ointments, gel, lotions) intended for the treatment of local 
skin disorders; 
ii. dermatological formulations (creams, ointments, gels, lotions, sprays) intended for regional 
disorders; 
iii. dermatological formulations and delivery systems (creams, ointments, gels and transdermal 
patches) intended for the treatment or prevention of systemic diseases (6,7). 
 
While topical formulations to treat local and/or regional ailments have been in existence for centuries, 
those used to treat systemic ailments only started to appear on the market towards the end of the last 
century (8). Interestingly, the principles underlying the development and optimisation of topical 
formulations for systemic therapy appear to be better understood than those for local and/or regional 
therapy (3,4). Since absorption through the skin (percutaneous) is pivotal to the effectiveness of 
topical formulations for local, regional or systemic activity, there is a tendency amongst researchers to 
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misinterpret the intentions of topical delivery systems where a great deal of confusion currently reigns 
with respect to definitions and semantics. It is therefore extremely important to distinguish the actual 
objectives of topical formulations, i.e., whether intended for local, regional or systemic use, and the 
associated clinical outcomes. 
 
1.2. Topical formulations intended for local and/or regional delivery 
1.2.1. Objectives 
Topical formulations for local activity are intended to treat cutaneous disorders (e.g., acne) or the 
cutaneous manifestations of a general disease (e.g., psoriasis) whereas topical formulations for 
regional activity are intended to treat diseases or alleviate disease symptoms in deep tissues (e.g., 
inflammation) beneath the site of application (9). 
 
1.2.2. Principle 
The intention of local delivery is to confine the pharmacological effect of the drug to the surface of 
the skin (i.e., at the site of application) or within the skin whereas the intention of regional delivery is 
to effect the pharmacological action of the drug within musculature, vasculature, joints and tissues 
beneath and around the site of application (9). Since the skin is the site of delivery for drugs intended 
for either local or regional activity, high dermal drug concentrations with low exposure to systemic 
circulation are desirable (3,4). 
 
1.2.3. Types of formulation 
Semisolid formulations dominate systems for local delivery but foams, sprays, medicated powders, 
solutions and even adhesive systems are also used. Regional delivery has been traditionally 
accomplished by administration of ointments and creams onto the skin as well as using large adhesive 
patches, plasters, poultices and cataplasms (9). 
 
1.2.4. Formulation characteristics 
Formulations are generally applied (rubbed) over diseased or inflamed skin with no visible mass left 
on the skin surface after repeated application. In most cases the formulation is left unoccluded, which 
permits the components of the formulation to be absorbed through the skin, evaporated from the skin 
or sloughed off the skin. This class of topical formulation usually contains several excipients which 
may partition into the skin in accordance with their physico-chemical properties. Excipients present in 
the formulation may change the integrity of the stratum corneum (SC) which alters the solubility of 
the active ingredient within the horny layer and/or facilitates the ease with which they diffuse through 
the affected tissue. The act of physically rubbing the formulation on the skin usually results in 
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changes in physico-chemical and thermodynamic conditions which may enhance the permeation of 
the drug through the skin following application (3,4). 
 
1.3. Topical formulations intended for systemic delivery 
1.3.1. Objective  
Topical formulations intended for systemic effects also involve the application of the drug product to 
the skin (9) but are used to treat systemic diseases. 
 
1.3.2. Principle 
The intention is to achieve systemically active concentrations of drug with minimum or no drug 
retention in the skin although such accumulation is largely unavoidable (9). The drug diffuses through 
the relatively small diffusional window at the application site which is defined by the contact area of 
the delivery system, e.g., a patch. 
 
1.3.3. Formulation types 
Although traditional dosage forms such as ointments can be employed in this kind of therapy (e.g., 
nitroglycerin ointments used in the management of angina), transdermal adhesive systems of precisely 
defined size are commonly used (9). 
 
1.3.4. Formulation characteristics 
Topical formulations for systemic effects usually involve the use of prefabricated devices, commonly 
known as transdermal patches, in which the drug is incorporated into a reservoir or as a dispersion in 
an adhesive. The system is fastened adhesively to the skin surface and the drug, contained in a matrix, 
is rarely exposed to atmospheric conditions. Although such dosage forms may cause perspiration, the 
physico-chemical and thermodynamic conditions remain constant and therefore provide an 
approximately constant rate of drug delivery through the skin (3,4). Semisolid preparations may also 
be used for systemic effects, however such dosage forms are usually associated with unpredictable 
plasma drug concentrations due to the difficulty in controlling the amount applied which results in 
variability of drug concentration in the systemic circulation. Furthermore, variability in the method of 
application (involving the degree of rubbing), area of application and the need for frequent application 
are distinct disadvantages (2). 
 
For the purposes of this research, only topical formulations intended for local and/or regional activity 
will be considered. 
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1.4. Bioavailability and bioequivalence 
1.4.1. Definitions 
• Bioavailability is defined by regulatory bodies as the rate and extent to which the active 
ingredient or active moiety is absorbed from the drug product and becomes available at the 
site of action (10-12). 
 
• Relative bioavailability is defined as the rate and extent to which the active ingredient or 
therapeutic moiety becomes available in the organism from a dosage form, compared with a 
reference standard administered by the same route (9). 
 
• Absolute bioavailability is the extent to which the active ingredient or therapeutic moiety 
becomes available in the organism from a dosage form in comparison with an intravenously 
administered reference standard, which is taken to be 100% bioavailable (9). 
 
• Pharmaceutical alternatives are dosage forms that have the same chemical moiety but differ 
in chemical form, dosage form type or strength of the therapeutic moiety (13). 
 
• Bioequivalence is the absence of a significant difference in bioavailability between 
pharmaceutical equivalents or pharmaceutical alternatives when administered at the same 
molar dose under similar conditions in an appropriately designed study (9,12,14). 
 
• Formulation performance is defined as the release of the drug substance from the drug 
product leading to bioavailability of the drug substance and eventually leading to 1 or more 
pharmacologic effects, both desirable and undesirable (12,15). 
 
• Pharmaceutical equivalents are defined as dosage forms that contain the same active 
ingredient(s), are of the same dosage form, route of administration and are identical in 
strength or concentration when compared with a reference product (13). 
 
• Multisource drug products are pharmaceutically equivalent or pharmaceutically alternative 
products that may or may not be therapeutically equivalent. Multisource pharmaceutical 
products that are therapeutically equivalent are interchangeable (14,16). 
 
• Therapeutic equivalent products are pharmaceutical products which when administered in the 
same molar dose, their effect with respect to both efficacy and safety are essentially the same 
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when administered to patients by the same route under the conditions specified in the 
labelling (16). 
 
In the early 1960s, reports of physiological availability of vitamins were found to be erratic, which 
provided initial indications of the potential for bioavailability and bioequivalence problems with 
multisource drug products (9). The variations in absorption profiles of active ingredients from generic 
drug products when compared to the innovator or “Brand” product were soon recognised as a 
potential health hazard when episodes of drug toxicity were reported. Such variations were noted 
when excipients in pharmaceutical delivery systems or in manufacturing processes were changed or 
altered. Major advances in bioanalytical technology led to further investigations which permitted the 
determination of bioavailability of marketed drug products through the measurement of their 
concentration in biological fluids. Reports of bioinequivalence of a number of drugs such as digoxin, 
phenytoin and chloramphenicol, amongst others (9,15) were published in the scientific literature. The 
bioavailability of drugs and/or bioequivalence of drug products have therefore emerged as important 
national and international regulatory and scientific issues (9,17) and assessment of bioavailability has 
therefore being employed as a tool by regulatory authorities to monitor the quality, safety and efficacy 
of multisource drug products (generic), labelled as “test” versus the innovator or “Brand” product, 
labelled as “reference”. For generic drug products to be interchangeable with the innovator drug 
product, a generic drug product must not only be pharmaceutically equivalent or a pharmaceutical 
alternative, but must be bioequivalent to an acceptable relevant reference product. 
 
Innovator/“Brand” companies utilise bioavailability and/or bioequivalence in formulation 
development to assess formulation performance between 2 or more pharmaceutically equivalent drug 
products (15). E.g., based on the outcome of a clinical study that made use of the initial formulation, 
manufacturers effected minor changes to the formulation or altered the manufacturing protocol to 
improve the formulation. The revised formulation (test) is compared with the initial clinical trial 
product (reference). Therefore, bioequivalence not only plays an important role in assuring the 
therapeutic quality of multisource drug products but is also useful during formulation development. 
 
1.4.2. Topical bioavailability and bioequivalence 
There is an increased interest amongst pharmaceutical and medical scientists in the development of 
topical formulations intended for local and/or regional activity. In spite of confirmed data showing 
that significant concentrations of NSAIDs have been found in tissues underlying the application site 
of topical products (18-22) some medical practitioners and rheumatologists remain sceptical about 
how the non-steroidal anti-inflammatory drugs in particular, can penetrate the skin barrier in sufficient 
amounts to reach the joints and muscles and exert local and/or regional therapeutic effects. This 
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scepticism is based partly on the presumption that any clinical effect found after topical application of 
a drug product intended for local or regional effects was due to systemic absorption. However, 
concentrations attained in blood following topical applications intended for local and/or regional 
activity generally do not achieve drug levels associated with therapeutic activity and moreover, there 
is no clear explanation as to how such clinical effects can result from plasma drug concentrations that 
are otherwise considered sub-therapeutic following orally administration of the same drug (23). 
 
Bioavailability relates to the “release/availability” of drug into (usually) the systemic circulation 
following extravascular administration or, when not intended for the systemic circulation, 
“availability” at the site of action. For orally administered drugs, it indicates “absorption” whereas for 
topically applied products intended for local and/or regional action, no “absorption” per se is intended 
so it is simply a measure of in vivo release or “availability in vivo”. On the other hand, the use of 
bioavailability as a surrogate measure of safety or efficacy is premised on the assumption that there is 
a relationship between safety/efficacy and the concentration of drug in the systemic circulation. 
 
The assessment of bioavailability of topical formulations intended for local and/or regional activity 
should therefore be performed by measuring drug concentrations within the skin (i.e., at the site of 
action) (9,24,25) and not in blood/plasma/serum or urine (26) which is the norm for topical 
formulations intended for systemic activity or for drugs administered orally. However, the 
determination of plasma drug concentrations after the application of a topical formulation intended for 
local and/or regional activity may be used as an indicator of toxicity since the principle of local and/or 
regional activity indicates high dermal drug concentrations and minimal or no drug in the plasma. 
E.g., with inhaled corticosteroids from aerosol delivery systems, the corticosteroid is intended for 
local action in the lung (alveoli etc.) and appearance in the systemic circulation has implications for 
possible adrenal suppression, especially if fairly high concentrations result. That can quite easily 
occur if after a dose, a large amount is swallowed rather than inhaled. 
 
1.4.2.1. Bioavailability of drugs from dermatological formulations 
The determination of the bioavailability of drugs from dermatological formulations requires a 
thorough understanding of the human skin. The structure of the human skin and its barrier functions 
have previously been published (27). In summary, the skin is the largest organ of the human body and 
it is composed of 3 layers namely the SC, which is the outermost part of the epidermis, the living 
epidermis and the dermis penetrated by a highly complex network of capillaries involved in the 
removal of drugs from the skin into the systemic circulation. In addition, several pilosebaceous and 
sweat glands are dispersed throughout the skin, in various numbers and size, depending on body site 
(28). A detailed illustration of the structure of the skin is shown in Figure 1.1. 
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Figure 1.1. Anatomy and physiology of the skin with the potential target or sites of action of selected 
analgesics. Adapted from Reference (27). 
 
The most important function of human skin is to act as a barrier by reducing water loss while barring 
the percutaneous absorption of harmful or unwanted molecules from the external environment. The 
SC contributes the rate-limiting step in the sequence of processes involved in percutaneous 
absorption, although the viable tissue can hinder the penetration of very hydrophobic compounds (29). 
Biophysical, morphological and biochemical data indicate that the SC forms a continuous sheet of 
protein enriched corneocytes embedded in an intercellular matrix enriched in non-polar lipids and 
organised as lamellar lipid layers (30). It has a thickness of about 10-20 µm and comprises about 20 
cell layers (28,31). Penetration of drug substances through the skin involves complex processes but 
the major barrier to permeation resides within the SC. The reason for the impermeability of the skin is 
that a diffusing molecule has first to pass through a tortuous route around the dead corneocyte cells 
and through the intercellular lipids which comprise mainly ceramides, cholesterol and cholesterol 
derivatives (32). Generally, small non-polar, lipophilic molecules are most readily absorbed, while 
high water solubility confers poor percutaneous absorptive capacity through normal skin. The 
octanol/water partition coefficient (log P) of a drug is an indication of its lipophilicity and substances 
with a log P value of 2 are absorbed best across the skin (33). 
 
However, despite its barrier properties, the skin is an important route of entry into the body for many 
topically applied drugs. Topical formulations for local use are assumed to exert their effect through 
the penetration of the active ingredient directly into deeper tissues although controversy exists over 
whether the dermal blood supply removes many drugs before they reach their site of action (34). The 
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sites of action of selected analgesics when applied topically from formulations intended for local 
and/or regional activity are illustrated in Figure 1.1. The occurrence of a response, its time of onset, 
duration and magnitude when a topical formulation is intended for local and/or regional activity, 
depends upon the relative efficiency of 3 sequential processes: 
i. release of the drug from the vehicle, 
ii. penetration of the drug through the skin barriers and 
iii. activation by the drug of the desired pharmacological effect (7,35). 
 
1.4.2.2. Bioequivalence of topical formulations 
Bioequivalence assessment between 2 sources of a drug product as stipulated by the FDA (36) can be 
evaluated by 4 methods in order of preference: pharmacokinetic, pharmacodynamic, comparative 
clinical trials or in vitro studies. 
 
Currently, in the USA, with the exception of topical corticosteroids, the only means by which a 
generic company can demonstrate bioequivalence of a topical formulation intended for local and/or 
regional activity to a formulation manufactured by an innovator/“Brand” company is through 
comparative clinical trials with a bioequivalence endpoint (37,38). 
 
An innovator/“Brand” company that wishes to replace an approved post-1962 topical dermatological 
product with a new formulation that involved appreciable compositional changes, must demonstrate 
bioequivalence using data from clinical studies (39,40). For topical corticosteroid formulations, the 
demonstration of bioequivalence of 2 pharmaceutically equivalent (e.g., cream versus cream) products 
may be accomplished by performing a human skin blanching assay (HSBA) and following the 
appropriate protocol outlined in the FDA Guidance (41). 
 
Clinical endpoint trials, generally considered as the “gold standard” in establishing bioequivalence of 
drug products, usually involve the use of large population sizes which makes these studies time 
consuming and expensive. A clinical endpoint study which involved the topical application of 
tretinoin gel formulations in the management of acne reported that, in order for bioequivalence to be 
established with significant statistical power, a study population size of between 275 and 300 is 
required (25). Therefore, there is increasing interest in developing and validating appropriate 
methodologies including a method permitting the measurement of drug concentrations within the skin 
to assess bioavailability. However, there is still some uncertainty as to which is the most appropriate 
layer of skin to measure drug concentrations for a given topical product (42). 
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1.4.2.3. Bioequivalence assessment 
A 2 one-sided test procedure is the currently recommended statistical method for use in 
bioequivalence assessment (43,44). The area under the plasma concentration versus time curve (AUC) 
is used as an index of the extent of drug penetration (topical application) and maximum concentration 
(Cmax) is used as an index of the rate of drug penetration (topical application). By convention, 
bioequivalence data are expressed as a ratio of the average response (AUC and Cmax) for 
Test/Reference. The statistical criteria for acceptance of bioequivalence are that both the AUC and 
Cmax confidence intervals (CIs) for the generic product (test) must fall within 80-125% of the 
innovator/“Brand” product (reference) based on log transformed data. These statistical tests are 
carried out using an analysis of variance (ANOVA) procedure and calculating the 90% CI for each 
pharmacokinetic parameter (AUC and Cmax) (12). 
 
Wide sample collection intervals and an insufficient number of enrolled human subjects are 2 main 
reasons why a clinical study may fail to establish bioequivalence between 2 pharmaceutically 
equivalent products unless the products are indeed inequivalent. The use of wide sampling intervals 
affects the Cmax values due to the possibility that the true Cmax value may be missed. Inherent intra-
subject variability requires that a sufficient number of subjects are included. This is necessary to 
provide the requisite power to be able to detect a 20% difference in bioavailability. A pilot 
bioequivalence study using a relatively few subjects (8-12) can provide useful information relating to 
the choice of the appropriate sampling times and also provide data on intra-subject variability which 
can then be used to estimate the number of subjects to be enrolled (12). 
 
1.4.2.4. Add-on study 
In Canada, if an insufficient number of enrolled human subjects results in a clinical study failing to 
establish bioequivalence, an additional number of subjects may be studied so that when included to 
the initial study, the total number may be sufficient to pass the bioequivalence assessment (45). In 
addition to performing the bioequivalence assessment for the combined number of subjects, a second 
statistical test is required which seeks to establish homogeneity between the 2 sets of data. The 
residual variances between the 2 separate groups are compared using an F test and pooling of data can 
only be done when no statistically significant difference is reported, although it is not a requirement 
that each group meet the 90% CI for AUC and Cmax (46). Suitable F tests used for the determination of 
homogeneity of variances are the Levene’s test (47) and the Brown-Forsythe’s test (48) which are 
described by Equations 1.1 and 1.2 respectively. 
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where: 
• N  is the total number of observations 
• k  and p represent the number of groups 
• .ij ij iZ Y Y= −  with .iY  either the mean (Levene’s test) or median (Brown-Forsythe test) of 
group i . 
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1.4.2.5. In vitro determination of dermal drug concentration  
Considerable effort has been directed towards the development of in vitro methods for the 
determination of bioavailability of drugs or bioequivalence of topical formulations. However these 
methodologies have been associated with high variability when determining drug release from the 
topical dosage forms and therefore provided neither adequate nor consistent information. The high 
variability associated with these studies usually resulted from the source and treatment of skin tissues 
used as membranes to study drug diffusion in vitro. With excised human skin, the problem 
encountered was that the skin tissue was not only obtained from various body parts of cadavers but 
the absence of a standard protocol for the pre-treatment of such skin tissues had also been identified as 
the major cause of variability. This problem was also observed with animal tissue (35). Moreover the 
use of excised skin (i.e., either human or animal) tissue does not take into account the possible effects 
of skin flora and skin metabolism on drug release from topical formulations. 
 
The use of commercially available synthetic membranes has been demonstrated to be useful in the 
development of topical formulations (1). Synthetic membranes function as an inert support which 
separates the formulation from the receptor phase (17). Several reports using various diffusion cells 
for the determination of drug release from topical formulations have been published (49-51). 
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Diffusion cells frequently used are the Franz diffusion cell (FDA approved) and the European 
Pharmacopeia diffusion cell (1,52,53). 
 
While these in vitro experiments are generally conducted under controlled laboratory conditions, in 
vitro data bear little relation to delivery kinetics in vivo because vehicles also have an effect on the 
barrier properties of the skin and such vehicle effects cannot be assessed in vitro (54). 
 
Whilst in vitro drug diffusion experiments are useful to evaluate quality, batch-to-batch uniformity 
and evaluation of changes in manufacturing process and drug release from the dosage form, the use of 
in vitro methods for the assessment of bioavailability/bioequivalence has not found acceptance by 
most regulatory agencies around the world. 
 
1.4.2.6. In vivo determination of dermal drug concentration 
Animal skins have been reported to be more permeable to drugs than human skin (6,55). This makes 
animal skin an inaccurate predictor for percutaneous penetration in man. 
 
Although various in vivo techniques such as suction blister sampling or biopsies have been developed 
to study kinetic and dynamic parameters of topical drug applications, they are either too non-specific 
or too traumatic to be used readily and repeatedly in both normal and diseased skin in human subjects 
because of their invasive nature (9). Additionally, the cost, technical demands and ethical 
considerations limit the applicability of these techniques in human volunteers (30,56). None of these 
techniques permit the continuous monitoring of drug penetration and metabolism in the same 
individual on the same test area. Moreover, the determination of drug concentration in the skin 
requires that the skin be excised, homogenised, extracted and the extract analysed. This methodology 
defeats the purpose of monitoring drug concentration at the site of action, i.e., either the SC (local) or 
tissues (regional). Moreover, these in vivo techniques are quite restrictive with respect to the amount 
of information generated and also require a large number of subjects or a large number of sampling 
sites per subject, which increases invasiveness. 
 
Currently, there are no sampling techniques which can demonstrate dermal bioavailability and 
bioequivalence of topical formulations intended for local and/or regional activity which are both 
minimally invasive and provide an indication of tissue concentration at the target site with time. 
Hence, recourse to clinical end-point studies remains the only route to assess bioequivalence of 
topical drug products. It is thus apparent that the development of a method to assess topical 
bioavailability of drugs or bioequivalence of topical drug products not intended for the systemic 
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circulation without the need to conduct expensive and time consuming clinical studies in humans 
should make a significant contribution to this particular area of endeavour. 
 
Recently, the 2005 Bio-International Conference hosted by the Royal Pharmaceutical Society of Great 
Britain (London, UK) recognised dermal microdialysis (Chapter 4) and a revised tape stripping 
technique (Chapter 5) as having the potential for use in assessing the bioavailability of drugs from 
topical formulations intended for local and/or regional activity.  
 
Hence the aim of this research was to develop and evaluate dermal microdialysis and tape stripping 
techniques for use in the assessment of the bioavailability/bioequivalence of ketoprofen from topical 
gel formulations. 
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CHAPTER TWO 
REVIEW OF TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
 
2.1. Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are amongst the most commonly prescribed drugs 
worldwide (57-62). NSAIDs are central to the long-term pharmacologic treatment of patients with 
musculoskeletal and joint disorders, ankylosing spondylitis, osteoarthritis (OA) and rheumatoid 
arthritis (RA) (27). They are also used in peri-articular disorders such as tendonitis and in mild-to-
moderate pain (58), muscle pain syndromes and various spine-related neck and lower back conditions 
(27). Approximately 30 million people consume NSAIDs on a regular basis (62) and with the 
availability of many different NSAID formulations as over-the-counter (OTC) products, this further 
significantly increases the number of people exposed to this class of drugs. 
 
2.2. Disadvantages of oral NSAID therapy 
Oral administration of NSAIDs in the management of acute conditions is generally not associated 
with significant issues of toxicity. However, chronic use of oral NSAIDs have been associated with a 
variety of adverse effects, which mainly involve the GIT, kidney, cardiovascular system, skin and 
respiratory tract (58,59,63,64). GIT damage includes small multiple lesions, gastric and duodenal 
ulcers, perforated ulcers and even severe bleeding of the upper GIT (58). As many as 15-30% of 
patients on chronic regimens of oral and/or systemic NSAIDs develop endoscopically detectable 
gastrointestinal ulcers (62,65). Moreover due to the fact that oral NSAIDs have to be administered in 
multiple daily doses to maintain therapeutic effects, patient non-compliance is a common therapeutic 
problem in the management of chronic inflammatory diseases (66). 
 
The extensive use of prescription and OTC NSAIDs that is associated with significant adverse effects 
prompted efforts to find solutions to curtail this problem. Strategies which may reduce adverse effects 
include attempts to minimise oral NSAID use by education or legislation, co-administration of 
gastroprotective agents, development of potentially better tolerated drugs such as selective cyclo-
oxygenase-2 (COX-2) inhibitors and modification of the delivery system (58,60,63,67). 
 
2.3. Topical NSAID formulations 
Humans have used salves, lotions, potions and the like, on their skin from ancient times and the 
concept of delivering drugs through the skin is a practice which dates as far back as the 16th century 
(8). Phenylbutazone cream was utilised over 30 years ago to treat superficial thrombophlebitis (19) 
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and the renewed interest in the development of topical formulations intended for local and/or regional 
activity stems from the potential advantages of topical formulations intended for systemic activity. 
There has been a dramatic increase in the development and marketing of topical NSAIDs. In 1980, 
benzydamine was the first topical NSAID to be licensed in the UK and since then several other topical 
NSAIDs have been licensed in Europe, Japan and South Africa (19,57). Recently, the first topical 
diclofenac gel and patch products were approved in the USA (68-70) further reflecting the increasing 
demand for topical NSAIDs by both physicians and patients which may be attributable primarily to 
their good safety record (59). Topical NSAIDs are also readily available without prescription in many 
countries (58,63,67). A list of commercially available topical NSAIDs intended for local, regional or 
systemic activity registered in South Africa is shown in Table 2.1 (5). Topical NSAID products 
applied for local and/or regional effects should achieve therapeutic concentrations in the tissues 
subjacent to the site of application while maintaining low plasma concentration which minimises 
possible systemic adverse effects (19,60). 
 
2.3.1. Topical dosage forms available in South Africa 
Various topical NSAID dosage forms available on the South African market are listed in Table 2.1. 
 
Table 2.1. Commercially available preparations of topical NSAIDs in South Africa 
Generic name Trade name Manufacturer Strength Dosage form 
     
Aescin Reparil Altana Madaus 5 g/100 g Gel 
     
Diclofenac Athru-Derm Sandoz 1 g/100 g Lotion 
 DicloHexal Hexal Pharma 1.16 g/g Gel 
 Panamor Aspen Pharmacare 1292 g/100 g Gel 
 Voltaren Novartis Consumer 1.16 g/100 g Emulgel 
     
Flurbiprofen TransActLAT Boots 40 mg Patch 
     
Ibuprofen Nurofen Boots 50 mg/g Gel 
     
Indomethacin Adco-Indogel Adcock-Ingram 10 mg/g Gel 
 Elmetacin Pharmafrica 10 mg/g Solution 
     
Ketoprofen Fastum Adcock-Ingram 2.5 g/100 g Gel 
     
Methyl salicylate Counterpain Adcock-Ingram 102 mg/g Cream 
 Docrub Aspen Pharmacare 1.77 ml/100 g Ointment 
 Thermo-Rub Adcock-Ingram 10 g/100 g Ointment 
     
Piroxicam Rheugesic Cipla Medpro 5 mg/g Gel 
 
2.3.2. Benefits and limitations  
Topical administration of NSAIDs intended for local and/or regional activity offer the advantage of 
local and/or regional enhanced drug delivery to affected tissues, with reduced incidence of systemic 
adverse effects, such as peptic ulcer disease and gastrointestinal haemorrhage. The short distance of 
transmission from the site of application to the target site and the avoidance of the enterohepatic cycle 
are attractive benefits (60). A summary of the benefits and limitations of topical formulations intended 
for local/regional activity (27) are listed below in Table 2.2. 
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Use of topical NSAID dosage forms lessens the risk of potentially serious systemic adverse effects 
secondary to NSAID-induced prostaglandin inhibition such as acute renal insufficiency, nephritic 
syndrome, gastropathy, prolonged bleeding time and fluid retention. Topical application also 
minimises the risk of drug-drug interactions, such as NSAID displacement of protein bound warfarin 
(19). This is particularly profound in patients on chronic medication and in the elderly who have been 
reported (60) to be the largest consumers of topical NSAIDs as they tend to be more sensitive to 
adverse effects of oral NSAIDs than younger individuals. 
 
Table 2.2. Benefits and limitations of topical NSAID formulations (27). 
Benefits Limitations 
  
• First pass effect and other variables associated with 
the GIT (such as pH and gastric emptying time) are 
avoided. 
• Reduced side effects and the minimisation of 
systemic availability 
• Ease of dose termination in the event of untoward 
side effects. 
• Delivery can be sustained and controlled over a 
prolonged period. 
• Direct access to the target site. 
• Convenient and painless administration. 
• Improved patient acceptance and adherence to 
therapy. 
• Ease of use may reduce overall health treatment 
costs. 
• Provide a viable solution for treatment when oral 
dosing is not feasible (i.e., in unconscious or 
nauseated patients). 
• Diffusion across the SC only occurs for molecules 
less than 500 Da. 
• Topical agents must have both aqueous and lipid 
solubility. 
• Both intra- and inter-individual variability in the 
permeability of skin, as well as differences between 
healthy and diseased skin, cause variable efficacy. 
• Skin enzymes can cause metabolism before 
cutaneous absorption, reducing the potency of the 
drug. 
• Localised skin irritation, such as erythema, can 
occur. 
 
2.4. Clinical indications 
Topical NSAIDs are primarily indicated for well-localised musculoskeletal conditions where pain or 
inflammation is likely to respond to inhibition of prostaglandin and leukotriene production from 
arachidonic acid (57). Common conditions for which topical NSAID formulations intended for local 
and/or regional activity are recommended include OA, RA, lower back pain (LBP), sport injuries and 
inflammatory conditions in the eye and breast. 
 
Arthritis is a term that describes over 100 conditions affecting joint and connective tissue. The most 
common of these conditions are OA and RA. In the USA an estimated 7 million people are coping 
with this disease (65). The pain and decreased mobility associated with arthritis have a significant 
impact on the quality of life. Patients with this disease have to rely on the assistance of others for their 
routine daily activities. This disability often contributes to feelings of helplessness, anxiety, 
depression, stress and anger. Social isolation and decreased involvement in the community are not 
uncommon (65). First-line treatment of localised arthritic pain and joint stiffness normally consists of 
oral paracetamol (acetaminophen). Oral and/or systemic NSAIDs are effective (71-73) but are 
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generally considered second-line therapy because of their adverse effect profile. In the UK, topical 
NSAIDs and counter-irritants such as capsaicin have been found to be useful (19,65,74). 
 
LBP is another common musculoskeletal disorder that creates a significant burden on society due to 
its high prevalence and consequent economic impact. LBP is the most reported musculoskeletal pain 
and as many as 84% of adults will experience LBP in their lifetime. In chronic situations, the 
management of LBP has been found to be challenging as it involves both musculoskeletal and 
neuropathic components (27). 
 
Pain and inflammation brought on by physical activity such as sports injuries are another indication 
for the use of NSAIDs which are the foundation treatment for athletic injuries. In acute injuries such 
as ankle sprain, studies have not been able to demonstrate that topical NSAIDs reduce the 
inflammatory response. Medical practitioners and rheumatologists believe that topical NSAIDs offer 
analgesic relief rather than an inflammatory relief to patients. The use of topical NSAIDs has a 
valuable application in this area where pain is usually limited to a distinct region (75). 
 
NSAIDs can be used topically in the eye to reduce inflammation and pain (76,77). Over the past 2 
decades, topical NSAID solutions have been investigated for ophthalmic use. Ketorolac tromethamine 
(0.5%, m/v) has been evaluated for cystoid macular oedema (78), allergic conjunctivitis (79), 
surgically induced miosis (80) and for the management of pain and inflammation associated after 
cataract surgery (81). Topical indomethacin (0.1%, m/v) (82) and diclofenac (0.1%, m/v) (83) 
solutions have also been evaluated for inflamed pterygia and pingueculae, and glaucoma. 
 
Breast pain is an important clinical feature and a common problem in women of all ages. 
Occasionally, it can be a distressing symptom, which may or may not be associated with nodularity 
(73). Re-assurance following the exclusion of cancer is the keystone of management for the majority 
of patients. However, in spite of this, there remains a small group of patients with severe and 
persistent mastalgia who require therapy. Severe breast pain significantly impairs the quality of life of 
these women including work performance, sleep, personal and sexual relations, which are all 
indications for active treatment. Topical NSAIDs have been shown to be useful in the management of 
mastalgia (73,84). 
 
Topical NSAIDs may also be of value in erythema nodosum, urticarial vasculitis, nodular prurigo, 
palmoplantar pustulosis or erthyromelalgia (57). Roles for topical NSAIDs are being investigated for 
postoperative pain, prevention of thrombophlebitis in peripheral cannulation, periodontal disease (85), 
herpetic neuralgia, human pain models and burn injuries (63). 
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2.5. Pharmacokinetic studies 
The concept of local and/or regional delivery of topical formulations requires proof that the drug does 
indeed reach the dermis and its surrounding tissues in high and therapeutically effective 
concentrations. The determination of dermal concentrations of NSAIDs from topical formulations is 
essential to clarify the issue of whether topical formulations do indeed bring about relief through their 
anti-inflammatory action or whether they simply act as rubefacients. Clarification and confirmation of 
the modus operandi of topical NSAIDs are needed in order to dispel the current scepticism amongst 
medical practitioners and rheumatologists regarding the efficacy of topical NSAID formulations. 
 
Pharmacokinetic data suggest that topically applied NSAID formulations intended for local 
and/regional activity result in significant dermal concentrations of the drug without significant toxic 
effects. In a two-way crossover design, 11 healthy volunteers received either oral ibuprofen (800 mg) 
or ibuprofen gel (5%, m/m) applied (16 g) onto the skin of the thigh of a defined area (17 x 19 cm). 
For determination of drug in the subcutaneous and muscle, concentric microdialysis probes were 
inserted 4-5 mm and 25-30 mm respectively (20). Mean values of dialysate after topical and oral 
administration were 731.2 ± 605.0 ngh/ml and 176.6 ± 122.9 ngh/ml for subcutaneous tissue and 63.5 
± 90.3 ngh/ml and 213.4 ± 117.2 ngh/ml for muscle respectively. The ibuprofen concentrations in the 
dermis were 22.5-fold greater when delivered topically than via the oral route (20). In another 
microdialysis study involving 20 human volunteers, Müller et al. (86) determined diclofenac 
concentrations at superficial and deep layers within the skin after topical administration of a single 
dose (~ 300 mg/100 cm2). Higher concentrations were observed in the superficial layers (532 ± 197 
µgmin/ml) in comparison to the deeper layer (438 ± 249 µgmin/ml). Rolf et al. (18) determined 
ketoprofen concentrations in the intra-articular tissues of 100 patients following either a single 
application of a 30 mg plaster, multiple applications daily for 5 days, or administration of a 50 mg 
oral dose. The median Cmax values for topical and oral administration were 568.9 ng/g and 85.7 ng/g 
respectively in the cartilage. In contrast, the plasma values were 18.7 ng/ml for topically administered 
ketoprofen and 2 595.3 ng/ml for the oral route. Overall, when applied topically, the ketoprofen 
concentration was 30-fold greater in the cartilage than in the plasma (18). Similar results were also 
observed in a study conducted by Brunner et al. (87). These authors also noted that relative 
bioavailability of diclofenac in subcutaneous adipose and skeletal muscle tissue was substantially 
higher after topical application compared with oral dosing whereas the plasma bioavailability was 50-
fold lower. Plasma Cmax values were approximately 250-fold lower after topical treatment compared 
with oral administration (87). 
 
In summary, these studies have demonstrated that following the application of topical NSAID 
formulations intended for local and/or regional activity, high concentrations of the drug were achieved 
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in underlying tissues and moreover, peak plasma drug concentrations were only 3-5% of total 
systemic absorption compared with oral administration and without any associated systemic toxicity. 
 
2.6. Efficacy 
The analgesic and anti-inflammatory properties of NSAIDs are assumed to be primarily related to 
their ability to inhibit prostaglandin synthesis at the damaged tissue, therefore topical administration 
of these medicines should offer the advantage of relieving the damaged tissue by suppressing the local 
inflammatory responses with reduced incidence of systemic adverse effects (59). 
 
2.6.1. Topical NSAIDs versus placebo formulations 
Although topical NSAID formulations intended for local and/or regional activity have been 
demonstrated to produce high concentrations in the dermis (18-22) and despite being licensed in a 
number of countries including more recently, the USA (68,70), scepticism still exists as to whether 
topical NSAID formulations have any action other than as rubefacients (22,88). This has been 
attributed to the relatively high placebo positive response that has been claimed to be associated with 
rubefacients (19,67). These findings suggest that physical rubbing of the formulation into the skin at 
the affected site contributes significantly to the reduction of inflammation and pain rather than 
through the pharmacological action of the active ingredients present in the formulation. Additionally, 
topical NSAID dosage forms intended for local and/or regional activity have been misrepresented as 
rubefacients which were classified as topical anti-rheumatic agents, despite the lack of efficacy data 
from clinical trials to show that rubefacients provide true clinical benefit (67). 
 
Vaile and Davis (63) reported that the placebo response associated with topical treatment of soft tissue 
complaints can be as high as 60-80%. While the natural progression of healing may account for the 
high placebo effect in patients with acute musculoskeletal complaints, the rate of inflammatory 
suppression reported in chronic rheumatological diseases remains unclear. 
 
Moore et al. (22) in their systematic review, evaluated the impact of topical NSAIDs. Based upon data 
from placebo-controlled trials, they reported that topical NSAIDs were effective and that the effect of 
topical NSAIDs was not simply due to rubbing. 
 
Nevertheless the continued popularity of rubefacients (i.e., topical applications without NSAID) 
supports the idea that responses of patients to topical NSAIDs may also be partly due to rubbing the 
affected tissue (89). Studies, however, have reported (22,59,60,77) that patients who received topical 
NSAIDs achieved pain relief quicker than those who received placebo. 
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2.6.2. Duration of action  
Trials conducted by Moore et al. (22) compared topical NSAIDs intended for local and/or regional 
activity with their systemic oral equivalent in both acute and chronic conditions. None of these trials 
found oral NSAIDs to be superior to the same agent applied topically. Similar outcomes were 
observed in another study reported by Lin et al. (90). These authors, in a meta-analysis that explored 
the use of topical NSAIDs in the treatment of OA, found that topical NSAIDs intended for local 
and/or regional activity were superior to placebo in the reduction of pain and improvement of 
function. Interestingly, this study indicated that topical NSAIDs only showed efficacy over a 
fortnight, but also reported that these effects were lost after 4 weeks suggesting the development of 
tolerance. The authors therefore concluded that little evidence existed to support the long term use of 
topical NSAIDs in OA. Similar observations were noted in studies conducted by Bjordal et al. (91) 
and Mason et al. (72). This observation was not immediately noted because most randomised 
controlled trials were of short duration (i.e., 2 weeks or less) and not a single study extended beyond a 
period of a month (61). In an attempt to conduct clinical studies for longer than 2 weeks, Baer et al. 
(92) and Bookman et al. (93) evaluated the efficacy of topical diclofenac solutions in the treatment of 
primary OA of the knee. Although efficacy was established within 2 weeks, skin irritation, typically 
dryness was reported leading to the discontinuation of some patients from the studies. 
 
The early effective waning off of topical NSAIDs intended for local and/or regional activity, 
suggested that topical therapy was best used for short periods in acute conditions. Since topical 
NSAIDs have been found to be effective only over a relatively short period of time their use in acute 
conditions (22,59,72) may be justified whereas use for chronic inflammatory disease is questionable 
(19). 
 
2.7. Safety 
Topical NSAIDs are generally well tolerated. Skin reactions, which are reversible on discontinuation 
of therapy, are the most commonly observed side effects (94). The incidence of skin reactions is 
however low and also often observed with placebos (64,67), suggesting that the vehicle itself may be 
responsible for a significant proportion of the adverse effect (19,63). The vast majority of adverse 
effects occurring in approximately 10-15% of patients are localised pruritis, itching, burning and/or 
rash at the site of administration (59). Local reactions in the form of delayed hypersensitivity 
dermatitis may occur at the site of the application, but these are also relatively uncommon. Cross-
sensitisation between topical ketoprofen and other propionic NSAIDs has been reported (60,73,95).  
 
Whereas most NSAIDs administered topically could potentially induce phototoxic reactions, in 
particular, topical formulations of ketoprofen have been associated with the highest frequency of 
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photosensitivity reactions which include both phototoxic and photoallergic reactions (58,59,63). Since 
their introduction in France in 1989, ketoprofen gels have been responsible for various cutaneous 
adverse effects, essentially photosensitisation and photocontact dermatitis (58). These reactions have 
been linked to the carbonyl functionality within the chemical structure, possibly related to the 
benzophenone chromophore (74). Since these products have often been classified as OTC allowing 
patients to obtain these formulations without any medical supervision, a distinct possibility exists that 
patients may exceed their recommended use. 
 
Topical application of copious amounts of NSAIDs intended for local and/or regional activity may 
result in systemic adverse effects including hypersensitivity and asthma (60). On the other hand, 
systemic reactions due to the use of topical NSAID formulations intended for local and/or regional 
treatment, such as dyspepsia, nausea and diarrhoea, have rarely been reported (95) following 
recommended use.  
 
While extensive clinical experience has generally shown the use of topical ocular NSAIDs to be well-
tolerated, side effects including impaired corneal sensation, persistent epithelial defects, superficial 
punctuate keratitis, stromal infiltrates and subepithelial infiltrates have been reported (76). Recently, 
more severe lesions including corneal stromal ulceration requiring treatment with tissue adhesive, 
patch grafting and penetrating keratoplasty have been described in association with topical ocular use 
of Falcon®, a generic version of Voltaren® (diclofenac 0.1%, m/m). Interestingly, however, the 
generic product has been withdrawn from the market because of adverse effects (76). 
 
 Patients should also be cautioned on the use of heating pads in conjunction with topical NSAIDs, as 
the threshold to induce a burn is reduced. In addition, patients with pre-existing salicylate allergy may 
experience allergic reactions when salicylates are topically applied (65).  
 
2.8. Cost effectiveness 
It has been reported that the cost of therapy involved in treating a patient on chronic oral NSAID 
therapy is higher than the cost to treat a patient on topical NSAIDs. Hosie and Bird (67) reported 
significant cost savings to hospital budgets when topical NSAIDs were prescribed instead of oral 
NSAIDs. The economic argument was based on a model produced by Knill-Jones (96) that showed 
the probability of how a patient would be treated as well as the treatment costs in the UK, if peptic 
ulceration were to develop. Using an oral NSAID ulcer rate of 10%, the total cost (the basic drug 
price of the NSAID plus the cost of treating any resulting GIT adverse effect) of treating 1 000 
patients with a month’s supply of oral NSAIDs ranged from £39 678 to £58 858, while the equivalent 
total cost of treating 1 000 patients with topical NSAIDs was just £7 319. If the ulcer rate was reduced 
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to 5%, this study showed that treatment with any oral NSAID would still be more expensive than with 
topical NSAIDs. 
 
Generally, topical NSAID formulations (gels, sprays, and patches) are significantly more expensive 
than oral NSAID dosage forms. E.g., a 100 g tube of a topical NSAID gel was reported as being 
approximately 3 times the cost of the equivalent oral dosage form required for a week’s therapy (95). 
This led to the concern by Bagheri et al. (58) regarding benefit/risk and cost/benefit of topical 
NSAIDs. These authors noted that ₤30 million is spent each year in the UK on topical NSAIDs. 
However it is only possible to assess the true cost/benefit by considering the total cost of oral 
NSAIDs, which includes side effects and/or adverse reactions. It could be argued that the total cost 
associated with treatment with oral NSAIDs could potentially be reduced by co-prescription of gastro-
protective drugs, however, Knill-Jones (96) showed that topical NSAIDs are more cost-effective than 
a combination product containing the oral NSAID diclofenac plus the prostaglandin analogue, 
misoprostol. Although there are regional variations in drug and treatment costs, this study highlighted 
the importance of investigating the direct costs involved for any drug which in most circumstances is 
borne by the patient. 
 
 
3. Ketoprofen analysis 
Ralph Tettey-Amlalo  - 22 - 
CHAPTER THREE 
KETOPROFEN ANALYSIS 
 
3.1. Introduction 
The development of rapid and efficient procedures for quantitative analysis is considered as a high 
priority objective in the pharmaceutical industry (97,98) since it permits a large number of samples to 
be analysed by reducing sample run times. The amount of high purity and expensive solvents used in 
the preparation of mobile phases (MPs) and associated wash solutions are thereby significantly 
reduced (99). 
 
3.1.1. High performance liquid chromatography (HPLC) 
Liquid chromatography (LC) coupled with different universal and/or selective detectors still remains 
the preferred method of choice in pharmaceutical analysis for the determination of drug in various 
matrices (97). The commonly used HPLC is, however, often associated with relatively lengthy sample 
run times (97,98). A key objective over recent times has been to develop strategies which can be 
employed to significantly reduce sample run times to a few min and even to less than 1 min where 
possible, without compromising efficiency. 
 
The main limitation of HPLC is the lack of high efficiency, especially when compared to gas 
chromatography (GC) and capillary electrophoresis (CE). The small diffusion coefficient of solute in 
MPs translates into slow diffusion speeds into the stationary phase and has been attributed to the 
lower efficiency experienced in HPLC in comparison to GC and CE (100). 
 
The efficiency of separation is reflected by the column equivalent to a theoretical plate (HETP) which 
varies with linear velocity of the MP (101). Separation efficiencies can be improved by using smaller 
column particles to shorten the diffusion path of drugs. This is described by the simplified van 
Deemter equation below. 
 
222 ( )m pp
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where, efficiency is expressed as HETP, ( H ), ( )u is the linear velocity, ( )pd is particle size in which 
λ  is the packing constant, γ  is an obstruction factor for diffusion in a packed bed, mD  is the 
diffusion coefficient in the MP and ( )f k  is a function of the retention factor ( )k . The symbol a  
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describes the labyrinthine nature of the packed bed, the molecular diffusion (in the direction of the 
axis) is represented by b  and c  represents the resistance to mass transfer in the MP. 
 
Since increasing the MP flow rate is normally the simplest approach to reduce analysis time, as seen 
in Equation 3.1, an increase in optimal linear velocity without compromising efficiency is only 
possible using columns packed with small particles (99,102). However, the use of columns packed 
with smaller particles is limited by a rapid increase in pressure drop (101) according to Darcy’s law as 
shown in Equation 3.2. This necessitates the use of extremely high operating pressures which are not 
possible using conventional HPLC pumps since these instruments generally have a maximum 
operating pressure of ~ 400 bar (~ 5800 psi). 
 
2
p
LuP
d
ηφΔ =            3.2. 
 
where L  is the column length, u  is the average MP velocity, η  is the MP viscosity, φ  is the flow 
resistance and 2d  is the particle size. Since u  increases while 2d  decreases, a back-pressure higher 
than ~ 400 bar (~ 5 800 psi) could be generated with column lengths longer than 30 mm (97,101). 
 
Various methodologies have been proposed to bypass the inherent limitations of HPLC. The use of 
high temperature liquid chromatography (HTLC) is considered as a valuable tool to reduce sample 
run time (97,99). An increase in temperature (80-200°C) can induce a 5-10 fold reduction in MP 
viscosity, allowing the application of high flow rates with limited back-pressure (98) even with small 
particle columns. However, the availability of stationary phases that are stable at elevated temperature 
is limited. Moreover, the HPLC instrumentation may have to be modified to accommodate and 
maintain the temperature of the MP (97) and there is also a possible risk of thermal degradation of 
labile compounds (98,103). 
 
Another strategy is the use of monoliths as the stationary phase in columns (97,104,105). While 
conventional HPLC columns are filled with small silica spherical particles, monolithic columns 
contain special silica, which are not formed by particles. They are made by sol-gel technology, which 
enables formation of highly porous material, containing macropores and mesopores. The macropores 
(i.e., large pores, ~ 2 µm) are responsible for a low flow resistance and therefore allow the application 
of high eluent flow rates, while the mesopores (i.e., small pores, ~ 12 nm) ensure sufficient surface 
area for separation efficiency. Columns fitted with monoliths as stationary phases require short 
column equilibration times and are used in HPLC. This is especially beneficial when gradient elution 
is used (105). Monoliths exhibit equivalent quantitative features compared with conventional 
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stationary phase column packing. However, their need for high eluent flow rates invariably results in 
consumption of large volumes of organic solvents and limits their compatibility with mass 
spectrometry (98). 
 
More recently, columns packed with 1.7 µm particles have become commercially available and which 
generate a 27 times higher column pressure drop than with 5 µm particles (99). Hence, dedicated 
instrumentation with low extra-column volumes and high detection acquisition rates that can 
accommodate such high back-pressures generated from the use of columns packed with sub-2 µm 
particles (106) have been developed. Hence, ultra-high pressure liquid chromatography (UHPLC) 
associated with high separation efficiencies on columns packed with sub-2 µm particles have been 
designed. 
 
3.1.2.  Ultra performance liquid chromatography (UPLC) 
The first commercially available system that addressed the challenge of using elevated pressures 
coupled with sub-2 µm column particle sizes was introduced by Waters® Corporation (Milford, 
Massachusetts, USA). Pressures of up to ~ 1034 bar (~ 15 000 psi) with the use of commercially 
available columns packed with 1.7 µm particles are attainable with this system (107,108). These 
systems required extensive modifications compared to conventional instrumentation. Not only was 
there a need to develop high pressure pumps, sample injector systems needed to be re-designed to 
handle fast injection cycles, low injection and overall system volumes, negligible carryover and 
temperature control (4-40°C) which together contribute to rapid sample analysis (102).  
 
The Acquity™ UPLC system incorporates specially designed Acquity™ UPLC columns with 1.7 µm 
Ethylene Bridged Hybrid (BEH) particles. A newer particle technology, 1.8 µm High Strength Silica 
(HHS) has recently been introduced. Although both technologies ensure column stability under high 
pressure, BEH is applicable for use over a wider pH range (i.e., 1-12) whereas HSS is used over a 
narrower pH range (i.e., 1-8). BEH is available in 5 column chemistries namely C18, C8, Shield RP18, 
phenyl and HILIC whereas HHS is currently available in 2 column chemistries T3 and C18. 
 
These UPLC systems may be equipped with a range of detectors such as a Photo Diode Array (PDA) 
UV detector and/or mass spectrometer (MS). It is therefore expected that the use of UPLC coupled to 
a MS should provide for fast, high resolution separations with significant advantages over 
conventional HPLC-MS/MS systems. 
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3.2. HPLC-UV method development and validation 
3.2.1. Methods 
3.2.1.1. Reagents and chemicals 
Ketoprofen (99.4%) (Figure 3.1) was purchased from Sigma-Aldrich (Atlasville, South Africa). 
Acetonitrile 200 far UV ROMIL-SpS™ Super Purity Solvent and Methanol 215 ROMIL-SpS™ Super 
Purity Solvent were purchased from ROMIL Ltd. (Cambridge, UK). The following analytical grade 
chemicals and reagents were obtained from MERCK (Wadeville, South Africa); acetic acid glacial, 
sodium hydrogen pellets and potassium dihydrogen orthophosphate. Sterile normal saline solution 
(sodium chloride 0.9%, m/v) was purchased from Bodene (Pty) Ltd. (Port Elizabeth, South Africa). 
HPLC grade water was obtained from a Milli-Q® A10 water purification system (Millipore, 
Molsheim, France) that comprised a Quantum™ EX ultrapure organex cartridge and a Q-Gard™ 
purification pack. The water was filtered through a 0.22 µm Millipak stack filter prior to use. 
 
O
CH3H
CO2H
C16H14O3 MM 254.3 g/mol
pKa = 4.23  
Figure 3.1. Structure of ketoprofen 
 
3.2.1.2. Instrumentation 
Sample analysis was performed on an Alliance 2695 HPLC system equipped with a 2996 PDA 
detector, autosampler and column heater (Waters® Corporation, Milford, Massachusetts, USA). 
Instrument control, data acquisition and evaluation were carried out with Empower Pro™ software 
(Waters® Corporation, Milford, Massachusetts, USA). 
 
3.2.1a. HPLC analysis of microdialysis (MD) samples 
3.2.1a.1. Equipment 
A Model AG 135 analytical balance (Mettler Toledo, Greifensee, Zurich, Switzerland) and an 
ultrasonic bath Model 8845-30 (Cole-Parmer Instruments, Chicago, Illinois, USA) were used for 
sample preparation. 
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The method employed for the analysis of dialysis samples was adapted from a previously developed 
method used for the quantitative determination of ketoprofen obtained from diffusion experiments (1). 
 
Samples (10 µl) were injected onto a Spherisorb® ODS2 C18 (250 x 4.1 mm i.d., 5 μm) stainless steel 
analytical column (Waters® Corporation, Milford, Massachusetts, USA) maintained at ambient 
temperature (22 ± 0.5°C) using a MP consisting of acetonitrile/20 mM phosphate buffer (pH 2.5): 
(60/40, v/v) at a flow rate of 1.0 ml/min. The eluate was monitored at a wavelength of 255 nm. 
 
3.2.1a.2. Sample preparation 
Relevant quantities of ketoprofen for the preparation of stock solutions were accurately weighed and 
made up to volume with normal saline solution. All weights were performed in 4 x 12 x 4 mm 
weighing boats (Sigma-Aldrich, Atlasville, South Africa). Calibration standards (0.2-15 µg/ml) and 3 
quality control (QC) standard solutions (low, medium and high) were prepared by serial dilution of a 
stock solution (~ 100 µg/ml) and the solutions were sonicated for 10 min. A separate stock solution 
was used to prepare the QC solutions. 
 
Since ketoprofen photodegradation under normal laboratory lighting conditions at room temperature 
(22 ± 0.5°C) has previously been established (1,109), all sample handling was performed under 
filtered fluorescent (deep golden amber) light (Lee Filters, Andover, Hampshire, England). This 
precaution prevents the transmission of light at wavelengths lower than 530 nm and protects 
ketoprofen photodegradation. Amber glassware was used as a further precaution to prevent the 
possibility of ketoprofen photolysis. 
 
3.2.1a.3. Linearity 
Plots of peak areas of ketoprofen versus concentrations were constructed following the analysis of 
relevant standard solutions (n=3) and the data was evaluated using linear regression analysis. 
 
3.2.1a.4. Accuracy and precision 
Intra- and inter-day precision and accuracy of the assay were assessed over a period of 3 days using 3 
QC standards (low, medium and high). Five separate determinations of each concentration were 
analysed to assess accuracy using freshly prepared working standards. For the precision studies, a 
single working stock solution was used and stored at ambient temperature under filtered light and also 
served as an indicator of stability. 
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3.2.1a.5. Limits of quantification and detection 
Standard stock solutions were diluted appropriately to obtain concentrations for the estimation of the 
limit of detection (LOD) and the lower limit of quantification (LLOQ) based on signal-to-noise (S/N) 
ratios of 3:1 and 10:1, respectively.  
 
3.2.2a. Results and discussion 
A typical chromatogram showing the elution of ketoprofen (RT = 3.5 min) in normal saline is shown 
below (Figure 3.2). Samples in normal saline were directly injected unto the column without any pre-
treatment or deleterious effects on separation efficiency, quantitation or significant increase of column 
back-pressure. Care was taken to ensure that all saline was flushed out daily from the column with 
HPLC-grade water (~ 10 column volumes) using a flow rate of 1 ml/min. 
 
 
Figure 3.2. HPLC PDA chromatogram of ketoprofen (10 µg/ml) in normal saline solution 
 
Conditions:- Elution chromatography: Isocratic; Column: Waters® Spherisorb® ODS2 C18 (250 x 4.1 mm i.d., 5 μm); Column temperature: 22 ± 0.5°C; MP: 
Acetonitrile/20 mM PBS (acetic acid glacial, pH 2.5) (60/40, v/v); Flow rate: 1.0 ml/min; Injection volume: 10 µl; UV detection wavelength: 255 nm. 
 
3.2.2a.1. Linearity 
The calibration plot for ketoprofen was linear with correlation coefficients better than 0.9999 
( 33799 2366y x= + ). 
 
3.2.2a.2. Accuracy and precision 
The accuracy of the method (Table 3.1) was found to be in the range 100.47-102.35% with RSDs less 
than 3.5%. Intra- and inter-day results (Table 3.2) showed good precision and also demonstrated that 
samples prepared under filtered fluorescent light were stable over a period of 3 days when kept at 
ambient temperature. 
 
Ketoprofen peak 
Solvent front 
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Table 3.1. Accuracy studies of ketoprofen MD QC samples (n=5) 
MD samples Day Actual Conc 
(µg/ml) 
Calculated Conc 
(µg/ml) 
Accuracy 
(%) 
Inter-day 
RSD (%) 
      
 1 0.85 0.87 102.35 3.25 
Low 2 0.88 0.90 102.27 2.59 
 3 0.86 0.88 103.19 2.22 
      
 1 6.15 6.26 101.78 2.15 
Medium 2 6.37 6.40 100.47 1.56 
 3 6.42 6.32 98.44 1.11 
      
 1 13.15 13.25 100.76 2.01 
High 2 13.62 13.78 101.17 0.87 
 3 12.84 13.06 101.69 1.18 
 
Table 3.2. Precision studies of MD QC samples 
MD 
samples 
Day 1 
Mean Conc (µg/ml) ± 
SD (RSD %) (n=5) 
Day 2 
Mean Conc (µg/ml) ± 
SD (RSD %) (n=5) 
Day 3 
Mean Conc (µg/ml) ± 
SD (RSD %) (n=5) 
Inter-day 
Mean Conc (µg/ml) ± 
SD (RSD %) (n=3) 
     
Low 0.87 ± 0.01 (1.51) 0.85 ± 0.02 (0.02) 0.88 ± 0.01 (1.30) 0.87 ± 0.01 (1.29) 
     
Medium 6.26 ± 0.04 (0.57) 6.26 ± 0.02 (0.38) 6.27 ± 0.02 (0.38) 6.26 ± 0.01 (0.15) 
     
High 13.26 ± 0.02 (0.11) 13.25 ± 0.01 (0.06) 13.26 ± 0.01 (0.11) 13.26 ± 0.01 (0.02) 
 
3.2.2a.3. Limits of quantification and detection 
The LOD and the LLOQ of ketoprofen were found to be 0.2 and 0.5 µg/ml respectively and the 
ULOQ set at 15 µg/ml. 
 
3.2.1b. HPLC analysis of tape strips  
The method, equipment and chemicals were the same as described for the analysis of MD sample 
except for the following: 
 
3.2.1b.1. Method 
Initially, an un-spiked non-stripped tape strip was extracted as described below (section 2.3.1b.3) and 
injected into the chromatographic system using the same MP employed in the analysis of MD samples 
which involved isocratic elution. The MP was subsequently adjusted for use in gradient elution using 
Solvent A [Acetonitrile/20 mM phosphate buffer (pH 2.5) (60/40, v/v)] and Solvent B [Methanol].  
 
3.2.1b.2. Equipment 
A Model 5415 centrifuge (Eppendorf®, Hamburg, Germany) and a 100 µl Model 710SNR digital 
syringe (Hamilton, Reno, Nevada, USA) were used. 
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3.2.1b.3. Sample preparation and extraction 
Calibration standards (5-200 µg/ml) and 3 QC solutions of ketoprofen in methanol were prepared. 
Pre-cut tape strips (2 x 2 cm) prepared from Transpore™ 1527 (24 mm x 5 m) dressing tapes (3M, 
Isando, South Africa) were spiked by applying 100 µl of each standard solution onto the tape strips 
which had previously been applied to human skin (stripped) and then removed to provide a layer of 
intact SC. The tape strips dried for 10 min, after which each tape strip was carefully rolled up, placed 
into a polyethylene (1.5 ml) centrifuge tube (Eppendorf®, Hamburg, Germany) and ketoprofen 
extracted with methanol (1 ml). Samples were vortexed for 10 s prior to centrifugation at 12 000 rpm 
(8050 × g) for 5 min and filtered through 0.45 µm hydrophilic low protein binding durapore (PVDF) 
filters (Millipore®, Molsheim, France). Approximately 200 µl of the supernatant was pipetted into 
glass sample inserts (300 µl) with pre-installed plastic springs and placed into 9 mm screw top glass 
amber sample (12 x 32 mm) vials (Waters® Corporation, Milford, Massachusetts, USA) and analysed. 
Sample preparation and extraction were conducted at ambient temperature (22 ± 0.5°C) under filtered 
light. All validation procedures were based on the extraction of tape strips spiked with relevant 
ketoprofen standards. 
 
3.2.1b.4. Linearity 
Same as previously described in section 3.2.1a.3. 
 
3.2.1b.5. Accuracy and precision 
Same as previously described in section 3.2.1a.4. 
 
3.2.1b.6. Limits of quantification and detection 
Same as previously described in section 3.2.1a.5. 
 
3.2.1b.7. Recovery 
Extraction recovery of ketoprofen was assessed by analysing spiked samples (n=5) of 3 different 
concentrations corresponding to the concentrations of the QC samples (low, medium and high) and 
compared with data from the analysis of methanolic solutions of ketoprofen at similar concentrations.  
 
3.2.1b.8. Specificity 
Specificity was evaluated by injecting an extract from a blank (non-stripped and un-spiked) tape strip 
as well as an extract from a blank (stripped but un-spiked) tape strip. 
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3.2.2b. Results and discussion 
Injections of extracts of blank (non-stripped and un-spiked) tape strips following isocratic elution are 
shown in the chromatogram below (Figure 3.3). 
 
 
Figure 3.3. HPLC PDA chromatogram of a non-stripped un-spiked blank tape strip extract 
 
Conditions:- Elution chromatography: Isocratic; Column: Waters® Spherisorb® ODS2 C18 (250 x 4.1 mm i.d., 5 μm); Column temperature: 22 ± 0.5°C; MP: 
Acetonitrile/20 mM PBS (acetic acid glacial, pH 2.5) (60/40, v/v); Flow rate: 1.0 ml/min; Injection volume: 10 µl; UV detection wavelength: 255 nm. 
 
 
Injections of extracts of blank (un-spiked) tape strips including stripped tape strips following the step 
gradient elution are presented in Figures 3.4 and 3.5 respectively. 
 
 
Figure 3.4. HPLC PDA chromatogram of a blank non-stripped tape strip extract 
 
Conditions:- Elution chromatography: Step gradient; Column: Waters® Spherisorb® ODS2 C18 (250 x 4.1 mm i.d., 5 μm); Column temperature: 22 ± 0.5°C; 
MP: Solvent A [Acetonitrile/20 mM PBS at pH 2.5 (60/40) (v/v)]: Solvent B [Methanol]; Flow rate: 1.0 ml/min; Injection volume: 10 µl; UV detection 
wavelength: 255 nm. 
 
Solvent front 
Interfering peak Effect of step 
gradient elution 
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Figure 3.5. HPLC PDA chromatogram of a blank stripped tape strip extract 
 
Conditions:- Elution chromatography: Step gradient; Column: Waters® Spherisorb® ODS2 C18 (250 x 4.1 mm i.d., 5 μm); Column temperature: 22 ± 0.5°C; 
MP: Solvent A [Acetonitrile/20 mM PBS at pH 2.5 (60/40, v/v)]: Solvent B [Methanol]; Flow rate: 1.0 ml/min; Injection volume: 10 µl; UV detection 
wavelength: 255 nm. 
 
More interference was seen in the early portion (i.e., 1.5-2.5 min) of the chromatogram (Figure 3.5) 
following injection of a stripped tape strip extract using step gradient elution. With isocratic elution 
the interfering peaks eluted up to approximately 18 min (Figure 3.3) thus prolonging the run time. 
Hence a step gradient elution method was necessary to introduce methanol after the elution of the 
ketoprofen peak in order to flush out the interfering peaks to reduce the run time (~ 12 min) which 
also incorporated a 2 min re-equilibration (Figure 3.5). 
 
3.2.2b.1. Linearity 
The calibration plot for ketoprofen was linear with correlation coefficients better than 0.9999 
( 37948 6412.3y x= − ). 
 
3.2.2b.2. Accuracy and precision 
The accuracy of the method (Table 3.3) was found to be in the range 100.07-102.58% with RSDs less 
than 3%. Intra- and inter-day results (Table 3.4) showed good precision. 
 
Solvent front 
Interfering peak Effect of step 
gradient elution 
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Table 3.3. Accuracy studies of ketoprofen from tape strips (n=5) 
Tape strip Day Actual Conc 
(ng/ml) 
Calculated Conc 
(ng/ml) 
Accuracy 
(%) 
Inter-day 
RSD (%) 
      
 1 5.12 5.23 102.15 2.15 
Low 2 5.31 5.42 102.07 2.14 
 3 4.98 5.02 100.80 2.58 
      
 1 50.34 50.41 100.14 1.02 
Medium 2 52.21 52.33 100.23 2.01 
 3 48.97 50.01 102.12 2.25 
      
 1 150.41 150.54 100.09 0.52 
High 2 155.99 160.02 102.58 1.15 
 3 146.31 146.45 100.10 1.25 
 
Table 3.4. Precision studies of tape strips 
Tape 
strips 
Day 1 
Mean Conc (ng/ml) ± 
SD (RSD %) (n=5) 
Day 2 
Mean Conc (ng/ml) ± 
SD (RSD %) (n=5) 
Day 3 
Mean Conc (ng/ml) ± 
SD (RSD %) (n=5) 
Inter-day 
Mean Conc (ng/ml) ± 
SD (RSD %) (n=3) 
     
Low 5.24 ± 0.03 (0.57) 5.23 ± 0.02 (0.41) 5.25 ± 0.01 (0.19) 5.24 ± 0.01 (0.20) 
     
Medium 50.45 ± 0.03 (0.06) 50.41 ± 0.02 (0.05) 50.47 ± 0.04 (0.07) 50.44 ± 0.03 (0.06) 
     
High 150.58 ± 0.04 (0.03) 150.53 ± 0.02 (0.02) 150.45 ± 0.10 (0.07) 150.52 ± 0.07 (0.04) 
  
3.2.2b.3. Limits of quantification and detection 
The LOD and the LLOQ of ketoprofen were found to be 2 and 5 µg/ml respectively and the ULOQ 
was set at 200 µg/ml. 
 
3.2.2b.4. Recovery 
The recovery of ketoprofen ranged from 98.48-98.51% with RSDs less than 2.5% (Table 3.5). 
 
Table 3.5. Ketoprofen recovery from tape strips 
Tape 
strips 
Actual 
 Conc 
(ng/ml) 
Calculated 
Conc 
(ng/ml) 
% 
Recovery 
% 
RSD 
(n=5) 
     
Low 5.26 5.18 98.48 2.15 
Medium 50.14 49.39 98.50 1.26 
High 150.19 147.95 98.51 1.59 
 
3.2.2b.5. Specificity 
Although various compounds were co-extracted from the tape strips, none of those interfered with the 
elution of ketoprofen (Figures 3.4, 3.5 and 3.6). 
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Figure 3.6. HPLC PDA chromatogram of a spiked (5 µg/ml) stripped tape strip extract 
 
Conditions:- Elution chromatography: Step gradient; Column: Waters® Spherisorb® ODS2 C18 (250 x 4.1 mm i.d., 5 μm); Column temperature: 22 ± 0.5°C; 
MP: Solvent A [Acetonitrile/20 mM PBS at pH 2.5 (60/40, v/v)]: Solvent B [Methanol]; Flow rate: 1.0 ml/min; Injection volume: 10 µl; UV detection 
wavelength: 255 nm. 
 
3.2.3. Conclusions 
Analytical methods were developed and validated for the quantitative determination of ketoprofen in 
a) MD samples and b) tape strips. Normal saline solutions did not appear to affect the analysis nor 
cause any significant increase in column back-pressure. Using a gradient elution for tape strips 
resulted in a reduction in run time since tape strip extracts resulted in late eluting peaks which would 
have necessitated longer run times using the isocratic system applied to analyse MD samples. The 
concentration ranges for MD samples and tape strip extracts were from 0.5-15 µg/ml and from 5-200 
µg/ml, respectively. Both methods were accurate (100.47-102.35% and 100.07-102.58% for MD and 
tape strips, respectively) and precise (with % RSDs less than 2% and 1% for MD and tape strips, 
respectively) and recovery of ketoprofen from the tape strips was approximately 98%.  
 
3.3. UPLC-MS/MS analysis of dermal microdialysis (DMD) samples 
The reagents, chemicals and equipment used were the same as described under 3.2 except for the 
following: 
 
3.3.1. Reagents and chemicals 
Naproxen (98%), flurbiprofen (99%) and ibuprofen (97%) were purchased from Sigma-Aldrich 
(Atlasville, South Africa). HPLC grade isopropyl alcohol was purchased from Burdick & Jackson, 
Inc. (Muskegon, Michigan, USA) and ethyl acetate, n-hexane, sodium dichromate dehydrate and 
sulphuric acid (98%, v/v) were of analytical grade and obtained from MERCK (Wadeville, South 
Africa). 
Effect of step 
gradient elution 
Interfering peak 
Solvent front 
Ketoprofen peak 
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3.3.2. Equipment  
A Model MX5 analytical ultra-microbalance (Mettler Toledo, Greifensee, Zurich, Switzerland), a 200 
µl pipette (Pipetman®, Gilson Medical Electronics, Villiers-le-Bel, France), a N-EVAP 24 place 
Model 112 nitrogen analytical evaporator (Organomation Associates Inc., South Berlin, 
Massachusetts, USA) coupled to a cylinder of high purity nitrogen gas (Afrox, Port Elizabeth, South 
Africa). 
 
3.3.3. Instrumentation 
Sample analysis was performed on an Acquity™ UPLC system (Waters® Corporation, Milford, 
Massachusetts, USA) which consisted of a binary pump solvent manager capable of generating 
pressures up to 1000 bar (~ 15 000 psi). Detection was carried out using an Acquity™ PDA UV-Vis 
detector coupled in series with an Acquity™ TQD tandem-quadrupole MS equipped with a Z-spray 
electrospray interface (Manchester, UK). The UV-Vis detector contained a 500 nl flow cell, the time 
constant was set at 25 ms and data sampled at 80 Hz. The system was equipped with strong and weak 
wash solution reservoirs. Instrument control, data acquisition and processing were carried out with 
MassLynx™ (version 4.1) and IntelliStart™ software (Waters® Corporation, Milford, Massachusetts, 
USA) was used to control the fluidics device to infuse solutions for tuning the MS. 
 
The objective was to develop a rapid, accurate, precise and reproducible analytical method with the 
requisite sensitivity suitable for the quantitative determination of ketoprofen in DMD samples 
obtained from human subjects using UPLC-MS/MS. HPLC-MS/MS methods in negative-ion (NI) or 
positive-ion (PI) with electrospray ionisation (ESI) or atmospheric pressure chemical ionisation 
(APCI) for ketoprofen analysis previously reported in the literature are shown in Table 3.6.
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Table 3.6. Published methods/reports using HPLC-MS/MS for the analysis of ketoprofen 
Stationary phase MP and 
elution chromatography 
Flow rate 
(ml/min) 
RT 
(min) 
LOD Sample type 
analysed 
Sample 
cleaning 
Ionisation 
mode 
Injection 
vol (µl) 
Reference 
          
Genesis C18  
(150 x 2.1 mm, 4 µm) 
Solvent A 
[Acetonitrile/methanol (40/60, 
v/v)]; Solvent B [20 mM 
ammonium acetate]-Gradient 
elution 
0.20 8.51 20.00 pg/ml Sewage samples SPE NI ESI 25 (110) 
          
LiChrospher 100  
RP-18 
Acetonitrile/water (formic acid, 
pH 2)-Gradient elution 
1.00 16.50 28.00 pg/ml Surface and waste 
water samples 
SPE NI ESI 20 (111) 
          
LiChrospher RP-18  
(125 x 3.0 mm, 5 µm) 
Acetonitrile/water (formic acid, 
pH 2)-Gradient elution 
0.30 9.90 0.10 ng/ml River sediment 
samples 
SPE NI APCI 50 (112) 
          
Purospher Star RP-18 
(125 x 2.0 mm, 5 µm) 
Methanol/water-Gradient 
elution 
0.20 17.13 26.00 pg/ml Natural and treated 
water 
Samples 
SPE NI ESI 10 (113) 
          
Symmetry C18 
(150 x 2.1 mm, 3 µm) 
Methanol/water-Gradient 
elution 
0.20 4.80 0.10 pg/ml Surface and waste 
water samples 
SPE NI ESI 20 (114) 
          
Shimpack GLC-CN 
(150 x 4.0 mm, 5µm) 
Acetonitrile/20 mM ammonium 
acetate (84/16, v/v)-Isocratic 
elution 
1.00 3.63 100.00 ng/ml Pharmaceutical 
formulations 
 NI APCI 10 (115) 
          
OASIS HLB SPE 
(20 x 2.1 mm) 
Acetonitrile/water (ammonium 
hydroxide 0.025%) (80/20, 
v/v)-Isocratic elution 
0.50  25.00 ng/ml Rat MD interstitial 
fluid samples 
SPE NI ESI 10 (116) 
          
Agilent Zorbax Eclipse  
XDB C18 
(150 x 4.6 mm, 5 µm) 
Acetonitrile/water (acetic acid 
0.1%)-Gradient elution 
1.00 19.90 150.00 ng/ml Homeopathic 
medical products 
filter (0.22 
µm) 
NI ESI 5 (117) 
          
Symmetry C18 
(150 x 2.1 mm, 5µm) 
Acetonitrile/water (formic acid 
0.1%)-Gradient elution 
0.25 10.67  Milk filter (0.22 
µm) 
PI ESI 40 (118) 
          
Purospher Star RP-18 
(125 x 2.0 mm, 5 µm) 
Methanol/water-Gradient 
elution 
0.20 14.71 6.00 ng/ml Wastewaters 
samples 
SPE NI ESI 10 (119) 
          
Phenomenex® Luna™ 
C8 
(50 x 4.6 mm, 3 µm) 
Acetonitrile/water (acetic acid 
0.1%) (65/35, v/v)-Isocratic 
elution 
1.00 1.10 0.47 ng/ml Human MD normal 
saline samples 
SPE NI APCI 40 (21) 
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3.3.4. Method development and validation 
3.3.4.1. UPLC conditions 
An Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm) stainless steel analytical column (Waters® 
Corporation, Milford, Massachusetts, USA) maintained at ambient temperature (22 ± 0.5°C) was used 
for the analysis. Methanol/water and acetonitrile/water mixtures were initially investigated for use as 
MP. A MP consisting of acetonitrile/methanol/water (60/20/20, v/v/v) was used at flow rate of 0.30 
ml/min and the eluate monitored at a UV wavelength of 255 nm. Ibuprofen, naproxen and 
flurbiprofen were investigated as possible candidates for use as an internal standard (IS). The 
chemical structures of these compounds are shown below in Figure 3.7. 
 
F
CH3H
CO2H
CH3
CH3
H CH3
CO2H
CH3O
H
CH3
CO2H
Flurbiprofen
C15H13FO2 MM 244.3 g/mol
pKa = 4.14
Ibuprofen Naproxen
C13H18O2 MM 206.3 g/mol
pKa = 4.41
C14H14O3 MM 230.3 g/mol
pKa = 4.40  
Figure 3.7. Chemical structures of ibuprofen, naproxen and flurbiprofen 
 
3.3.4.2. MS tuning 
The MS was tuned in NI ESI for the detection of precursor ions [M−H]¯ and the dissociation of these 
ions was induced. Methanolic solutions (100 ng/ml) of ketoprofen and IS were infused at 10 µl/min 
under software control, into the mass analyser. Nitrogen, used as a nebulising and desolvation gas, 
was provided by a high purity nitrogen generator NM 30LA 230VOC (Peak Scientific Instruments, 
Renfrewshire, Scotland, UK) and 2.55 x 10-4 mbar instrument grade (IG) argon (99.999%) (Afrox, 
Port Elizabeth, South Africa) was used as the collision gas. 
 
3.3.4.3. MS optimisation 
The most abundant ESI-MS/MS transition for each compound was monitored in the multiple reaction 
monitoring (MRM) mode to obtain the highest quantitative sensitivity. The choice of fragmentation 
products for each analyte based on the most intense signal and the optimisation of cone voltages, 
energy collisions and other instrument parameters were individually investigated for each compound 
in the combined flow-state mode through direct infusion of standard solutions in methanol (100 
ng/ml). This was performed by UPLC where the MP was pumped directly into the MS via a switching 
valve. The optimised MS settings employed for both ketoprofen and IS are reported in Table 3.7. 
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Table 3.7. Optimised MS instrument parameters for NI ESI 
Capillary voltage 3.50 kV 
Extractor voltage 2.00 V 
RF lens voltage 0.50 V 
Source temperature 120°C 
Desolvation temperature 500°C 
Cone gas flow rate 109 l/h 
Desolvation gas flow rate 509 l/h 
Multiplier voltage 650 V 
Gas cell Pirani pressure 2.55e-3 mbar 
 
3.3.4.4. Sample carryover 
Sample carryover was evaluated by sequential serial injections of a blank methanol solution, followed 
by the injection of a solution that contained a relatively high concentration (1 µg/ml) of ketoprofen 
and IS and subsequently by the injection of further blank solutions. Sample inserts and sample vials 
were also assessed for possible carryover or contamination. Approximately 30 µl of methanol was 
pipetted into randomly selected sample inserts from 3 different lots (Lot number 4170672080), then 
placed in sample vials, capped and analysed. 
 
3.3.4.5. Matrix effects 
Matrix effect on MS response was evaluated by comparing responses obtained by injecting standard 
solutions of KET (200 ng/ml) in normal saline and methanol onto the column for on-line MS/MS 
analysis. 
 
3.3.4.6. Sample preparation and extraction 
Calibration standards (0.5-500 µg/ml), 3 QC solutions of ketoprofen and IS (20 ng/ml) in normal 
saline solution were prepared. Equal volumes (30 µl) of ketoprofen and IS were pipetted into 
centrifuge tubes making a total volume of 60 µl. Samples were extracted ethyl acetate (200 µl) and the 
tubes were vortexed for 10 s prior to centrifugation at 12 000 rpm (8050 × g) for 5 min. 
Approximately 180 µl of the supernatant from each centrifuge tube was pipetted into sample inserts 
which were placed into amber sample vials and evaporated to dryness in a nitrogen evaporator under a 
slow stream of high purity nitrogen gas. Samples were then reconstituted with methanol (30 µl), the 
sample vials capped and vortexed for a further 10 s before analysis. Sample preparation and extraction 
were conducted at ambient temperature (22 ± 0.5°C) under filtered light. All validation procedures 
were based on extracts of the relevant standard solutions of ketoprofen in normal saline. 
 
3.3.4.7. Linearity 
Same as previously described in section 3.2.1a.3. 
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3.3.4.8. Accuracy and precision 
Same as previously described in section 3.2.1a.4. 
 
3.3.4.9. Limits of quantification and detection 
Same as previously described in section 3.2.1a.5. 
 
3.3.4.10. Recovery 
Same as previously described in section 3.2.1b.7. 
 
3.3.5. Results and discussion 
3.3.5.1. UPLC conditions 
To my knowledge, to-date there has not been any publications or reports which have focused on the 
development and validation of an analytical method using UPLC for the quantitative determination of 
ketoprofen for use in human DMD studies. Most published HPLC-MS/MS methods have reported the 
use of buffers or inclusion of acids or bases in the MP (21,110-112,115-118) for the analysis of 
ketoprofen, although there have been reports that used MPs without incorporating such reagents 
(113,114,119). Special caution is however, necessary when using a UPLC system which involves 
columns packed with sub-2 µm particles and equipment which utilises very narrow tubing and fittings 
coupled with very high operation pressures. 
 
Previously reported methods that used “non-buffer” MPs employed gradient as opposed to isocratic 
elution. Although gradient elution has been purported to provide an increase in sensitivity (106) by 
increasing peak capacity and decreasing peak widths (120), the use of gradient elution is more 
complex than isocratic procedures. Many more variables need to be controlled when using gradient 
elution compared to isocratic elution with gradient elution being a generally slower technique since 
the column has to be re-equilibrated after each run. Gradient elution is also associated with a higher 
incidence of the appearance “ghost” peaks and increased baseline noise (121). 
 
During the initial method development, the influence on RT, peak symmetry and detection sensitivity 
was investigated by varying the volume of the organic modifiers (methanol and/or acetonitrile) in the 
MP. Tailing of the leading edge of the ketoprofen peak was observed using a MP consisting of 
varying proportions of methanol/water (Figure 3.8). Sensitivity increased with increasing methanol 
content to 70% but was associated with broadening and deteriorating peak shapes. 
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Figure 3.8. UPLC PDA chromatogram of a ketoprofen standard (200 ng/ml) employing a MP 
composition of methanol/water (50/50, v/v) 
 
Conditions:- Column: Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm); Column temperature: 22 ± 0.5°C; MP: (methanol/water) (50/50, v/v); Flow rate: 0.3 
ml/min; Injection volume: 5 µl; Ionisation mode: NI ESI; MRM: 253.00 > 209.00; Capillary voltage: 3.5 kV; Source temperature: 120°C; Desolvation 
temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
 
When methanol was replaced with acetonitrile, sharp symmetrical peaks but with reduced sensitivity, 
was observed. (Figure 3.9). 
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Figure 3.9. UPLC PDA chromatogram of a ketoprofen standard (200 ng/ml) employing a MP 
composition of acetonitrile/water (50/50, v/v) 
 
Conditions:- Column: Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm); Column temperature: 22 ± 0.5°C; MP: (acetonitrile/water) (50/50) (v/v); Flow rate: 0.3 
ml/min; Injection volume: 5 µl; Ionisation mode: NI ESI; MRM: 253.00 > 209.00; Capillary voltage: 3.5 kV; Source temperature: 120°C; Desolvation 
temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
 
Initially, an isocratic MP consisting of acetonitrile/methanol/water (30/35/35, v/v/v) resulted in the 
requisite sensitivity, but the peaks were somewhat asymmetrical with tailing on the leading edge. As 
expected, increasing the composition of acetonitrile, while concurrently decreasing the composition of 
methanol (although maintaining an equal ratio of methanol/water), produced an acceptable 
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symmetrical peak (Figure 3.10) with a composition of acetonitrile/methanol/water (60/20/20, v/v/v) 
without compromising sensitivity. 
 
The associated increase or decrease in sensitivity with the use of methanol or acetonitrile respectively 
was in agreement with the published methods/reports presented in Table 3.6. The published methods 
that used an acetonitrile-based MP system incorporated either acid (formic acid or acetic acid) or base 
modifiers (ammonium hydroxide) to achieve high sensitivity (21,110-112,115-118), whereas reports 
that used methanol/water MPs were not only unmodified (i.e., no acids or bases), but produced the 
highest sensitivity (113,114,119), which suggested that methanol might have a significant role in the 
ionisation of ketoprofen in NI ESI. 
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Figure 3.10. ESI-MS/MS chromatogram of a ketoprofen standard (10 ng/ml) employing a MP 
composition of acetonitrile/methanol/water (60/20/20, v/v/v) 
 
Conditions:- Column: Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm); Column temperature: 22 ± 0.5°C; MP: (acetonitrile/methanol/water) (60/20/20, v/v/v); 
Flow rate: 0.3 ml/min; Injection volume: 5 µl; Ionisation mode: NI ESI; MRM: 253.00 > 209.00; Capillary voltage: 3.5 kV; Source temperature: 120°C; 
Desolvation temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
 
Another interesting observation reported in the published literature was the high sensitivity obtained 
with acid modifiers in NI ESI. It is commonly accepted that for weakly acidic analytes in NI mode, 
base modifiers facilitate analyte deprotonation resulting in increased sensitivity, whereas acid 
modifiers facilitate analyte protonation thereby resulting in decreased sensitivity. However, a number 
of weak carboxylic acids (e.g., acetic acid) have been reported to increase NI ESI response. The 
magnitude of this response however depends on the acid modifier, its concentration and the properties 
of the analyte (122). The decreased sensitivity with acetonitrile/water MPs has been related to the 
unavailability of protons from either water or analyte for chemical reduction, which is the principal 
electrochemical reaction that occurs in NI ESI at the MS spray tip. The protons are reduced to 
hydrogen gas and thus additional protons provided by an acid modifier will facilitate the reduction 
process by providing excess negative charges hence increasing sensitivity (122). Since methanol is a 
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weak acid and may also make protons available to facilitate the reduction process, the increased 
sensitivity with methanol/water MPs may then be explained by the reduction potential of methanol. 
 
The increased sensitivity observed with the combination of acetonitrile/methanol/water MP 
compositions confirmed that methanol indeed acted as an acid modifier, although increasing volumes 
of methanol resulted in asymmetric peaks. The decreased sensitivity observed when the methanol 
content was reduced by 5% or more, suggested that the volume of the acid modifier (methanol) 
insufficiently provided protons to the ketoprofen for chemical reduction. An isocratic composition of 
acetonitrile/methanol/water (60/20/20, v/v/v) at a flow rate of 0.30 ml/min was therefore deemed 
optimum for use as the MP. 
 
No significant improvement in peak sensitivity was observed with increased flow rates, although 
shorter elution times were observed. Moreover the higher flow rates resulted in undesirable higher 
column back-pressures. 
 
Flurbiprofen, naproxen and ibuprofen compounds which are structurally and physico-chemically 
similar to ketoprofen, were investigated as an IS in order to compensate for possible errors in the 
extraction procedure. However, the former 2 compounds co-eluted with ketoprofen at 1.15 and 1.21 
min respectively, whereas ibuprofen was well-resolved from ketoprofen and eluted at 1.49 min. The 
chosen flow rate of 0.3 ml/min was compatible with the use of ibuprofen as IS (Figure 3.11). 
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Figure 3.11. ESI-MS/MS TIC chromatogram of ketoprofen (50 ng/ml) and IS (50 ng/ml) 
 
Conditions:- Column: Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm); Column temperature: 22 ± 0.5°C; MP: (acetonitrile/methanol/water) (60/20/20, v/v/v); 
Flow rate: 0.3 ml/min; Injection volume: 5 µl; Ionisation mode: NI ESI; MRM: 253.00 > 209.00 and 205.00 > 161.00; Capillary voltage: 3.5 kV; Source 
temperature: 120°C; Desolvation temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
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3.3.5.2. MS tuning and optimisation 
NI ESI (110,111,113,114,116,117,119) was the commonly used ionisation mode presented in Table 
3.6. However, Daeseleire et al. (118) reported ketoprofen detection in PI ESI and conditions for NI 
APCI have also been reported (21,112,115). The most sensitive methods/reports were attained with 
the use of NI ESI, hence this mode was subsequently investigated. The TQD MS tuned spectra 
methanolic solutions (100 ng/ml) of ketoprofen (Figure 3.12) and IS (Figure 3.13) revealed 2 product 
ions in each spectrum. Under the tuned conditions, product ions were produced for ketoprofen (m/z 
209.01 and 196.99) and ibuprofen (m/z 160.82 and 158.87) with the most abundant fragmentations 
observed were m/z 209.01 and m/z 160.82, respectively. 
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Figure 3.12. Spectrum of precursor (m/z 252.94) and product (m/z 196.99; 209.01) ions of ketoprofen 
 
Conditions:- Ionisation mode: NI ESI; Flow state: Combined; Solvent: Methanol; Infusion flow rate: 10 µl/min; MP: (acetonitrile/methanol/water) (60/20/20, 
v/v/v); Flow rate: 0.3 ml/min; MRM: 253.00 > 209.00; Cone voltage: 15 V; Collision energy: 8 eV; Capillary voltage: 3.5 kV; Source temperature: 120°C; 
Desolvation temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
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Figure 3.13. Spectrum of precursor (m/z 204.92) and product (m/z 158.87; 160.82) ions of IS 
 
Conditions:- Ionisation mode: NI ESI; Flow state: Combined; Solvent: Methanol; Infusion flow rate: 10 µl/min; MP: (acetonitrile/methanol/water) (60/20/20, 
v/v/v); Flow rate: 0.3 ml/min; MRM: 205.00 > 161.00; Cone voltage: 21 V; Collision energy: 7 eV; Capillary voltage: 3.5 kV; Source temperature: 120°C; 
Desolvation temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
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As previously mentioned, since the principal electrochemical reaction in NI ESI is reduction or 
deprotonation of molecules [M], the detection of the precursor ions was achieved by the loss of the 
carboxylic acid proton [M−H] ¯. For both analytes, the product ions formed by the expulsion of CO2 
[M−H−CO2]¯ were the most intense ions and this was in agreement with published MS/MS methods 
(110-114). Secondary fragments [M−H−C2H3O2]¯ and [M−H−CO2−H]¯ corresponding to ketoprofen 
and IS respectively were too low to be used quantitatively. The MRM transitions used for the 
quantification of ketoprofen and IS are presented in Table 3.8. 
 
Table 3.8. MRM NI ESI-MS/MS conditions for ketoprofen and IS 
Analyte Collision 
(eV) 
Cone voltage  
(V) 
MRM transition 
(m/z) 
Precursor and product ions 
(m/z) 
      
Ketoprofen 8.0 15.0 253.00 > 209.00 252.94 
209.01 
196.99 
[M−H]  
[M−H−CO2]¯ 
[M−H−C2H3O2]¯ 
      
Ibuprofen 7.0 21.0 205.00 > 161.00 204.92 
160.94 
158.99 
[M−H]  
[M−H−CO2]¯ 
[M−H−CHO2]¯ 
 
3.3.5.3. Sample carryover 
The UPLC system is equipped with 2 needle wash solution reservoirs, one containing a “weak” 
needle wash using 200 µl/run and the other a “strong” needle wash using 600 µl/run which clean the 
needle and wash station before, during and after each injection cycle. This is an added measure to 
avoid carryover and trace contamination when using highly sensitive systems. During the initial 
stages of method development, small peaks were seen at the RTs of ketoprofen and IS following 
blank methanol injections. The composition of the strong wash solution was initially MP but 
subsequently replaced with (1500 µl/run) isopropanol alcohol/methanol/acetonitrile (40/35/35, v/v/v) 
while the weak wash solution (500 µl/run) was maintained with MP. This modification in the strong 
wash solution and change in the volumes of the washes resulted in the elimination of those peaks. 
  
Different ESI-MS/MS responses from 3 batches of sample inserts using the same blank methanol 
solution are presented in Figures 3.14-3.16 below. The analysis of Lot 1 sample inserts showed no 
interference in both ketoprofen and ibuprofen MRM transitions whereas blank injections from Lot 2 
inserts produced a response which interfered with the ibuprofen MRM transition and blank injections 
from Lot 3 inserts resulted in interference with both ketoprofen and ibuprofen MRM transitions. 
Although the sample vials were only used as supports for the sample inserts, methanol was added to 
those vials and injected into the system but no response was observed indicating contamination only 
from Lot 2 & 3 sample inserts. 
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Figure 3.14. ESI-MS/MS chromatogram illustrating analysis of blank methanol solution from sample 
inserts (Lot 1) 
 
Conditions:- Column: Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm); Column temperature: 22 ± 0.5°C; MP: (acetonitrile/methanol/water) (60/20/20, v/v/v); 
Flow rate: 0.3 ml/min; Injection volume: 5 µl; Ionisation mode: NI ESI; MRM: 253.00 > 209.00 and 205.00 > 161.00; Capillary voltage: 3.5 kV; Source 
temperature: 120°C; Desolvation temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
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Figure 3.15. ESI-MS/MS chromatogram illustrating analysis of blank methanol solution from sample 
inserts (Lot 2) 
 
Conditions:- Column: Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm); Column temperature: 22 ± 0.5°C; MP: (acetonitrile/methanol/water) (60/20/20, v/v/v); 
Flow rate: 0.3 ml/min; Injection volume: 5 µl; Ionisation mode: NI ESI; MRM: 253.00 > 209.00 and 205.00 > 161.00; Capillary voltage: 3.5 kV; Source 
temperature: 120°C; Desolvation temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
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Figure 3.16. ESI-MS/MS chromatogram illustrating analysis of blank methanol solution from sample 
inserts (Lot 3) 
 
Conditions:- Column: Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm); Column temperature: 22 ± 0.5°C; MP: (acetonitrile/methanol/water) (60/20/20, v/v/v); 
Flow rate: 0.3 ml/min; Injection volume: 5 µl; Ionisation mode: NI ESI; MRM: 253.00 > 209.00 and 205.00 > 161.00; Capillary voltage: 3.5 kV; Source 
temperature: 120°C; Desolvation temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
 
Examination of the sample vials and inserts revealed that LCMS grade sample vials were supplied 
(Microsep, Sandton, South Africa) with HPLC grade sample inserts from the same supplier. Attempts 
were made to clean the sample inserts by individually flushing with methanol but without success. 
Further attempts were made to remove the contamination by immersing the inserts in a solution of 
chromic acid for 12 h followed by removal from the acid and thorough flushing, first with double 
distilled deionised water and then with HPLC grade water and finally sonicated in methanol for 30 
min. This treatment was successful and all sample inserts were subsequently treated in this way prior 
to use. 
 
3.3.5.4. Matrix effects 
Signal suppression was observed when analytes in normal saline were introduced into the MS (Figure 
3.17) and, moreover, the column back-pressure increased with increasing number of normal saline 
sample injections. 
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Figure 3.17. ESI-MS/MS TIC chromatogram of normal saline solutions ketoprofen (200 ng/ml) 
 
Conditions:- Column: Acquity™ BEH C18 (100 x 2.1 mm i.d., 1.7 µm); Column temperature: 22 ± 0.5°C; MP: (acetonitrile/methanol/water) (50/25/25, v/v/v); 
Flow rate: 0.3 ml/min; Injection volume: 5 µl; Ionisation mode: NI ESI; MRM: 253.00 > 209.00 and 205.00 > 161.00; Capillary voltage: 3.5 kV; Source 
temperature: 120°C; Desolvation temperature: 500°C; Desolvation gas flow: 509 l/h; Cone gas flow: 109 l/h. 
 
DMD samples generally contain various salts and other components since the perfusates are often 
normal saline. Such solutions are not compatible for use with MS as these samples clog the ionisation 
source which creates high background noise (123). In an attempt to circumvent signal suppression and 
high column back-pressure, a gradient elution method was developed using MP [Solvent A] and water 
[Solvent B] to introduce a water wash before and after the elution of the ketoprofen and IS. If the 
increased column back-pressure was attributed to precipitation of normal saline, water was expected 
to dissolve and flush out the precipitate while the eluent was simultaneously diverted away from the 
ESI probe and the eluent later diverted towards the ESI probe for analyte detection. Although signal 
suppression was reduced, the column back-pressure still increased exponentially until the system 
maximum of 15 000 psi was reached following approximately 50 sample injections. This unexplained 
phenomenon re-occurred when the column was replaced on 2 further occasions and the problem was 
not resolved even when the columns were flushed with aqueous MP (0.3 ml/min) at elevated 
temperatures (50°C) over 2 days. 
 
Subsequently, sample clean-up techniques were considered and among the various available 
techniques such as SPE, silica filtration and attempts at “salting out” the analyte, a sample extraction 
method was developed. Various solvents such as n-hexane, diethyl ether and ethyl acetate were 
initially investigated as extraction solvents due their low polarity indices. Ethyl acetate and diethyl 
ether both gave similar extraction efficiencies but faster evaporation times were obtained with diethyl 
ether. Diethyl ether was however problematic for use as a routine extraction solvent due to its high 
volatility and low viscosity making it difficult to accurately dispense. Use of n-hexane resulted in low 
recoveries of both ketoprofen and IS. Re-extraction with n-hexane to improve the recovery was not 
Signal suppression caused by the 
introduction of normal saline at the ESI 
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Reduced ketoprofen response 
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considered since a single step extraction was preferred, hence ethyl acetate was selected. Methanol 
was used to re-constitute samples due to its ability to enhance the sensitivity in NI ESI and moreover, 
both ketoprofen and IS are highly soluble in methanol. 
 
3.3.5.5. Linearity 
The calibration plot for ketoprofen was linear with correlation coefficients better than 0.9999 
( 0.0427 0.0079y x= + ). 
 
3.3.5.6. Accuracy and precision 
The accuracy of the method (Table 3.9) was found to be in the range 99.97-104.67% with RSDs less 
than 2%. Data from the precision studies are presented in Table 3.10. 
 
Table 3.9. Accuracy studies of ketoprofen DMD samples (n=5) 
DMD samples Day Actual Conc 
(ng/ml)  
Calculated Conc 
(ng/ml)  
Accuracy 
(%) 
Inter-day 
RSD (%) 
      
 1 1.46 1.52 104.11 3.22 
Low 2 1.42 1.44 101.41 2.15 
 3 1.48 1.49 100.67 2.51 
      
 1 152.32 152.61 100.19 1.52 
Medium 2 148.15 148.32 100.11 1.15 
 3 154.41 154.43 100.01 1.05 
      
 1 453.84 453.71 99.97 0.57 
High 2 441.42 441.44 100.01 0.82 
 3 460.07 460.10 100.01 0.25 
 
Table 3.10. Precision studies of DMD samples 
DMD 
samples 
Day 1 
Mean Conc (ng/ml) ± 
SD (RSD%) (n=5) 
Day 2 
Mean Conc (ng/ml) ± 
SD (RSD %) (n=5) 
Day 3 
Mean Conc (ng/ml) ± 
SD (RSD %) (n=5) 
Inter-day 
Mean Conc (ng/ml) ± 
SD (RSD %) (n=3) 
     
Low 1.50 ± 0.02 (1.38) 1.52 ± 0.03 (1.96) 1.50 ± 0.02 (1.61) 1.51 ± 0.01 (0.67) 
     
Medium 152.50 ± 0.28 (0.18) 152.62 ± 0.06 (0.04) 152.68 ± 0.03 (0.02) 152.60 ± 0.09 (0.06) 
     
High 453.71 ± 0.01 (0.00) 453.71 ± 0.01 (0.00) 453.72 ± 0.01 (0.00) 453.71 ± 0.01 (0.00) 
 
3.3.5.7. Limits of quantification and detection 
The LOD and the LLOQ of ketoprofen were found to be 0.1 and 0.5 ng/ml respectively and the 
ULOQ set at 500 ng/ml. 
 
3.3.5.8. Recovery 
The recoveries of ketoprofen and ibuprofen are depicted in Table 3.11 below. 
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Table 3.11. Recovery studies of ketoprofen and ibuprofen in DMD samples 
DMD 
samples 
Actual 
Conc 
(ng/ml) 
Calculated 
Conc 
(ng/ml) 
% 
Recovery 
% 
RSD 
(n=5) 
     
Low 1.44 1.27 88.25 2.16 
Medium 150.23 131.72 87.68 1.68 
High 447.61 394.57 88.15 0.53 
     
Ibuprofen 20.23 19.25 95.16 0.86 
     
 
3.3.6. Conclusions 
An analytical method was developed and validated for the quantitative determination of ketoprofen in 
DMD samples. This method demonstrated that small injection sample volumes (5 µl) not only 
achieved rapid, accurate and reproducible analysis but attained the requisite sensitivity. Methanol 
acted as a weak acid which provided protons that promoted chemical reduction at the ESI spray tip 
thereby enhancing sensitivity. Optimisation of wash solution volumes was necessary which 
eliminated sample carryover and system contamination and sample inserts were identified as the 
source of interfering peaks which were subsequently cleaned with chromic acid. Ibuprofen was 
identified for use as IS which eluted at 1.49 min and the most abundant fragments in NI ESI for 
ketoprofen and ibuprofen were 209.01 m/z and 160.82 m/z respectively. Normal saline solutions 
caused considerable signal suppression hence sample extraction was necessary. Calibration plots were 
linear over the range, 0.5-500 ng/ml and the method was accurate (99.97-104.67%) and precise with 
% RSDs less than 2% and recovery of ketoprofen and ibuprofen from DMD samples were 
approximately 88 and 95% respectively. 
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CHAPTER FOUR 
MICRODIALYSIS 
 
4.1. Introduction 
MD is an in vivo sampling technique used to measure endogenous and/or exogenous compounds in 
extracellular spaces (124-126). The technique involves the implantation of a semi-permeable 
membrane into a specific region of a tissue or fluid-filled space (127). The technique was originally 
developed for use in neuroscience research which monitored rodent behaviour; subsequently the 
procedure was adapted for use in humans from which studies in many tissues have been reported 
(125,128). Although the MD technique was introduced for pharmacokinetic studies in animals in 
1972, it was not until 1987 that the first pharmacokinetic study in humans was published (129). 
Preliminary clinical studies that employed MD demonstrated the potential of this technique for the 
determination of drug concentrations in the interstitium of target tissues. This allowed relative 
changes of concentration-time profiles of drugs to be described. While MD is used in neuroscience 
and metabolic studies to detect metabolic disorders, its application in clinical pharmacokinetics 
provides information on concentration-time profiles of drugs in the interstitial fluid (ISF) (129). The 
development and refinement of this technique over the past 2 decades has led to its increased 
acceptance in studies of drug distribution, metabolism and pharmacodynamics (127,130). This 
technique has been successfully used for the continuous sampling of low molecular weight 
compounds including glucose, lactose, pyruvate, glycerol, glutamate and urea as well as 
pharmacologically active agents in extracellular fluid (ECF) (131). MD has also been used to 
investigate basic physiology and endogenous substances, as well as the pathophysiology of 
inflammation and allergic responses, pharmacokinetics and pharmacodynamics of topical and 
systemic drugs, skin barrier function and drug penetration into the skin (30,125,132,133). 
 
4.2. Theoretical principles 
The principle of the MD technique is based on the passive diffusion of compounds down a 
concentration gradient across the semi-permeable membrane of a dialysis fibre (134). This technique 
mimics the functions of a capillary blood vessel which permits the exchange of solutes in and out of 
the ECF (55,125,135,136). Movement of drug across the membrane is based on Fick’s Law of 
diffusion (137). Facilitated diffusion has also been reported with the use of certain types of perfusates 
(138). 
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4.2.1. Dermal microdialysis 
DMD is a relatively new application of MD which allows continuous monitoring of endogenous 
and/or exogenous solutes in the interstitial fluid (ISF) of dermal tissue with minimal tissue trauma 
(127). The technique involves the placement of small perfused membrane systems at given depths 
within the dermis (Figure 4.1).  
 
 
Figure 4.1. Membrane system implanted into the dermis. Modified from Benfeldt (55) 
 
When a topical formulation is applied onto the skin and perfusate is pumped through the implanted 
membrane system, drug molecules from the topical formulation present in the dermal ISF diffuse 
(driven by the concentration gradient) into the lumen of the membrane resulting in the presence of net 
gain of drug in the perfusion medium collected (dialysate). The dialysate is collected at timed 
intervals and the drug concentration in the dialysate can be determined quantitatively (127). 
 
Since the first report of DMD, this technique has been used successfully in human volunteers to: 
• study the endogenous cutaneous release of histamine in response to various topical stimuli 
and the penetration of a number of topically applied organic solvents (e.g., ethanol, 
isopropanol) (34) 
• measure inflammatory mediators in the dermis 
• study skin metabolism 
• determine the absorption of drugs or other agents in the skin. 
DMD has also been utilised as an alternate route of drug administration (139). 
 
Dermal tissue is an attractive sampling site since the tissue is relatively uniform with the ECF in 
constant equilibrium with the systemic circulation. Moreover, the implantation of the membrane 
system in the dermis involves a relatively simple procedure although training is imperative (134). 
DMD has been considered as a promising technique for the assessment of bioavailability and 
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bioequivalence of topical formulations and has garnered a lot of interest amongst research scientists, 
dermatologists and the pharmaceutical industry (39,40,125,140). The technique is minimally invasive 
and capable of producing concentration-time profiles sampled directly in the dermis, the target tissue, 
and is therefore suited to study the local and/or regional delivery of drugs following topical 
administration. Table 4.1 depicts the various applications of MD to study drug diffusion through 
human and animal skin. 
 
4.2.2. Membrane system design 
Membrane systems used for MD differ extensively in shape and type of material, depending on the 
tissue being sampled (126). Two types of membrane systems commonly used in skin studies are either 
linear or concentric. Linear systems are normally employed in DMD studies (55,140-142) whereas 
concentric systems are normally employed in deeper tissue studies involving the cutaneous and 
subcutaneous regions (20,21,86). The application of the different types of membrane systems 
employed in dermal, cutaneous and subcutaneous MD studies are reported in Table 4.1. 
 
Linear membrane systems are fabricated from hollow fibres (heamodialysis cylinders) often taken 
from artificial kidneys. These membrane system types are not generally commercially available but 
are simple to manufacture in the laboratory and are therefore inexpensive. Their use requires entry 
and exit punctures by means of a guide cannula through the skin when placed in the tissue. In 
contrast, commercially available concentric membrane systems require 1 entrance puncture (125). 
 
MD membrane systems are commonly referred to as “probes” which comprise the permeable 
membranes attached at either one or both ends to impermeable nylon or other inert materials such as 
Peek® tubing. Henceforth MD membrane systems will be referred to as MD probes. 
 
The membrane materials used in MD probes are available in different types and pore sizes (30). 
Common substances used as membrane materials are cellulose acetate, polyacrylonitrile, 
polycarbonate, AN-69 copolymer (which consists of polyacrylonitrile and methylsulphonate), 
polyethersulphone and cuprophan (regenerated cellulose membrane) (126,136,143-147). MD 
membranes are porous in nature which permits diffusion to occur through water spaces within the 
pores of the membrane (146). 
 
The physico-chemical properties of these membranes have been reported (148). Different membrane 
materials have different chemistries and will have an effect on recovery and/or delivery of drugs. The 
molecular weight cut-off (MWCO), a physical property commonly used by manufacturers of these 
membranes, describes the ability of a membrane to reject 90% of molecules with a specific molecular
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Table 4.1. Dermal, cutaneous and subcutaneous MD studies 
Drug Probe specification Perfusate Analytical method Species References 
      
17-β-Oestradiol Concentric, 20 kDa Ringer’s solution Radioimmuno assay Healthy human volunteers (149) 
      
5-Fluorouracil Linear, 9 kDa  HPLC-UV Fuzzy rats (150) 
      
Acyclovir 
 
Linear, 2 kDa Ringer’s solution HPLC-UV Healthy human volunteers (33) 
      
Betamethasone-17-
valerate 
Linear, 2 kDa Ringer’s solution or  
sterile PBS 
HPLC-UV Healthy human volunteers 
and Hairless rats 
(142) 
      
Diclofenac Concentric, 20 kDa Ringer’s solution HPLC-UV Healthy human volunteers (86) 
      
Ethanol Concentric, 20 kDa Ringer’s solution GC-Flame ionisation Healthy human volunteers (143) 
      
Fluconazole Linear, 5 kDa 0.01 M Na2HPO4/NaCl  
8.288 g/l 
HPLC-UV Hairless rats (151,152) 
      
Fluconazole Concentric, 20 kDa Normal saline HPLC-UV Healthy human volunteers (56) 
      
Flurbiprofen Linear, 5 kDa Isotonic PBS (pH 7.4) HPLC-Fluorescence Hairless rats (153) 
      
Fucidic acid Linear, 2 kDa Ringer’s solution HPLC-UV Healthy human volunteers 
and Hairless rats 
(142) 
      
Ibuprofen Concentric, 20 kDa Normal saline HPLC-MS/MS Healthy human volunteers (20) 
      
Ketoprofen Concentric, 20 kDa Normal saline HPLC-MS/MS Healthy human volunteers (21) 
      
Lidocaine Linear, 2 kDa  HPLC-MS/MS Healthy human volunteers (140,154) 
      
Nicotine Concentric, 20 kDa Ringer’s solution HPLC-UV Healthy human volunteers (149,155) 
      
Pencyclovir Linear, 2 kDa Ringer’s solution HPLC-UV Healthy human volunteers (33) 
      
Salicylic acid Linear, 2 kDa Sterile PBS (pH 7.4) HPLC-UV Healthy human volunteers 
(perturbed skin) 
(141) 
      
Salicylic 
compounds 
Linear, 5 kDa 0.05 M PBS (pH 7.4) HPLC-UV, Liquid scintillation Hairless rats (156,157) 
      
Toluene Linear, 3000 kDa Albumin solution (5%) GC-Electrochemical detector Hairless rats (158) 
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weight. The MWCO value however gives little insight into whether or not a particular membrane will 
result in a higher recovery for a particular drug except for larger drugs such as neuropeptides and 
hormones where their size is the major constraining factor. It is important to note that the MWCO 
value does not describe the porosity of the membrane, i.e., how many pores per unit area exist for 
drug diffusion to occur, nor does it predict possible drug interactions with the material of the 
membrane (146). However, even if the drug molar weight falls below the MWCO value, an 
acceptable extraction efficiency ( EE ) will only be attained with substances having a molar weight 
lower than approximately one-fourth of the value. 
 
Although most membrane pore sizes range from 6 to 3000 kDa, the majority of MD experiments have 
been conducted using membranes with MWCO of 20 kDa (30). Researchers make do with this 
MWCO size because it is small enough to permit diffusion of a large number of drugs, whilst 
restricting the entry of large endogenous compounds such as proteins and other macromolecules 
(123). A study of the effect of diffusion of acetaminophen, 3,4-dihydroxyphenylacetic acid, 5-
hydroxyindoleacetic acid and homovanillic acid by 3 different semi-permeable membranes has been 
reported (159). This study indicated that although in vitro differences were observed between 
membranes, no significant difference was observed in vivo. 
 
The choice of the membrane type is an essential element in searching for the optimal probe for a 
particular application. It is important that the membrane as well as any other component of the MD 
system does not interact with the drug since this would reduce the drug concentration in the dialysate 
(147). The membranes incorporated in linear probes are usually reinforced with stainless steel guide 
wire during manufacture for mechanical strength. Klimowicz et al. (160) reported no significant effect 
on the presence of an intra-luminal guide wire in linear MD probes during sampling. When 
manufacturing MD probes, the length and inner diameter of the outlet tubing should be considered to 
minimise mixing of the dialysate and to prevent hydrostatic pressure build-up across the probe 
membrane (147). 
 
4.2.3. Probe calibration 
MD probes should be checked to ensure reproducible recovery of the study drug to ensure 
minimisation of probe-to-probe differences. This is especially important for in-house fabricated MD 
probes (146,148). Calibration of probes may be performed in vitro and in vivo. For in vitro studies the 
surrounding medium is referred to as the periprobe whereas the surrounding medium for in vivo 
studies is the tissue ISF. 
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Since MD is a dynamic technique with the perfusate continuously being pumped through the probe, 
equilibrium is not established and dialysate concentrations represent only a fraction of actual 
concentrations in the tissue ISF or the periprobe (161,162). The fraction obtained is referred to as the 
extraction efficiency EE  which has to be determined in order to quantitatively relate drug dialysate 
concentrations in either the tissue or in the periprobe. However if the desired information from a MD 
experiment is the relative change in drug concentration, knowing the in vivo EE  is not absolutely 
necessary. However, knowledge of the in vitro EE  provides information on the reproducibility and 
patency of the MD probe being used (162). 
 
The general working definition of the EE  is shown in Equation 4.1. 
 
p d
p s
C CEE
C C
−= −  4.1. 
 
where dC  is the drug dialysate concentration, sC  is the known concentration in the external medium 
and pC  is the drug concentration in the perfusate. If the pC  equals zero, EE  is also referred to as the 
relative recovery ( )RR . The EE  describes the overall mass transport of drugs to and from the MD 
probe and is commonly used as a means to calibrate the device (145,163).  
 
Several approaches have been reported to determine the EE . The most frequently used calibration 
methods are: 
• the low-flow rate method 
• the no-net-flux (or zero-net-flux) method 
• the dynamic (or extended) no-net flux method  
• retrodialysis by drug or by calibrator methods (127). 
 
The assumption employed with the use of most calibration techniques such as no-net-flux, 
extrapolation to zero flow rate and the use of very slow perfusion rates, is that at very slow flow rates 
equilibrium is established across the dialysis membrane (162,164). These approaches are however 
time consuming and require long steady-state periods before any kinetic information is obtainable 
(144). 
 
The simplest approach to calibrate a MD probe is by using a standard solution. For in vitro calibration 
studies, since the drug concentration in the periprobe is known and the perfusate contains no drug 
(i.e., 0pC = ), diffusion of the drug occurs from the periprobe into and through the membrane and is 
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collected as dialysate. The EE obtained from a measure of drug concentration recovered in the 
dialysate ( )rEE  is described by Equation 4.2. rEE  is also referred to as recovery by gain. 
 
d
r
s
CEE
C
=  4.2. 
 
For in vivo and/or in vitro calibration studies, EE  may be determined by using a standard solution as 
perfusate with no drug in the tissue or periprobe ( 0sC = ). Diffusion occurs from the perfusate into the 
tissue or periprobe. The EE  in this instance, referred to as retrodialysis, recovery by delivery or 
recovery by loss ( )dEE , is defined as the ratio of loss of drug from the perfusate relative to the 
perfusate drug concentration as described in Equation 4.3. 
 
p d
d
p
C CEE
C
−=  4.3. 
 
Retrodialysis experiments can either be performed using the same drug as the calibrant (i.e., 
retrodialysis by drug; DRD ) or using a calibrant with physico-chemical properties identical to the 
drug and which does not interfere with the experiment (i.e., retrodialysis by calibrant; CRD ). It is 
worth noting that if CRD is the preferred option, the development of an analytical method to ensure 
that no peak interference between the drug under study and the calibrant exists which is very likely 
due to their similar physico-chemical properties. Although the advantage of performing DRD  
involves the use of the actual study drug for calibration, the DRD  cannot be performed during the MD 
experiment due to possible tissue contamination. It must be performed before and/or after the actual 
experiment. It is however assumed that the EE  does not change (162). 
 
Initially the rEE  determined in vitro was used as the EE  for experiments performed in vivo. This was 
mostly because the rEE  was easily determined in vitro while calibration in vivo was cumbersome. 
However, considerable evidence has shown that it is not reliable to use an EE  determined in vitro for 
the EE  in vivo. For most in vivo systems, transport through the tissue is the rate limiting step 
determining the EE  rather than transport through the dialysis membrane as is the case for most 
systems in vitro. It is advisable to perform in vitro experiments before human use, to check for in vitro 
adsorption to tubing, time delays in drug movement and to compare drug gain and loss (125,127). 
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4.2.3.1. Effect of temperature on EE  
The diffusion process is directly proportional to temperature and therefore the MD study should be 
conducted at a constant, preferably body temperature environment. The relationship with temperature 
is depicted in Equation 4.4 which describes the Stokes-Einstein equation: 
 
6
bk TD πησ=  4.4. 
 
where bk  is the Boltzmann constant (1.38 x 10-23 J/K), T is the absolute temperature, η  is the 
viscosity of the suspending fluid and σ  is the particle radius (126). 
 
4.2.3.2. Effect of perfusion flow rate on EE  
An influential factor on EE  is the flow rate. In general, low flow rates result in higher recoveries and 
high flow rates in lower recoveries, according to Equation 4.5 below. 
 
/(1 ) 100rA FEE e−= − ×  4.5. 
 
where r  is the mass transport coefficient, A  is the surface area of the MD membrane and F  is the 
flow rate. Low perfusion rates are often limited by the small sample volumes and the quantification 
limit of the analytical method. Therefore, it is not advisable to choose minimal flow rates as this 
would increase the sample collection interval and consequently result in worse temporal resolution 
(126,165). On the other hand, it is also not advisable to choose a flow rate of 10 µl/min or higher as 
this would significantly result in reduced EE . Increasing the flow rate might also be conducive to the 
process of ultrafiltration due to the built-up pressure in the dialysis tubing, resulting in a net flow out 
of the probe (126). 
 
EE  is also influenced by several solute and tissue-related factors. Among these factors are the 
physico-chemical properties of the solute of interest and its diffusion coefficient in the tissue, the ECF 
volume fraction and the processes for elimination from the tissue, including active transport 
mechanism (30,127). 
  
4.2.4. Assessment of probe depth in DMD 
The effect of probe depth on drug concentration has been a subject of debate. Whereas Benfeldt and 
Serup (141) found increased drug concentrations in the dialysate with superficial probe insertions, in 
contrast, Benfeldt et al. (166), Hegemann et al. (155), Müller et al. (86) and Simonsen et al. (156) 
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reported no such correlation. A probe depth of 0.6-1.0 mm is considered acceptable for DMD studies 
(125). The depth of the probe insertion, i.e., the distance of the dialysis membrane within the skin to 
the skin surface can be measured by ultrasound imaging using a frequency of 20 MHz. 
 
4.2.5. Composition of perfusates 
Perfusates used in MD experiments vary widely in composition and pH. Ideally the composition, ion 
strength, osmotic value and pH of the perfusate should be identical to those of the ECF of the dialysed 
tissue (147) i.e., the perfusate chosen should be physiologically compatible with the dermis 
environment (123). This prevents the excessive migration of molecules into or out of the periprobe 
fluid due to osmotic differences. The perfusate is normally perfused at low flow rates of 1-10 µl/min 
(161). Although isotonic perfusates have been employed during MD experiments, fluid losses in the 
dialysates have been reported (146). These losses have been attributed to sample evaporation during 
the experiment at ambient conditions. Table 4.1 shows a list of commonly used perfusates (Ringer’s 
solution, isotonic phosphate buffers (PBS) and normal saline) in skin MD, although a comprehensive 
list of different perfusates have been reported (147). Perfusates should be sterile when used in human 
and animal experiments. 
 
The choice of perfusate used in MD studies affects drug recovery. Studies have demonstrated that the 
inclusion of β-cyclodextrin in the perfusate as a complexing agent enhanced the relative recovery 
( RR ) of ibuprofen in an in vitro experiment by a factor of 1.5-2.0 (167). Cyclodextrins have also 
been used to prevent adsorption of hydrophobic materials onto plastics (145). Trickler and Miller 
(168) studied the inclusion of an osmotic agent, bovine serum albumin (BSA), to the perfusate which 
increased the recovery of macromolecules such as tumor necrosis factor and interleukin-1. In vivo 
studies have also demonstrated the use of Intralipid®, a fat emulsion used for nutritional disorders, and 
2-hydroxypropyl-β-cyclodextrin as perfusate for recovery enhancement of lipophilic, highly protein-
bound compounds (138). 
 
4.2.6. Invasiveness and trauma 
Although DMD has been described by authors as a minimally invasive technique 
(30,56,137,161,169), human subjects under study do experience some degree of reversible trauma 
caused by the insertion of probes (126). The trauma thus experienced is a result of inflammatory 
reactions that occur due to the implantation of the probes but the inflammation is reversible with little 
bleeding and oedema (123). 
  
Insertion of MD probes has been reported (143) to increase local blood flow which has been 
confirmed with laser Doppler perfusion imaging. The skin blood flow has been observed to return to 
 
4. Microdialysis 
 
Ralph Tettey-Amlalo - 58 -  Rhodes University, 2008 
normal by 60 min after insertion. Probe implantation also causes histamine release into the skin which 
returns to baseline after 40 min (143). 
 
Histological examinations have shown no cellular infiltration or tissue disruption around dialysis 
probes in the skin within the first 6-10 h (150). However to my knowledge, no DMD studies in human 
volunteers have been published that extended this time interval (30). Apart from the inflammatory 
response, the probe might also introduce bacteria therefore causing infection and purulent response. It 
is important to sterilise the probes before they are implanted in the dermis. Ethanol has been reported 
not to damage the dialysis membrane and ethanol solution (70%, v/v) has been used as sterilisation 
medium before implantation in human tissue (143). 
 
4.2.7. Analytical challenges 
A major limitation with the use of MD is the production of extremely small volumes (1-30 µl) of 
dialysate. Due to the low perfusion flow rates normally employed in MD, long sampling collection 
times may be necessary in order to collect sufficient volumes of dialysate for reliable quantification 
(170). Volumes deemed as sufficient will be dictated by the minimum volume required by the 
analytical instrumentation required for reproducible analysis. The generating of more sample volume 
by increasing the perfusion rate, thereby decreasing the sample collection interval, results in sample 
dilution. Therefore, an analytical method that can either make use of small sample volumes collected 
during the MD process, or be of sufficient sensitivity to measure the drug concentration in the 
dialysate i.e., the lower quantification limit (LLOQ) of the analytical method, is essential (126). 
Moreover, the temporal resolution is determined by a combination of perfusion rate through the MD 
probe and sample volume requirement of the analytical technique (151,170). Commonly used 
analytical techniques employed in DMD studies are reported in Table 4.1 above. 
 
4.2.8. Advantages and limitations 
DMD has several advantages for in vivo sampling of drugs. No endogenous fluid is removed, so 
continuous sampling can be performed with minimal disruption of the physiological system (123). 
This technique is also valuable in patients with minimal blood supply such as children or neonates 
(126). Although minimally invasive, the procedure is well tolerated by subjects and dermal 
implantation of the probes may be achieved without the use of drug anaesthesia (171). The probe can 
be implanted directly into the tissue of interest and since the probe collects only free fraction of the 
drug, the therapeutically active portion of the dose can be monitored (165). 
 
Provided that the perfusate used is simple and the type of the analytical method employed for the 
analysis of samples, the MD technique eliminates the need for complex, elaborate and time-
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consuming sample preparation which is normally the case with plasma samples (126,147,161). The 
membrane can also act as an effective enzyme inhibitor because it excludes enzymes that could cause 
degradation of the drug especially during sample storage (123). 
 
DMD may also address the issue of bioequivalence of topical formulations intended for local and/or 
regional delivery as acknowledged at a FDA workshop (39,40). Since more than 1 probe can be 
inserted in a subject, this reduces the number of subjects needed for pharmacokinetic investigations 
(130,147). Drug metabolism in tissues can be studied locally (171). The method can be used to 
evaluate drug permeation across both normal and diseased skin. MD may also have the potential to 
quantify a biomarker, or concentration of another surrogate measure, for therapeutic activity. 
Concomitant pharmacokinetic and pharmacodynamic evaluations are therefore possible (28). Finally 
MD can be performed in almost any organ or tissue of the body (i.e., brain, blood, liver, muscle, heart, 
subcutaneous tissue, etc.) (168). 
 
The MD technique has a few main limitations. As previously noted, the small sample volumes 
coupled with the extremely low drug concentrations, result in the necessity for very sensitive 
analytical methods (138). Lipophilic compounds adsorb onto the polymeric materials that are used in 
the manufacture of MD probes as well as the inlet and outlet tubing (145,164). Müller et al. (149) 
observed that 17-β-Oestradiol, even with the addition of albumin to the perfusion medium, was shown 
to be dialysable only in small amounts in vitro, whereas no detectable 17-β-Oestradiol concentration 
was obtained in vivo. Benfeldt and Groth (142) also reported a similar observation when an attempt to 
measure dermal concentrations of betametasone-17-valerate after topical drug administration resulted 
in no in vivo concentrations. 
 
Many pharmaceutically active compounds demonstrate substantial in vivo dermal protein binding. 
Therefore the actual recovery of total drug concentration at the site of interest within the skin in an in 
vivo MD study can be well below 1%. This limitation may be overcome with high doses or 
particularly sensitive analytical techniques. However, this overall poor recovery at therapeutic 
concentrations has limited the routine application of MD in some areas of research (138). 
 
Another limitation seems to be the high inter- and intra-individual variability associated with the 
recovery of exogenous substances. The variability has been reported (30) not to be caused by the MD 
technique itself, but due to variations in the dermal concentration after the penetration of an 
exogenous compound. However some aspects of the MD clinical methodology may contribute 
towards the variability. One of such aspects is the difficulty in the standardisation of a dose 
application procedure. 
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Finally, the MD technique requires training of the clinical investigators particularly with respect to the 
fabrication of the MD probes and the probe implantation procedure. 
 
A summary of the advantages and limitation of DMD sampling is presented in Table 4.2. 
 
Table 4.2. Advantages and limitations of DMD sampling (127) 
Advantages Limitations 
  
Highly dynamic continuous sampling Training of skills required 
High-resolution real-time sampling • Insertion of probes 
Both drug and metabolites in 1 sample • Probe manufacture 
Minimally invasive Sensitive analysis needed 
Multiple sites in 1 subject • Drug-specific problems 
Sampling and/or delivery via the probe • Lipophilic drugs 
Purified samples (protein free) • Highly protein-bound drugs 
Highly reproducible Absolute tissue levels more difficult to estimate 
Simultaneous use of auxiliary techniques Recovery dependent on tissue and time 
 
4.2.9. Dermatological application 
The application of topical formulations intended for local and/or regional activity is an attractive way 
of attaining high dermal concentrations of drug without significant systemic activity (Chapter 1; 
Section 1.2) but as previously mentioned it is often not clear whether adequate drug concentrations 
are reached at the site of action within the skin. Moreover there are currently no in vivo methods 
available for the direct characterisation of drugs applied topically for a local and/or regional effect. 
DMD provides the opportunity to address this problem due to its minimally invasive nature and its 
ability to generate concentration-time profiles at a target site with good time resolution provided a 
sufficiently sensitive analytical method is available (172). DMD may also be used to establish in vivo 
formulation performance with the possibility of optimising doses of topical formulations to produce 
minimum effective concentrations at the site of interest within the skin (127,148). 
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4.3. Validation of DMD probes 
4.3.1. Methods 
4.3.1.1. Reagents, chemicals and materials 
Ketoprofen (K1751) was purchased from Sigma-Aldrich (Atlasville, South Africa). 
 
Haemophan® fibre dialyser Alwall GFS Plus 12 (208 µm i.d., 216 µm o.d., 2 kDa MWCO) (Gambro, 
Hechingen GmBH, Germany), acetone UL (Ultrafine Ltd., Finchley, UK), stainless steel (0.10 mm 
o.d.) guide wire (At Sandvik Benelux Steel, Leuven, Belgium), Portex® non sterile autoclavable (0.50 
mm i.d., 0.63 mm o.d.) nylon tubing and Loctite® Super glue gel (Scientific Laboratories Supplies 
Ltd., Nottingham, UK) were used for manufacture of linear MD probes. 
 
Sterile normal saline (sodium chloride 0.9%, m/v) (Bodene (Pty) Ltd., Port Elizabeth, South Africa), 
ethanol (96%, v/v) solution (MERCK, Wadeville, South Africa), stainless steel (3 mm o.d., 0.0006 
sphericity) 440C metal balls (Small Parts, Inc., Miramar, Florida, USA), an adhesive sealant 
SewSimple™ (Bostik Findley Ltd., Swords, Dublin, Ireland), sample inserts (300 µl) with pre-installed 
plastic springs and amber (9 mm, screw top, 12 x 32 mm) sample vials (Waters® Corporation, 
Milford, Massachusetts, USA) and Terumo® 10 ml plastic syringes (Terumo Europe, Leuven, 
Belgium) were used during the MD study. 
 
4.3.1.2. Equipment 
Perfusion was performed with MD CMA Model 400 syringe pump systems (Chromatography 
Sciences Company, Quebec, Canada). Exmire microsyringes (2.5 ml) were purchased from Aurora 
Borealis Control BV (Schoonebeek, The Netherlands). Blue tubing adapters were purchased from 
CMA MD AB (Stockholm, Sweden). A shaker was purchased from The Chemical Rubber Company 
(Cleveland, Ohio, USA). 
 
A closed chamber MD cell (Figure 4.2) fabricated from a slab of perspex (7 x 4 x 4 cm) was used. 
The MD cell comprised 3 components, 2 identical inlet and outlet blocks (1 x 4 x 4 cm) and the main 
block (5 x 4 x 4 cm) which accommodates an enclosed circular chamber (5 x 1 cm i.d., 5 ml capacity) 
into which the periprobe solution was filled. Both inner and outer blocks had a minute opening in the 
centre through which the linear MD probe was introduced. Inlet and outlet tubes were connected to 
the periprobe chamber to permit filling and ultimately facilitate cleaning. Four holes were bored into 
each block which accommodated 4 bolts that secured the integrity of the cell. Leakages were 
prevented from the chamber by incorporating o-rings at each end. 
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Figure 4.2. MD cell for in vitro applications 
 
4.3.1.3. Preparation of linear MD probes 
Two lengths (30 cm each) of Portex® nylon tubes were glued, one to each end of a pre-cut length of a 
dialysis membrane fibre and left to dry for a minimum of 2 h. Normally, for a 3 cm active membrane 
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window, a 5 cm length of membrane fibre is used. Lengths (7 cm) of stainless steel wire for use as a 
guide were degreased by treatment with acetone and each fibre was carefully threaded with the guide 
wire. The Portex® tubing, membrane and guide wire thus constitute the probe. Preliminary leak tests 
were performed with double-distilled water and a blue CMA tubing connector, previously soaked in 
ethanol was attached to the inlet nylon tubing of the probe. All probes were prepared within 24 h prior 
to use. A schematic illustration with the specifications as per protocol is presented in Figure 4.3 
below. 
 
 
Figure 4.3. Linear MD probe for in vitro applications 
 
4.3.1.4. MD setup 
The probe (Figure 4.3) was inserted into the MD cell (Figure 4.2) as previously described. A stainless 
steel ball (3 mm o.d.) was placed in the periprobe chamber and the cell securely assembled. An 
adhesive sealant, SewSimple™, was used to seal both ends (probe entry and exit holes) of the MD cell. 
The periprobe chamber was completely filled with a relevant solution through the inlet tube using a 
plastic syringe and the cell assembly was then placed on a shaker. The blue tubing adapter at the end 
of the inlet probe tubing was attached to a microsyringe which was housed in the MD precision pump. 
The outlet end of the probe was placed into a pre-weighed sample insert-vial setup which served as 
the dialysate collection vessel. The system was equilibrated by pumping the relevant perfusate for 30 
min prior to sample collection. Calibration was performed using 3 separate probes and 6 samples were 
collected from each probe using a pump flow rate to result in the collection of approximately 30 µl 
equivalent to 30 µg of dialysate per sample based on the specific gravity of water. 
 
4.3.1.5. Determination of extraction efficiency 
For recovery studies ( )rEE , the periprobe chamber was filled with a standard solution of ketoprofen 
and the linear MD probes were perfused with normal saline solution whereas for delivery studies 
( )dEE , the periprobe was filled with normal saline solution and the linear MD probes perfused with a 
standard solution of ketoprofen. 
 
Percent recovery of ketoprofen was calculated as the ratio of the dialysate concentration ( )dC  to the 
concentration of the standard solution ( )sC in the periprobe, (Equation 4.6) i.e., 
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(%) 100dr
s
CEE
C
= ×  4.6. 
 
Percent delivery of ketoprofen was calculated as the ratio of the decrease in perfusate concentration 
( )p dC C−  to the initial perfusate concentration ( )pC , (Equation 4.7) i.e.,  
 
(%) 100p dd
p
C CEE
C
−= ×  4.7. 
 
4.3.1.6. Investigation of parameters affecting rEE  and dEE  
4.3.1.6.1. Sampling time 
The recovery of ketoprofen from a standard solution (1 µg/ml) was monitored every 10 min from flow 
initiation at zero time to 240 min, hence no equilibration time was permitted. 
 
4.3.1.6.2. Dialysis membrane length 
The recovery of ketoprofen from a standard solution (1 µg/ml) using 3 different lengths of dialysis 
membrane (1, 3 and 4 cm) was determined for 3 probes. Dialysis membrane length dependency was 
investigated for ketoprofen with a pump perfusion rate maintained at 3 µl/min, sampling every 10 
min. 
 
4.3.1.6.3. Perfusion rate 
The recovery of ketoprofen from a standard solution (1 µg/ml) was investigated using different 
perfusion rates and 4 cm lengths of dialysis membrane. Perfusion flow rates of 1, 2, 3 and 5 µl/min 
necessitated sampling collection intervals of 30, 15, 10 and 6 min, respectively, in order to provide 30 
µl of dialysate which was measured gravimetrically. The system was equilibrated for 30 min prior to 
sample collection for each perfusion flow rate investigation. 
 
4.3.1.6.4. Drug binding 
To evaluate possible binding effects of ketoprofen onto any portion of the probe, the recovery of 
ketoprofen from a standard solution (1 µg/ml) was investigated. The periprobe chamber was left 
unfilled (air filled). 
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4.3.1.6.5. Drug concentration 
Recovery and delivery of ketoprofen from 3 standard solutions (1, 2 and 5 µg/ml) were investigated. 
Equations 4.6 ( )rEE and 4.7 ( )dEE  were used to calculate recovery and delivery, respectively and the 
results from each determination were then reconciled. 
 
4.3.1.6.6. Ethanol sterilisation 
To evaluate the effect of ethanol solution (70%, v/v), used as sterilisation fluid, on the recovery of 
ketoprofen, a standard solution (1 µg/ml) of ketoprofen was investigated using probes that had been 
treated with ethanol for 20 min and compared to untreated probes. 
 
The above studies (4.3.1.6.1, 4.3.1.6.4-4.3.1.6.6) were conducted with 4 cm lengths of dialysis 
membranes using a pump perfusion rate at 3 µl/min with sampling every 10 min. All experiments 
were conducted in triplicates with 6 samples collected from each probe with the exception of 10 
samples collected from the sampling time study (4.3.1.6.1). 
 
4.3.1.7. Sample analysis 
Ketoprofen concentrations in MD samples were determined by a validated HPLC-UV method 
described in Chapter 3; Section 3.2.1a. 
 
4.3.2. Results 
4.3.2.1. Sampling time 
The mean recovery of ketoprofen was only 7.62% after the first sample was collected and increased to 
34.58% in the next sample after which the recovery of ketoprofen was seen to stabilise to a value of 
approximately 64% (Table 4.3). 
 
Table 4.3. Effect of sampling (n=3) 
Sample No Sampling time 
(min) 
Mean recovery 
(%) 
   
1 10 07.62 
2 20 34.58 
3 30 63.74 
4 40 63.69 
5 50 63.64 
6 60 63.56 
7 70 63.83 
8 80 64.41 
9 90 64.40 
10 100 64.87 
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4.3.2.2. Dialysis membrane length 
The mean recovery of ketoprofen increased with increasing membrane length (Table 4.4).  
Table 4.4. Effect of dialysis membrane length (n=3) 
Sample No Mean recovery (%) 
 1 cm 3 cm 4 cm 
    
1 19.75 36.12 64.08 
2 19.48 36.48 64.25 
3 20.02 38.77 64.51 
4 19.75 38.06 63.99 
5 20.19 39.47 64.16 
6 19.75 39.29 63.56 
 
4.3.2.3. Perfusion rate 
Ketoprofen recovery decreased linearly with increasing perfusion rates (Table 4.5). 
 
Table 4.5. Effect of perfusion rate on recovery of ketoprofen (n=3) 
Sample No Mean recovery (%) 
 1 µl/min 2 µl/min 3 µl/min 5 µl/min 
     
1 93.40 84.70 65.80 43.33 
2 93.45 84.90 65.43 43.41 
3 93.59 84.84 65.97 43.04 
4 93.82 84.79 66.67 43.33 
5 94.78 84.86 66.45 43.46 
6 93.31 84.67 66.29 43.41 
 
4.3.2.4. Drug binding 
The delivery of ketoprofen perfused through linear MD probes with air in the periprobe is presented 
in Table 4.6.  
 
Table 4.6. Delivery in air (n=3) 
Sample No Mean delivery 
(%) 
  
1 94.62 
2 93.68 
3 95.03 
4 96.04 
5 93.78 
6 92.76 
  
Mean ± SD 94.32 ± 1.16 
 
4.3.2.5. Drug concentration 
The recovery of ketoprofen from 3 different concentrations was independent of concentration and the 
data are presented in Table 4.7. 
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Table 4.7. Recovery and delivery at different concentrations (n=3) 
Concentration 
(µg/ml) 
Recovery and delivery 
(%) 
  
1 67.50 ± 1.84 
2 65.75 ± 1.63 
5 69.20 ± 0.43 
  
Mean ± SD 67.48 ± 1.72 
RSD (%) 2.55 
 
4.3.2.6. Ethanol sterilisation 
No difference was obtained between ketoprofen recovery from probes pre-treated with the ethanol 
(70%, v/v) solution (66.21 ± 0.52%) and probes without the sterilisation procedure (65.32 ± 0.25%). 
 
4.3.3. Discussion 
Various factors which could affect the recovery of ketoprofen during DMD were investigated 
including effects of experimental parameters/operation and conditions. In addition, it is important to 
emphasise that some precautions are necessary when fabricating the probes and preparing the 
membrane systems for DMD. The choice of glue for use to connect the Portex® tubing to the 
membrane fibre is important in order to avoid the development of leaks; cyanoacrylate glues proved 
successful in this respect. Insertion of the stainless steel guide wires must ensure that tips of the wires 
do not pierce the membranes during the threading procedure. Furthermore, care must be taken to 
prevent sharp tips being formed on the wires during cutting, which can be avoided by cutting the wire 
at a 90° angle.  
 
Investigations of the effect of sampling times on ketoprofen recovery established the minimum time 
required to equilibrate the probes. Several reports have indicated that different equilibration times are 
required for different drug candidates (131,136,160). Although a gradual increase in recovery with 
increasing time was initially observed where the rate of recovery of ketoprofen was extremely low 
after pumping for 10 min at a constant rate, continuation of the perfusion resulted in the recovery 
reaching a stable value after 30 min. The initial diffusion rate of ketoprofen was low and then 
increased after the first sample (10 min) until the second sample (20 min) and then decreased with 
time resulting in a relatively constant recovery after 30 min. The initial low diffusion rate was 
attributed to the initial state of the DMD probes before the inception of the experiment. After the 
probes were fabricated, they were checked for leaks by forcing distilled water (~ 1 ml) via a manually 
operated syringe (10 ml) and the wet probes were subsequently stored in a sealed container prior to 
use. The presence of the residual water likely resulted in some dilution of the ketoprofen 
concentration, thereby influencing the initial recovery data from 10-30 min. Hence, using a perfusion 
rate of 3 µl/min, an equilibration time of 30 min was established for use in DMD studies at that 
particular flow rate. The use of lower perfusion rates thus will require longer equilibration times and 
 
4. Microdialysis 
 
Ralph Tettey-Amlalo - 68 -  Rhodes University, 2008 
vice versa. Although equilibrium was perceived to have occurred under the abovementioned 
experimental conditions, it is important to note that true equilibration probably never occurs since 
recovery never reaches 100%, although the use of certain types of β-cyclodextrins as perfusate have 
been reported to generate recovery greater than 100% (164). 
 
Increasing the length of the dialysis membrane (i.e. from 1 to 4 cm) resulted in an increase in 
ketoprofen recovery. This is in accordance with Fick’s law of diffusion where the rate of perfusion 
across a membrane is proportional to its area. Hence, the increased surface area associated with the 
use of longer dialysis membrane lengths would account for the higher recovery of ketoprofen. This 
trend has also been reported in published studies (136,173). The use of a 1 cm membrane length in 
DMD studies is thus not recommended since it will generate a low recovery of drug. Although a 4 cm 
membrane provided a relatively higher ketoprofen recovery, its use in DMD may be impractical since 
the volar aspect of the forearms of most volunteers, where probe implantation occurs, will generally 
not accommodate the use of membranes longer than 3 cm.  
 
The lower recovery obtained with increased perfusion rate was attributed to less contact time of 
ketoprofen in the periprobe solution with the perfusate. However, the use of lower perfusion rates will 
necessitate sample collection over longer time intervals in order to provide sufficient sample volumes 
required for analysis. 
 
The relatively high recovery of ketoprofen (94.32%) confirmed the lack of significant binding of 
ketoprofen to the probe by performing a recovery study in air within the periprobe chamber in the MD 
cell. Although ketoprofen is a hydrophobic drug (174), high recovery has been obtained in vitro which 
suggested that measurable recovery would be expected in vivo. 
 
Recovery of ketoprofen was found to be independent of drug concentration in the range of ketoprofen 
concentrations studied. Ethanol solution (70%, v/v) used as the sterilisation medium did not have any 
effect on the recovery of ketoprofen from the linear MD probes. Anderson et al. (143) also reported 
that ethanol does not damage the membrane and therefore it can be safely used as a sterilisation 
medium prior to in vivo use. 
 
4.3.4. Conclusions 
An equilibration period after probe fabrication was essential to get reproducible recovery. These 
studies also provided useful data to facilitate the construction of appropriate probes for use in DMD 
studies to be conducted in human subjects. The effect of membrane length indicated that although a 
longer membrane length would provide a higher ketoprofen recovery, a membrane length of 3 cm as 
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opposed to 4 cm will be more practical in order to be accommodated on the volar aspect of human 
forearms. Data were also generated to establish the optimum perfusion rate which will be appropriate 
for use in DMD studies in human subjects. The decision is dependent on the sample collection volume 
and concentration of ketoprofen expected in the dialysate. If the perfusion rate is set too low, longer 
sampling intervals will be necessary to provide sufficient volume for analysis. However, on the other 
hand, if the pump flow rate is set too high, drug concentrations in the dialysate samples may be too 
low for quantitative analysis and the drug may even be undetectable. These preliminary investigations 
provided valuable information prior to undertaking DMD studies intended to be performed in human 
subjects. 
 
4.4a. Human study I (HS I): Preliminary investigations 
4.4a.1. Methods 
The reagents, chemicals, materials and equipment used were the same as described under 4.3.1.1 
except for the following: 
 
4.4a.1.1. Reagents, chemical and materials 
Medisan® mild liquid soap (Designer Group, Edenvale, South Africa), polyethylene (1.5 ml) 
centrifuge tubes (Eppendorf®, Hamburg, Germany), Leukoband® S (BSN medical (Pty) Ltd., 
Pinetown, South Africa), Medac ice packs (Medac (Pty) Ltd., Cape Town, South Africa), sterile latex 
surgical gloves (Neogloves, Middlesex, UK), Biocort® (hydrocortisone acetate 0.01%, m/m) cream 
(Adcock Ingram Ltd., Bryanston, South Africa), disposable (21G x 1½" ) needles (Korea Vaccine 
Ltd., Seoul, Korea), adhesive labels (Redfern Labels, Cape Town, South Africa), Micropore™ 1530 
(12 mm x 10 m) dressing tape (3M, Isando, South Africa) and isopropyl alcohol (70%, v/v) swabs 
(Tyco Healthcare (Pty) Ltd., Midrand, South Africa) were used. 
 
4.4a.1.2. Equipment 
A Dermascan C® (Cortex Technologies, Hadsund, Denmark) ultrasound scanning device was used to 
measure probe depth in the skin. The instrument comprised 3 main parts: the C-probe, the elaboration 
and visualisation system and the memorising and data-storing system. The C-probe was surrounded 
with water and sealed at the point of contact with an ultra-thin plastic diaphragm. 
 
4.4a.1.3. Formulations 
Fastum® Gel (reference formulation; R) containing ketoprofen 2.5%, m/m (Adcock Ingram Ltd., 
Bryanston, South Africa) and Ketum® Gel (test formulation; T) containing ketoprofen 2.5%, m/m 
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(Menarini (Pty) Ltd., Rungis Cedex, France) were purchased from local pharmacies in Grahamstown, 
South Africa and Montpellier, France respectively. 
 
4.4a.1.4. Ethics 
The study protocol (Appendix I) was approved by the Rhodes University Ethical Standards 
Committee (RUESC, Grahamstown, South Africa) and performed in accordance with the 
recommendation of the guidelines as set out in the Declaration of Helsinki (1964) and its amendments 
(175), and carried out in compliance with the guidelines on the conduct of clinical trials in South 
Africa as set out by the Medical Control Council (MCC) South Africa in concurrence with the South 
African Department of Health (176). 
 
4.4a.1.5. Subjects 
The study population comprised 10 (5 females and 5 males) healthy black subjects with ages ranging 
from 19-26 yr and body weights ranging from 52.4-91.6 kg. Subjects who met the inclusion and 
exclusion criteria (Table 4.8) and successfully completed the pre-experimental medical assessment 
were enrolled in the study. All subjects gave written informed consent. 
 
Table 4.8. Inclusion/exclusion criteria used in recruiting subjects 
Inclusion criteria Exclusion criteria 
  
Female subjects who were using reliable 
contraception or abstaining 
Female subjects who were breast feeding 
Subjects who were aged between 18 and 
50 years 
Female subjects who were contemplating becoming pregnant in the time 
immediately following the study 
Subjects who were in general good health Female subjects who were pregnant 
Subjects who were available for the 
entire study period 
Subjects who had a known allergy/hypersensitivity to ketoprofen or any NSAID 
including aspirin 
 Subjects who had any history of drug or alcohol abuse 
 Subjects who had any mental deficiency or handicap 
 Subjects who had hairy ventral forearm surfaces and/or abrasions on the 
underside of their forearms 
 Subjects who had engaged in any sun-tanning or taken any sunny vacations 
within the last month 
 Subjects who had participated in another NSAID DMD or tape stripping study 
within 2 months of the study date 
 Subjects who had used any NSAIDs within the last 3 months 
 Subjects who suffered from any allergic conditions (hayfever, allergic rashes, 
asthma or childhood eczema) 
 Subjects who suffered from any skin disorder such as psoriasis, eczema or other 
relevant skin disorder 
 Subjects who took regular medicine or tablets or used any creams within the 
last week (contraceptive pills excluded) 
 Subjects who tested positive for HIV and Hepatitis B 
 Subjects with a history of any neurological, kidney or liver disorders 
 
 
4. Microdialysis 
 
Ralph Tettey-Amlalo - 71 -  Rhodes University, 2008 
4.4a.1.6. Preparation of linear DMD probes 
The DMD probes were prepared as previously described in section 4.3.1.3 except that an 8 cm length 
of fibre was used with Portex® tubing glued at only at 1 end (Figure 4.4). 
 
 
Figure 4.4. Linear DMD probe for in vivo applications 
 
4.4a.1.7. Study design 
Subjects were admitted into the clinic (Faculty of Pharmacy, Rhodes University, Grahamstown, South 
Africa) and remained there for the duration of the study. The forearms of each subject were washed 
with mild liquid soap and the subjects assumed a supine position with their arms placed on an armrest. 
 
The wrists of the subjects were loosely restrained, to facilitate implantation of 4 probes into the 
dermis on the volar aspect of the forearm in each subject under the specific gel application sites 
(Figure 4.5) as indicated by the shaded areas.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. DMD study design (HS I) 
 
Experimental conditions: 4 probe insertions, 4 application sites, 1 probe per site, probes were 3 cm apart, probes covered approximately 2 quarters of the volar 
aspect of the forearm of each subject 
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Ice packs were placed directly over the area demarcated for the probes for approximately 5 min prior 
to the insertion of the cannulae in order to induce a local anaesthetic effect. The DMD probes, which 
had previously been sterilised in ethanol (70%, v/v), were introduced through guide cannulae which 
were subsequently withdrawn, leaving the DMD probes implanted within the dermis (Figure 4.6). The 
insertions were guided by entry and exit sites marked on the forearms, ensuring that a length of 30 
mm of the membrane portion of the MD probe was intra-dermally placed in each case. 
 
 
Figure 4.6. Implantation of linear DMD probes in the skin 
A: Guide cannula insertion at the entry point marked on the skin. B: Guide cannula pierced through the exit point and MD probes inserted into the guide 
cannula. C: Guide cannula withdrawal leaving the MD probe within the dermis. 
 
Pre-cut templates (25 x 45 mm with a fenestration measuring 10 x 30 mm in the centre) prepared from 
adhesive labels (Redfern Labels, Cape Town, South Africa), were positioned over the probes in the 
skin, covering the entry and exit sites as seen in Figure 4.5.  
 
Following a successful probe leak test, both entry and exit sites were sealed and perfusion of the 
probes was initiated at 0.5 µl/min (15 min) and subsequently increased to 1.25 µl/min (45 min) to 
ensure sufficient baseline equilibration (60 min) in order for the insertion trauma to subside (125). 
The inlet tubes were secured with Micropore™ 1530 dressing tape and blank samples were collected 
prior to product application. The ketoprofen formulation (30 mg) was dispensed in a randomised 
sequence according to Table 4.9 from pre-loaded Combitips® (0.5 ml) in a HandyStep® dispenser 
(Eppendorf®, Hamburg, Germany) and a glass rod was used to spread the formulation within the 
application area. In order to monitor any possible loss in the dose as a result of the spreading pre-
weighed glass rods were used to determine the amount removed by the glass rods. 
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Table 4.9. Randomisation sequence of applied formulations 
 Randomisation sequence 
Subject Probe 1 Probe 2 Probe 3 Probe 4 
     
1 T T R R 
2 T R T R 
3 T R R T 
4 R T T R 
5 R T R T 
6 R R T T 
7 T T R R 
8 T R T R 
9 T R R T 
10 R T T R 
 
4.4a.1.8. Sample collection and preparation 
The samples were collected every 0.5 h for 5 h into centrifuge tubes. A total of 44 samples per subject 
were collected (4 probes x 10 samples & 4 blanks) and the samples were stored in the dark at 4°C and 
analysed within 24 h. 
 
4.4a.1.9. Probe depth measurement 
At the end of the sampling period, the probes were disconnected from the pump and the templates 
removed from the application sites. Excess formulation was removed using isopropyl alcohol swabs 
and the depth of the probes measured in triplicate by ultrasound scanning at 20 MHz. The probe depth 
was measured, in the A-mode scan, as the vertical distance between the epidermis entrance echo and 
the echo of the DMD membrane (internal stabilising steel wire). At the end of the study, the probes 
were withdrawn from the skin, the sites dressed with alcohol swabs, and each subject was provided 
with a tube of hydrocortisone cream to apply twice daily for 2 weeks as a prophylactic measure 
against post-traumatic skin inflammation. Post-experimental medical follow-up examination of the 
skin sites were performed weekly for 4 weeks. 
 
4.4a.1.10. Dialysate analysis 
Ketoprofen concentrations in the DMD samples were determined with a validated UPLC-ESI-MS/MS 
analytical method described in Chapter 3; Section 3.3. 
 
4.4a.1.11. Pharmacokinetic evaluation 
The concentration-time profiles were generated by plotting ketoprofen concentrations at the mid-point 
between sample collections times and calculating the AUC from 0-5 h. 
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4.4a.1.12. Bioequivalence assessment 
Pharmacokinetic and statistical parameters to determine bioequivalence were calculated with a 
statistical package SAS® (SAS Institute Inc., Cary, North Carolina, USA). AUC0-5 was tested for 
comparative bioavailability using a 2 one-sided test procedure and bioequivalence was concluded if 
the 90% CI of the log transformed AUC0-5 data for pairs of test/reference application areas were 
within the acceptance range of 80-125%. 
 
4.4a.2. Results 
4.4a.2.1. Clinical observations 
The insertion of the guide cannulae with the subsequent implantation of the probes was acceptable for 
all subjects. Ice was well tolerated and efficient as an anaesthetic with no subjects finding the 
insertion procedure painful as such. All subjects completed the study and no disruptions to the study 
were recorded. No local adverse reactions from the formulations were reported during the study and 
the weekly post-trial medical examination showed no signs of residual inflammation, scarring or 
keloid formation at the sites of probe implantation. Six incidences of failed probes out of 44 probes 
were reported, however these probes were replaced before sampling occurred and did not affect the 
results obtained. 
 
4.4a.2.2. Dose assessment 
The mean actual dose on both the test and reference application sites for all subjects were 16.55 ± 
5.37 mg (ranged from 3.11-26.98 mg; %RSD = 32%) (n=20) and 17.39 ± 5.35 mg (ranged from 2.67-
28.68 mg; %RSD = 33%) (n=20) respectively (Table 4.10), calculated by re-weighing the glass rods 
after spreading. These results indicate that approximately 60% of the dose was removed by the 
spreading procedure. 
 
Table 4.10. Actual mean doses remaining on test and reference sites (n=20) 
 Dose rubbed (mg) (mean ± SD) 
   
Subject  Test sites Reference sites 
   
1 14.10 ± 5.23 12.71 ± 2.28 
2 17.55 ± 2.62 14.58 ± 1.66 
3 19.40 ± 2.12 17.16 ± 0.34 
4 18.90 ± 1.27 18.79 ± 0.55 
5 21.95 ± 0.49 19.93 ± 0.32 
6 15.20 ± 3.68 17.06 ± 0.19 
7 16.95 ± 1.77 10.69 ± 3.94 
8 22.70 ± 1.98 21.59 ± 0.55 
9 13.40 ± 6.08 17.53 ± 3.08 
10 22.25 ± 0.78 21.85 ± 0.64 
   
Mean 16.55 ± 5.37 17.39 ± 5.35 
RSD (%) 32 33 
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4.4a.2.3. Probe depth measurements 
A white hyper-reflecting dot confirming the presence of the stainless steel guide wire within the 
membrane was visualised in situ during the ultrasound scanning. The mean probe depths at the test 
and reference application sites for all subjects were 0.75 ± 0.076 mm (ranged from 0.62-0.88 mm; 
%RSD = 10%) (n=20) and 0.75 ± 0.088 mm (ranged from 0.62-0.89 mm; %RSD = 12%) (n=20) 
respectively (Table 4.11). The precision of probe insertions was extremely consistent and no 
correlation was observed between AUC0-5 and probe depth for all subjects. 
 
Table 4.11. Mean probe depth measurements (HS I) (n=4) 
 Probe depth (mm) (mean ± SD) 
   
Subject Test sites Reference sites 
   
1 0.81 ± 0.10 0.78 ± 0.01 
2 0.69 ± 0.08 0.70 ± 0.03 
3 0.80 ± 0.07 0.86 ± 0.06 
4 0.73 ± 0.04 0.63 ± 0.01 
5 0.84 ± 0.03 0.86 ± 0.01 
6 0.72 ± 0.05 0.65 ± 0.01 
7 0.84 ± 0.04 0.86 ± 0.02 
8 0.72 ± 0.07 0.77 ± 0.02 
9 0.67 ± 0.04 0.67 ± 0.03 
10 0.69 ± 0.02 0.75 ± 0.02 
   
Mean 0.75 ± 0.09 0.75 ± 0.08 
RSD (%) 12 10 
 
4.4a.2.4. Pharmacokinetic evaluation 
Mean dialysate concentration-time (a) and semi log-time (b) profiles (± SD) of both the test and 
reference formulations are illustrated in Figure 4.7. 
 
 
Figure 4.7. Mean dialysate concentration (a) and semi-log (b) time profiles (± SD) HS I (n=10) 
Experimental: 4 probe insertions, 4 application sites, 1 probe per site, probes were 3 cm apart, probes covered approximately 2 quarters of the volar aspect of 
the forearm of each subject, 10 subjects, Test: Ketum® gel, Reference: Fastum® gel 
 
The raw data and individual subject concentration-time profiles are located in Appendix II (DMD: HS 
I). Although most of the concentrations obtained were measurable, some concentrations were between 
the LOD and LLOQ. The AUC0-5 obtained for both the test and reference formulations were 54.99 ± 
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52.31 ngh/ml (ranged from 1.76-139.56 ngh/ml; RSD = 105.12%) and 38.79 ± 51.32 ngh/ml (ranged 
from 1.52-174.57 ngh/ml; RSD = 75.57%) respectively. 
 
4.4a.2.5. Bioequivalence assessment 
The bioequivalence assessment of the test and reference formulations are summarised in Table 4.12. 
The 90% CI for AUC0-5 and the point estimates were outside the acceptance range of 80-125%. 
 
Table 4.12. Bioavailability comparison of test and reference formulations (n=10) 
PK 
parameter 
Units Arithmetic means 
(mean ± SD) 
%Ratio 
(T/R) 
90% CI 
(lower limit, upper limit) 
Power of 
ANOVA 
(%) 
ANOVA CV 
(%) 
Test Reference 
        
AUC0-5 ngh/ml 54.99 ± 52.31 38.78 ± 51.32 149.77 (117.21, 191.37) 98.17 29.90 
 
4.4a.3. Discussion 
In general, the DMD technique was well tolerated with no residual scaring and inflammation observed 
after 4 weeks. Ice was effective as an anaesthetic which made probe implantation simple and virtually 
pain free. Probe failures and variable ketoprofen dialysate concentrations during the DMD studies 
appeared to be caused through attempts by some subjects to alleviate discomfort with resulting probe 
disturbance. In particular the posture of the relevant arm in relation to the body position was identified 
as the source of the problem. Normally, when a subject assumes the supine position with the arm 
stretched out, the level of the heart should be higher than that of the arm. This posture ensures 
sufficient blood circulation is available to the arm. When the converse occurs, i.e., the level of the 
heart is the same or below the level of the arm, poor blood circulation results inducing pain, with 
some subjects complaining of numbness and coldness. This discomfort causes subjects to 
momentarily flex their arms to improve blood circulation. Since, flexing resulted in the movement of 
the muscles underneath the probes, this reflex action may have mechanically disrupted the diffusion 
process by forcing more ketoprofen into the dermis thereby resulting in higher concentrations leading 
to variable results. Moreover, the cold arms may have resulted in poor ketoprofen diffusion since a 
decrease in temperature decreases diffusion. It was therefore important to ensure that the subjects 
were comfortable to minimise the effect any form of discomfort may have the outcome. 
 
Five issues were identified as shortcomings in the study design and also as possible sources of 
variability associated with HS I. Based on these issues, the study design was amended to take these 
issues into account and implemented in subsequent studies in an attempt to reduce variability and 
validate the model for the determination of bioequivalence of topical products using ketoprofen as the 
model drug. 
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The sources of the formulations were investigated. Fastum® gel is a registered product in South Africa 
whereas Ketum® gel is a registered product in France. Although in vitro information for both products 
were found to be similar (1) the in vitro data for both products indicated similar pharmaceutical 
availability of ketoprofen. However, in the absence of an established in vitro-in vivo correlation, such 
data do not provide adequate information to suggest that the products are bioequivalent. Moreover, 
since Fastum® gel is the only topical ketoprofen gel product on the South African market, no 
comparative product was available for use as a reference in order to assess bioequivalence of Fastum® 
gel. In order to employ DMD routinely to assess bioequivalence of topical formulations intended for 
local and/or regional delivery, a validated model is necessary to show proof-of-concept. Such a model 
would need to confirm bioequivalence between bioequivalent products. In the absence of a reference 
product, validation could not be performed under the circumstances of this particular study design. 
Hence, a future study was considered to use the same topical gel formulation as both the test and 
reference formulation. In this way, since bioequivalence is expected when paired sites designated as 
test and reference are compared, the ratios of AUC0-5 (T)/AUC0-5 (R) should provide 90% CIs within 
the acceptance range of 80-125% in order to validate the model. 
 
Although the probes were inserted within the region of the forearm between 3 cm from the elbow and 
3 cm from the wrist, the probes were inserted over a wide area spanning across a greater length of the 
forearm of each subject (Figure 4.5). The vasculature across the forearm is variable with the most 
dense areas towards the wrists and elbows (39,40,55) and these differences in vasculature along the 
forearm may affect drug diffusion. An area with increased vasculature may produce low dialysate 
concentrations whereas an area with decreased vasculature may produce increased dialysate 
concentrations. The distance between probes was subsequently decreased from 3 to 1.5 cm in order to 
reduce variability resulting from the differences in vasculature across the volar aspect of the forearm. 
 
The spreading of the formulation within the surface area of each template was another source of 
possible variability. Although an accurate amount of formulation from a calibrated formulation 
dispenser was dispensed at each application site, the use of a pre-weighed glass rod to spread the 
formulation across the surface area resulted in different amounts of the formulation remaining on each 
application site. On some sites, as much as 60% of the intended dose was lost to the glass rod during 
spreading. Differing amounts of ketoprofen were therefore available for diffusion through the SC into 
the dermis. Furthermore, the spreading procedure invariably contributed to the possibility of exerting 
variable pressures at the different application sites. Inconsistent pressures applied at different sites 
may have resulted in forcibly introducing more ketoprofen into the dermis. To avoid using a glass rod 
to spread the dispensed formulation across the surface area of the application site demarcated by the 
template, a sufficient amount of formulation was directly dispensed to cover the entire surface area of 
the application site. This ensured that each area received the same application dose. 
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The study was not conducted in a controlled environment. The clinic was not temperature or humidity 
controlled resulting in some fluctuation of both these conditions. During some study days, the clinic 
temperature was as low as 16°C and as high as 28°C on other days. The study was not conducted 
under filtered light to exclude UV rays from causing photodegradation of ketoprofen. Hence, 
subsequent studies should be conducted in a facility under controlled/regulated temperature and 
humidity conditions and performed under filtered lighting to exclude UV rays. 
 
Based on these recommendations, an amendment to the research protocol was submitted to the 
RUESC for approval (Appendix I: RP Ammendments). 
 
4.4a.4. Conclusions 
The probe implantations and the overall study design were well tolerated by all subjects with no 
residual inflammation or scarring after 4 weeks, facilitated by the application of an anti-inflammatory 
cream immediately post probe removal, and moreover, ice was an effective anaesthetic. The lack of 
bioequivalence between the 2 products may have been due to either the test and reference products 
indeed being bioinequivalent since no data were available to show the basis of marketing approval for 
either of the products or a poorly designed study protocol. Subject discomfort during the study, the 
spreading of the formulation across the surface area of the application sites, the widely distributed 
probes across the volar aspect of the forearm and the absence of a controlled environment were also 
identified as issues requiring attention.  
 
4.4b. Human study II (HS II): Bioequivalence model development and optimisation 
4.4b.1. Methods 
The methods were the same as described in section 4.4a.1 except for the following: 
 
4.4b.1.1. Formulation 
Fastum® Gel containing ketoprofen 2.5%, m/m (Adcock Ingram Ltd., Bryanston, South Africa) was 
used as the test and reference products. 
 
4.4b.1.2. Subjects (1-10) (HS II) 
The study population comprised 10 (5 females and 5 males) healthy black subjects with ages ranging 
from 20-45 yr and body weights ranging from 55.3-95.6 kg. 
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4.4b.1.3. Study design 
The study was conducted in the Biopharmaceutics Research Institute (BRI, Rhodes University, 
Grahamstown, South Africa). The probes were implanted 1.5 cm apart (Figure 4.8) and 50 mg of 
Fastum® gel formulation was dispensed using 1.0 ml preloaded Combitips®. No spreading of 
formulation was performed and the entire surface area of the application site was covered as 
previously discussed. The entire study was conducted under filtered fluorescent (deep golden amber) 
light (Lee Filters, Andover, Hampshire, England) which prevented the transmission of light at 
wavelengths lower than 530 nm and protected against ketoprofen photodegradation. Amber glassware 
was used as a further precaution to prevent the possibility of ketoprofen photolysis. 
 
 
 
 
Figure 4.8. DMD study design (HS II) 
 
Experimental conditions: 4 probe insertions, 4 application sites, 1 probe per site, probes were 1.5 cm apart, probes covered approximately 2nd quarter of the 
volar aspect of the forearm of each volunteer 
 
4.4b.1.4. Bioequivalence assessment 
In order to assess the resulting data for bioequivalence, 2 sites on each subject were designated as test 
sites (T) and the other 2 sites as reference sites (R). The designation of the sites was performed 
according to the following randomisation sequence: A (TTRR/RRTT), B (TRTR/RTRT) and C 
(TRRT/RTTR). The means of 2 pairs of sites for each subject were used in the bioequivalence 
assessment. The means of probes 1 and 2 versus 3 and 4 were designated as sequence A. The means 
of probes 1 and 3 versus 2 and 4 were designated as sequence B. The means of probes 1 and 4 versus 
2 and 3 were designated as sequence C. Sequence D was a randomisation of sequences A, B and C. 
 
4321
3 cm from elbow
3 
cm
1 cm
elbow
wrist
adhesive 
template
application
site
volar aspect 
of left forearm
inserted linear
microdialysis probe
1.5 cm
 
4. Microdialysis 
 
Ralph Tettey-Amlalo - 80 -  Rhodes University, 2008 
4.4b.2. Results 
4.4b.2.1. Clinical observations 
Similar insignificant clinical observations as in the previous study were noticed however, no failed 
probes were observed in this study. 
 
4.4b.2.2. Dose assessment 
The dose applied at the sites sufficiently covered the entire surface area of the application sites 
demarcated by the templates and no spreading of the formulation was conducted. 
 
4.4b.2.3. Probe depth measurements 
The mean probe depths per subject (n=4) for all subjects ranged from 0.64-0.87 mm and the %RSDs 
ranged from 2.95-11.09% (Table 4.13). 
 
Table 4.13. Mean probe depth measurements (HS II) (n=4) 
Subject Probe depth (mm) 
(mean ± SD) 
RSD 
(%) 
   
1 0.76 ± 0.08 11.09 
2 0.65 ± 0.03 5.22 
3 0.87 ± 0.05 6.23 
4 0.66 ± 0.07 10.47 
5 0.84 ± 0.08 9.00 
6 0.64 ± 0.05 7.95 
7 0.87 ± 0.03 3.15 
8 0.77 ± 0.02 2.95 
9 0.64 ± 0.06 9.27 
10 0.72 ± 0.08 10.81 
 
4.4b.2.4. Pharmacokinetic evaluation 
Mean dialysate concentration-time (a) and semi log-time (b) profiles (± SD) from 4 probes are 
illustrated in Figure 4.9. 
 
 
Figure 4.9. Mean dialysate concentration (a) and semi-log (b) time profiles (± SD) HS II (n=10) 
 
Experimental: 4 probe insertions, 4 application sites, 1 probe per site, probes were 1.5 cm apart, probes covered approximately 2 quarters of the volar aspect of 
the forearm of each volunteer, 10 subjects, Formulation: Fastum® gel  
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The raw data and individual subject concentration-time profiles are located in Appendix II (DMD: HS 
II). All the concentrations obtained were measureable and above the LLOQ. The AUC0-5 values 
obtained from probes 1-4 were 101.60 ± 56.65 ngh/ml (ranged from 17.12-180.37; RSD = 55.76%), 
127.89 ± 93.49 ngh/ml (ranged from 20.62-346.03 ngh/ml; RSD = 73.10%), 128 ± 122.96 ngh/ml 
(ranged from 18.52-460.16 ngh/ml; RSD = 95.47%) and 112.63 ± 98.57 ngh/ml (ranged from 18.21-
351.20 ngh/ml; RSD = 87.52%), respectively. Although inter-subject variability (%RSD) for each 
probe was approximately 77%, the intra-subject variability (%RSD) between probes was 11.04%. 
 
4.4b.2.5. Bioequivalence assessment 
The bioequivalence assessment of sequence A, B, C and D are presented in Table 4.14. The AUC0-5 
90% CI for sequence A (80.34, 108.53) and B (80.21, 112.81) were within the acceptance limits of 
80-125% but the AUC0-5 CIs for sequence C (75.17, 98.92) and D (70.79, 117.76) were just outside the 
lower limits. The power of the study for both sequence A (44.55%), B (34.44%) and D (45.69%) were 
rather low but high for sequence C (78.48%). The ANOVA CV% for sequences A, B, C and D were 
low. 
 
Table 4.14. Bioavailability comparison of sequences (n=10) 
Sequence PK 
Parameter 
Units Arithmetic means 
(mean ± SD) 
%Ratio 
(S1/S2) 
90% CI 
(lower limit, upper limit) 
Power of 
ANOVA 
(%) 
ANOVA CV 
(%) 
 Test Reference 
         
A AUC0-5 ngh/ml 114.95 ± 88.29 120.51 ± 90.01 93.37 (80.34, 108.53) 44.55 18.34 
B AUC0-5 ngh/ml 115.20 ± 84.20 120.26 ± 93.05 95.13 (80.21, 112.81) 34.44 20.80 
C AUC0-5 ngh/ml 107.12 ± 73.22 128.34 ± 106.04 86.23 (75.17, 98.92) 78.48 16.75 
D AUC0-5 ngh/ml 107.36 ± 91.86 120.54 ± 96.32 91.30 (70.79, 117.76) 45.69 19.67 
 
4.4b.3. Discussion 
The outcome of the study based on the recommendations implemented from HS I demonstrated the 
possibility of developing a DMD model to determine the bioequivalence of ketoprofen topical gel 
formulations in human subjects. The bioavailability comparisons showed that 2 out of 3 paired site 
combinations (T & R) met the AUC0-5 criteria for bioequivalence and moreover the improved 
ANOVA CV% was indicative of an improved study design. 
 
The exclusion of UV light, the use of sufficient amount of formulation and the reduction of probe-to-
probe distances minimised the variability associated with the study. A preliminary 2-subject study 
conducted under filtered light with the HS I dose (10 mg/cm2) confirmed that the higher 
concentrations obtained in HS II were due to the exclusion of UV rays and not to the increased 
amount of formulation dispensed at the application areas. Although similar dialysate concentrations 
were observed with either dose from HS I (10 mg/cm2) or HS II (16.67 mg/cm2) the use of the latter 
dose was preferred due to the ability to dispense reproducible amounts of the topical formulation onto 
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each application area. The failure to show bioequivalence for sequence C coupled with the low power 
of the study indicated that the increased dose did not affect the discriminatory power of the study as a 
result of possible ketoprofen site saturation. Reducing the distance between the inserted linear DMD 
probes (i.e., from 3 to 1 cm) appeared to have resulted in reduced variability and contributed towards 
an improved ANOVA CV% for all sequences. 
 
The probe depth measurements showed that very consistent implantation depths were obtained within 
the dermis of all subjects and was unlikely to contribute towards variability. No correlation between 
probe depth measurements and AUCs was observed. 
 
The data indicated dermal penetration of ketoprofen to varying degrees between subjects although a 
clear maximum concentration of ketoprofen could not be unequivocally established within the 5 h 
study duration. Hence Cmax could not be used as a bioavailability parameter in the bioequivalence 
assessment. Although the concentration-time profiles showed high inter-subject variability (~ 77%), 
more pronounced between 2-5 h, the study was associated with low intra-subject variability (11.04%). 
The high inter-subject variability is presumably associated with individual differences of the SC of the 
subjects and is not entirely unexpected (140,172). Whereas Cmax is normally included in the 
assessment of bioequivalence for drugs intended for systemic absorption, it remains questionable 
whether such a parameter is appropriate for products not intended for the systemic circulation. In this 
respect, a well-established precedent to waive such a requirement has long been used in the 
assessment of topical corticosteroid formulations where only a single criterion, the area under the 
effect curve (AUEC) is used to determine bioequivalence between such topical preparations (41). 
 
Although the 90% CI for AUC0-5 for sequences A and B were within the bioequivalence acceptance 
limits of 80-125%, the power of those studies was relatively low, 44.55% and 34.44%, respectively, 
indicating that more subjects would be required to show bioequivalence. The failure of sequence C to 
meet the bioequivalence assessment for AUC0-5 may be due to location of the application sites being 
compared which involved comparing data from sites 1 and 4 (outside sites) versus 2 and 3 (inner 
sites). Possible differences in vasculature may account for the variable diffusion patterns between the 
inner and the outer sites. Since sequence D involved the randomisation of sequences A, B and C, the 
failure of sequence D was attributed to sequence C not meeting the bioequivalence assessment. 
 
4.4b.4. Conclusions 
The recommendations implemented from the previous study (HS I) reduced the variability seen in this 
study (HS II). The use of sufficient amount of formulation to avoid the need to spread the formulation, 
reduction of the probe-to-probe distance as well as conducting the study in a controlled environment 
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under filtered lights reduced variability. A study population of 10 subjects was however insufficient to 
demonstrate bioequivalence and therefore and add-on study was necessary. 
 
4.4c. Human study III (HS III): Add-on study  
4.4c.1. Methods 
An add-on study involving an additional 8 (Subjects 11-18) healthy subjects (4 females and 4 males) 
with ages ranging from 18-23 yr and body weights ranging from 61.5-85.69 kg was conducted under 
the same conditions as previously described. 
 
4.4c.1.1.  Homogeneity test 
The Levene’s test and Brown-Forsythe test for homogeneity set at a 5% level of significance for the 2 
groups (HS II & HS III) of data were performed using SAS® (SAS Institute Inc., Cary, North 
Carolina, USA). The null hypothesis (Ho: σ2HS II = σ2HS III) described equal variances of data obtained 
from HS II and HS III whereas the alternate hypothesis (Ha: σ2HS II ≠ σ2HS III) described unequal 
variances. 
 
4.4c.2. Results 
Once again there were neither no failed probes nor any significant untoward clinical observations. The 
mean probe depths ranged from 0.67-0.87 mm and the %RSDs ranged from 5.38-16.70% (Table 
4.15). 
 
Table 4.15. Mean probe depth measurements (HS III) (n=4) 
Subject Probe depth (mm) 
(mean ± SD) 
RSD 
(%) 
   
11 0.84 ± 0.13 15.57 
12 0.70 ± 0.07 10.27 
13 0.80 ± 0.07 9.23 
14 0.67 ± 0.07 11.07 
15 0.87 ± 0.05 5.38 
16 0.79 ± 0.11 13.48 
17 0.84 ± 0.06 7.29 
18 0.75 ± 0.13 16.70 
 
4.4c.2.1. Pharmacokinetic evaluation 
4.4c.2.1.1. Subjects 11-18 (HS III) 
Mean dialysate concentration-time (a) and semi log-time (b) profiles (± SD) from 4 probes assessed 
for subjects 11-18 are illustrated in Figure 4.10. The raw data and individual subject concentration-
time profiles are located in Appendix II (DMD: HS III). All the ketoprofen concentrations obtained 
for subjects 11-18 were measureable and above the LLOQ. The AUC0-5 obtained from probes 1-4 
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were 192.38 ± 93.17 ngh/ml (ranged from 84.31-342.12; RSD = 48.43%), 220.55 ± 125.26 ngh/ml 
(ranged from 74.23-415.14 ngh/ml; RSD = 56.79%), 203.80 ± 114.42 ngh/ml (ranged from 68.53-
406.53 ngh/ml; RSD = 56.14%) and 169.33 ± 90.60 ngh/ml (ranged from 56.16-302.27 ngh/ml; RSD 
= 53.51%), respectively. Inter-subject variability (%RSD) for each probe was approximately 78% and 
the intra-subject variability (%RSD) between probes was approximately 13%. 
 
 
 
Figure 4.10. Mean dialysate concentration (a) and semi-log (b) time profiles (± SD) HS III (n=8) 
 
Experimental: 4 probe insertions, 4 application sites, 1 probe per site, probes were 1.5 cm apart, probes covered approximately 2 quarters of the volar aspect of 
the forearm of each volunteer, 8 subjects, Formulation: Fastum® gel 
 
4.4c.2.1.2. Homogeneity test 
The results of the statistical procedure are provided in the Table 4.16 below. 
 
Table 4.16.  Homogeneity testing of data generated from HS II and HS III 
Statistical test F value Pr > F 
   
Levene’s test 0.66 0.4201 
Brown-Forsythe’s test 0.07 0.7930 
 
Since both p-values > 0.05, the null hypothesis was not rejected, hence there is sufficient evidence of 
homogeneity of data between HS II and HS III. 
 
4.4c.2.1.3. Subjects 1-18 (HS II & III; Add-on) 
Mean dialysate concentration-time (a) and semi log-time (b) profiles (± SD) from 4 probes assessed 
for subjects 1-18 are illustrated in Figure 4.11. The raw data and individual subject concentration-time 
profiles are located in Appendix II (HS II and III). The AUC0-5 obtained from probes 1-4 were 141.95 
± 86.18 ngh/ml (ranged from 17.12-342.12; RSD = 60.72%), 169.07 ± 115.47 ngh/ml (ranged from 
20.61-415.14 ngh/ml; RSD = 68.29%), 162.13 ± 121.93 ngh/ml (ranged from 18.52-460.16 ngh/ml; 
RSD = 75.20%) and 137.83 ± 96.77 ngh/ml (ranged from 18.21-351.20 ngh/ml; RSD = 70.21%) 
respectively. Inter-subject variability (%RSD) for each probe was approximately 68% and the intra-
subject variability (%RSD) between probes was approximately 10% when the data obtained from the 
total number of subjects were pooled. 
 
4. Microdialysis 
 
Ralph Tettey-Amlalo - 85 -  Rhodes University, 2008 
 
 
 
Figure 4.11. Mean dialysate concentration (a) and semi-log (b) time profiles (± SD) HS II and III (n=18) 
 
Experimental: 4 probe insertions, 4 application sites, 1 probe per site, probes were 1.5 cm apart, probes covered approximately 2 quarters of the volar aspect of 
the forearm of each volunteer, 18 subjects, Formulation: Fastum® gel 
 
4.4c.2.2. Bioequivalence assessment 
The bioequivalence assessments of sequences A, B, C and D for 8 subjects are presented in Table 
4.17. The AUC0-5 CI for sequences A (102.00, 121.88), B (94.81, 114.26) and C (107.02, 122.71) 
were found to be within the acceptance limits and sequence D (79.89, 119.92) was only slightly 
outside the lower limit and the point estimates for all sequences were within the limits. However, the 
power of the various sequences was low, particularly for sequences B (24.23%) and D (20.54%). 
 
Table 4.17. Bioavailability comparison of sequences HS III (n=8) 
Sequence PK 
Parameter 
Units Arithmetic means 
(mean ± SD) 
%Ratio 
(S1/S2) 
90% CI 
(lower limit, upper limit) 
Power of 
ANOVA 
(%) 
ANOVA 
CV (%) 
 Test Reference 
         
A AUC0-5 ngh/ml 206.46 ± 108.29 186.57 ± 101.06 111.50 (102.00, 121.88) 51.11 22.23 
B AUC0-5 ngh/ml 198.09 ± 102.16 194.94 ± 107.51 104.08 (94.81, 114.26) 24.61 24.23 
C AUC0-5 ngh/ml 212.18 ± 118.90 180.86 ± 90.31 114.60 (107.02, 122.71) 45.67 21.25 
D AUC0-5 ngh/ml 197.44 ± 120.57 188.35 ± 89.54 101.60 (79.89, 119.92) 20.54 29.12 
 
The bioequivalence assessments of sequences A, B, C and D for all 18 subjects are presented in Table 
4.18. The AUC0-5 CIs and point estimates for all sequences were within the acceptance limits with low 
ANOVA CV%s, although the power obtained for sequences C (53.99%) and D (51.04%) were still 
low. 
 
Table 4.18. Bioavailability comparison of sequences (n=18) 
Sequence PK 
Parameter 
Units Arithmetic means 
(mean ± SD) 
%Ratio 
(S1/S2) 
90% CI 
(lower limit, upper limit) 
Power of 
ANOVA 
(%) 
ANOVA CV 
(%) 
 Test Reference 
         
A AUC0-5 ngh/ml 155.51 ± 98.89 149.98 ± 107.27 106.16 (97.39, 115.72) 92.88 14.88 
B AUC0-5 ngh/ml 152.04 ± 99.23 153.45 ± 103.93 99.01 (89.86, 109.09) 95.95 16.72 
C AUC0-5 ngh/ml 139.89 ± 87.28 165.60 ± 116.67 86.69 (80.37, 93.50) 53.99 13.04 
D AUC0-5 ngh/ml 149.39 ± 112.14 150.68 ± 97.03 95.74 (82.20, 111.52) 51.04 26.30 
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4.4c.3. Discussion 
In order to increase the power of the studies, an additional 8 subjects were enrolled into the study as 
determined from a power analysis based on the T/R ratio of %CV of the AUC0-5 data from the initial 
10 subjects to provide a probability of 90%. When the data from all subjects were pooled, 
bioequivalence was met for all 3 sequences. However, although sequences C and D met the criteria 
for bioequivalence, they were associated with relatively low power which indicated that the factors 
previously discussed for these sites were probably involved. Justification of pooling the data was 
confirmed with both the Levene’s and Brown-Forsythe’s tests. 
 
Although it is possible to improve the power of study sequences C and D with the use of even more 
subjects, modification of the study design may also be an important consideration. Since the least 
variable and thus strongest results were achieved with application sites 2 and 3, implantation of 2 
probes in each of those sites instead of a single probe at the 2 outer sites (1 and 4) may be more 
appropriate (Figure 4.12). 
 
 
 
 
 
Figure 4.12. Proposed DMD study design 
 
Experimental conditions: 4 probe insertions, 2 application sites, 2 probe per site, probes were 1.5 cm apart, probes covered approximately 2nd quarter of the 
volar aspect of the forearm of each volunteer 
 
4.4c.4. Conclusions 
The data from 10 initial subjects indicated that the study was under-powered to unequivocally show 
bioequivalence, hence the data from an add-on study of 8 additional subjects were pooled. As a result, 
the power of the study was increased to > 90% for 2 out of the 3 study sequences although all 3 of the 
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sequences indicated bioequivalence for those gel applications, with 1 of the 3 sequences being 
associated with a somewhat reduced power. The location of the application sites was seen to be an 
important consideration and a study modification to incorporate the implantation of 2 probes at sites 2 
and 3 is proposed to minimise variability. A randomisation sequence of site (sequence D) may be 
performed with 4 application sites but more subjects will be needed to attain significant power. Since 
paired applications of ketoprofen gel used in this study consisted of the same preparation, 
bioequivalence was expected and subsequently proven. AUC0-5 was used as the main bioequivalence 
parameter since Cmax was considered as an inappropriate parameter for products not intended to be 
absorbed into the systemic circulation in the same way as this parameter is not used for the assessment 
of the bioequivalence of topical corticosteroid preparations. The data from the study of the ketoprofen 
gel formulation provide the basis for and validates the use of DMD to assess bioequivalence of topical 
formulations applied to the skin and subsequently sampled in the target organ, the dermis. However, 
care must be taken to optimise the study design and application of the topical products to sites on the 
skin which have been appropriately identified. In order to justify the pooling of subjects, homogeneity 
testing is necessary. 
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CHAPTER FIVE 
TAPE STRIPPING 
 
5.1. Introduction 
Tape Stripping (TS) is a method used to measure drug concentrations within the SC (35) and is based 
on the reservoir principle of the SC (177). The SC has the property to store drugs applied to the skin 
depending on the drug, the formulation, the application procedure and the state of the skin (24). If a 
formulation is applied to the skin for a limited period of time and removed, the amount of drug in the 
upper layers of the SC will be predictive of the drug bioavailability in the skin (178-180) and hence 
this technique may also be employed for local bioavailability and/or bioequivalence of topical 
formulations intended for local and/or systemic effect. 
 
TS involves sequentially removing microscopic layers (~ 0.5-1.0 µm thick) of SC by placing an 
adhesive tape strip onto the skin surface, followed by gentle pressure to ensure good contact and 
subsequent removal by a sharp upward movement (28) which may be repeated 10 to more than 100 
times (9,181). This technique although painless and non-invasive (28), disrupts the integrity of the 
water barrier properties of the SC (182) which is rapidly repaired by a homeostatic response in the 
dermis. 
 
TS has been employed in the dermatological and pharmaceutical fields to evaluate the percutaneous 
penetration of drugs (24,140,183-192), barrier function (193-196), the possibility of animal skin as a 
surrogate for human skin, chemical toxicity (197), SC mass and thickness (198,199), wound healing 
processes and pharmacodynamic and clinical parameters (181). TS may also be useful for selecting or 
comparing vehicles for drugs to be applied topically.  
 
The initial TS methodology outlining the bioavailability/bioequivalence protocol for topical 
formulations intended for local and/or regional activity, published in a draft guideline (200) was 
subject to criticism and resulted in its withdrawal. A number of limitations associated with the draft 
guidance are listed below but many of them still remain unresolved. 
i. Dosing details such as size and duration of application as well as frequency of sampling were 
not clearly delineated. 
ii. The number of tape strips needed is considerable which renders a dermatopharmacokinetic 
(DPK) evaluation time-consuming. For example, 10 applications per arm require 10 strips per 
site. 
iii. Discarding of the first 2 tape strips was not substantiated. 
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iv. The same number of tape strips do not remove the SC from all subjects or even potentially 
within the same subject at different sites (28). 
 
Moreover, there are several sources of variability (177) associated with this technique namely: 
i. drug application procedure 
ii. type of tape 
iii. size of tape 
iv. pressure applied by investigator 
v. duration of application of pressure 
vi. drug removal procedure 
vii. drug extraction procedure 
viii. analytical methods 
ix. temperature 
x. relative humidity 
xi. skin type 
xii. skin surface uniformity  
 
Although most of these variables (i, ii, iii, vii, viii, ix and x) can be controlled, the degree of 
variability contributed by the others (iv, v, vi, xi and xii) is still significant (201-204). Löffler et al. 
(182) demonstrated significant influences of anatomical site, application pressure, application 
duration and TS removal from the application site during the skin stripping technique whereas the 
properties of adhesive tapes have been studied by Tsai et al. (193). 
 
Among the list of variables, the number of tape strips needed to remove the SC has received much 
attention lately. As mentioned previously, the same number of strips do not remove the SC in all 
subjects due to age, gender and possibly ethnicity (205) and therefore determination of the SC 
removed from each strip would provide objective data, which are comparable between different 
subjects. 
 
Sequential skin stripping permits fractions of the SC to be obtained after which the tape strips are 
extracted to allow the quantification of the absorbed drug which may be obtained from either 
combined or individual tape strips. Various analytical techniques have been employed for the 
quantification of drugs in tape stripped skin ranging from HPLC-UV, HPLC-florescence, HPLC-
MS/MS, GC and infra-red (IR) spectrophotometry amongst others (28). Besides tape strip weighing 
before and after SC harvesting which is often time consuming and prone to error because of the SC 
moisture content (206), spectroscopic measurements determining the protein absorption in the UV 
range, measurements in the visible spectral range after staining of the corneocytes (207), spectral 
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signal connected with the SC or the microscopic determination of the covering density of the 
corneocytes can also be employed (182,195,201,206,208). 
 
Transepidermal water loss (TEWL) is a non-invasive bioengineering technique that describes the 
outward diffusion of water through the skin (209). TEWL monitors the integrity of the SC water 
barrier function and is an indicator of skin water barrier alteration (182,205), with increased readings 
often indicating impairment of skin barrier function (209). Healthy SC typically has a water content of 
10-20% and TEWL can be dramatically altered if barrier function is perturbed by physical, chemical, 
therapeutic and/or pathological factors (205). Typical basal values of TEWL in adults with healthy 
skin are between 5-10 gm-2h-1 (31).  
 
Kalia et al. (31) reported the use of TEWL in TS experiments to determine the thickness of SC in an 
attempt to normalise the data by incorporating the SC thickness from each subject. This involves 
weighing each tape strip before and after SC harvesting to determine the amount ( )m  of tissue 
removed. Each stripped amount of SC can be converted to a distance ( )x which reflects thickness of 
the removed skin strip, using Equation 5.1 below where ( )A  is the area of the application site, ( )ρ  is 
the density of the SC , reported as ~ 0.88-1.42 gm/cm3 (210). 
 
( )
mx
A ρ= ⋅  5.1. 
 
The additional standardisation to determine SC thickness by incorporating TEWL measurements was 
based on the SC functioning as a homogenous barrier to water transport in vivo, with the diffusional 
resistance equally distributed and not restricted to a particular tissue layer (31). Baseline TEWL 
0( )TEWL  across non-stripped SC of thickness L  (µm) is given by Fick’s first law of diffusion 
expressed in Equation 5.2: 
 
0
D KTEWL C
L
⋅= Δ  5.2. 
 
where D  and K are the diffusion coefficient of water in the SC and the SC viable tissue partition 
coefficient of water, respectively and CΔ is the water concentration difference (55 M ≡ 1 gcm-3) 
across the membrane. After the TS procedure has removed a depth x  of SC, the TEWL increases to a 
new value by: 
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( )
x
D KTEWL C
L x
⋅= Δ−  5.3. 
 
Inversion of Equation 5.3 yields a linear relationship between TEWL and x  (Equation 5.4) where the 
intercept on the x-axis equals the SC thickness, L  (µm). 
 
1
x
L x
TEWL K C D K C D
= −Δ ⋅ Δ ⋅  5.4. 
 
This equation allows the TS data to be expressed as an amount per normalised fraction of SC removed 
( / )x L , a strategy which allows results from disparate subjects of different SC thickness to be 
normalised and compared. 
 
The TS procedure coupled to TEWL measurements is time consuming and may pose a problem for 
fast diffusing drugs. Static electricity on tapes and misleading weights due to the presence of 
formulation excipients complicates gravimetric measurements. 
  
This approach however demonstrates that the number of tape strips (10), as suggested in the FDA 
Draft Guidance (200) is a poor indicator of the actual amount of SC tissue removed since no 
information on the relative position within the SC is known and moreover 10 tape strips fail to permit 
meaningful comparisons between individuals (31). 
 
The procedure is simple, inexpensive, relatively painless and non-invasive, given that only dead cells 
(corneocytes) are removed (182,204) and is the commonly used technique in DPK for the assessment 
of drug amounts in SC. TS is applicable to all drugs that are topically applied (211). Although the TS 
technique is a single point determination, it is possible to derive pharmacokinetic parameters such as 
AUC, Cmax and Tmax by sampling different sites progressively with application time, thereby providing 
a means to assess topical bioavailability of dermatological formulations (25). 
 
Since the TS technique is accessible only to the SC but not the deeper tissues, e.g., the viable 
epidermis and dermis, this technique may not be applicable to drugs that have their activity in deeper 
tissues. Vehicle components of products influence both the adhesive properties of the tape as well as 
the cohesion of the corneocytes and even though TS is considered to be essentially non-invasive, 
stripped sites in certain dark-skinned individuals may remain pigmented for several months after 
healing (181). 
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5.2. Human study IV (HS IV): Preliminary investigations 
5.2.1. Methods 
The experimental protocols, ethical approval and subjects participating in this study were the same as 
previously described in section 4.4b.1 and 4.4c.1 except for the following: 
 
5.2.1.1. Reagents, chemical and materials 
Transpore™ 1527 (24 mm x 5 m) dressing tape (3M, Isando, South Africa) and Pelikan® clear film 
sheets (Hannover, Germany) were used. 
 
5.2.1.2. Equipment 
TEWL measurements were performed with a Vapometer Model SWL3N (Delfin Technologies, Oy, 
Kuopio, Finland). A Model AG 135 analytical balance (Mettler Toledo, Greifensee, Zurich, 
Switzerland) and a ZEROSTAT 3 anti-static gun (Sigma-Aldrich, Atlasville, South Africa) were used 
to weigh tape strips. 
 
5.2.1.3. Study design 
Three pre-cut templates (2 x 2 cm) prepared from a thin sheet of clear film were securely attached on 
the volar aspect of the arm. Two sites (Figure 5.1) were designated for formulation application 
whereas the third site was served as a blank for TEWL measurements. Forty milligrams (40 mg) of 
the ketoprofen gel formulation was dispensed onto application sites 1 and 2 and with the use of a pre-
weighed glass rod, the dispensed formulations were evenly distributed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. TS study design 
Experimental: 2 application sites, 1 blank TEWL site covering approximately 2 quarters of the volar aspect of the forearm of each subject 
2 
cm
1 2
3 cm from elbow
2 cm
elbow
wrist adhesive 
template
blank
TEWL site
application
sites
volar aspect 
of right forearm
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Each site, including the blank, was subsequently stripped with 15 pre-cut (2 x 2 cm) tape strips which 
were previously weighed. Stripping was performed by alternating removal directions (N, E, S and W) 
and TEWL measurements were immediately recorded over a 10 s period after each strip from the 
blank application site. Thirty min (30 min) after the dose, the first 3 strips from each application site 
(i.e., sites 1 & 2) were discarded. 
 
5.2.1.4. Sample collection 
Each strip was subsequently re-weighed and individually placed in a centrifuge tube and samples 
were stored in the dark at 4°C prior to sample extraction (Chapter 3; Section 3.2.1b.3). 
 
5.2.1.5. Sample analysis 
Ketoprofen concentration in tape strips were determined with a validated HPLC-UV analytical 
method described in Chapter 3; Section 3.2.1b. 
 
5.2.1.6. Data evaluation 
The concentration-skin depth profiles were generated by plotting ketoprofen concentration against the 
cumulative stripped thickness which were normalised with the SC thickness of each subject and 
AUCs calculated. The determination of individual SC thickness with TEWL measurements was based 
on the model developed by Kalia et al. (31). 
 
5.2.1.7. Bioequivalence assessment 
In order to assess bioequivalence, a site was designated as the test and the other the reference site. 
 
5.2.2. Results 
5.2.2.1. TEWL measurements 
The mean TEWL measurements for all 18 subjects are presented in Table 5.1. Although 
measurements were observed to be increasing with increasing number of stripped tapes, high RSDs 
were noted typically after the tenth strip. A linear relationship between 1 TEWL  and the cumulative 
SC thickness was observed for all subjects and the x-intercept which represents the SC thickness of 
each subject are reported in Table 5.2. 
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Table 5.1. Mean TEWL measurements of subjects per strip (n=18) 
Tape strip 
number 
TEWL ± SD 
(gm-2h-1) 
RSD 
(%) 
   
1 10.32 ± 2.73 26.47 
2 10.88 ± 3.71 34.11 
3 12.13 ± 3.35 27.58 
4 13.15 ± 1.58 11.98 
5 14.31 ± 1.76 12.29 
6 15.54 ± 2.51 16.17 
7 16.25 ± 2.37 14.57 
8 17.46 ± 3.37 19.32 
9 19.58 ± 5.87 29.97 
10 23.43 ± 17.05 72.76 
11 25.77 ± 17.37 67.41 
12 32.80 ± 34.31 104.60 
13 47.82 ± 65.10 136.14 
14 55.22 ± 71.47 129.42 
15 59.52 ± 75.23 126.40 
 
Table 5.2. SC thickness determined from TEWL measurements 
Subject SC thickness 
(µm) 
  
1 7.89 
2 9.38 
3 13.91 
4 10.17 
5 14.08 
6 22.29 
7 13.09 
8 15.16 
9 27.16 
10 23.40 
11 15.14 
12 18.21 
13 25.15 
14 27.18 
15 10.11 
16 12.25 
17 14.14 
18 18.15 
  
Mean ± SD 16.45 ± 6.17 
RSD (%) 37.40 
 
5.2.2.2. Tape strips weights 
The average weights of tape strips obtained from strips 4-15 from all subjects at both applications 
sites are presented in Table 5.3. Although reproducible weights were recorded at both application 
sites, high RSDs were observed (53.3-77.3%). 
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Table 5.3. Mean weights of tape strips from application sites 
 Site 1 Site 2 
Tape strip 
number 
Mean ± SD 
(mg) 
RSD 
(%) 
Mean ± SD 
(mg) 
RSD 
(%) 
     
4 0.3 ± 0.2 55.2 0.3 ± 0.2 53.3 
5 0.3 ± 0.1 60.2 0.3 ± 0.2 62.3 
6 0.3 ± 0.2 57.7 0.3 ± 0.2 60.2 
7 0.3 ± 0.2 58.8 0.3 ± 0.2 58.8 
8 0.3 ± 0.2 66.5 0.3 ± 0.2 64.0 
9 0.3 ± 0.2 63.5 0.3 ± 0.2 65.3 
10 0.3 ± 0.2 57.7 0.3 ± 0.2 57.9 
11 0.3 ± 0.2 59.5 0.3 ± 0.2 61.1 
12 0.3 ± 0.2 74.1 0.3 ± 0.2 68.9 
13 0.2 ± 0.2 68.3 0.3 ± 0.2 65.4 
14 0.2 ± 0.1 65.2 0.2 ± 0.2 77.3 
15 0.2 ± 0.1 66.6 0.2 ± 0.1 59.4 
 
5.2.2.3. Pharmacokinetics evaluation 
The mean concentration cumulative SC depth profiles (± SD) of both application sites (i.e., site 1 and 
site 2) are illustrated in Figure 5.2. The raw data and individual subject concentration-SC depth 
profiles are located in Appendix III (TS: HS IV). The AUCx/L obtained for both site 1 and site 2 were 
128.93 ± 82.74 (ranged from 33.86-367.01 ngm/l; RSD = 64.17%) and 105.93 ± 69.56 (ranged from 
24.45-321.07 ngm/l; RSD = 65.67%) respectively. Inter-subject variability (%RSD) for each probe 
was approximately 70% and the intra-subject variability (%RSD) between probes was approximately 
25%. 
 
 
Figure 5.2. Mean concentration-cumulative SC depth profiles (± SD) HS IV (n=18) 
Experimental: 2 application sites, 1 blank TEWL site, 15 strips, 12 strips harvested for analysis, 18 subjects, Formulation: Fastum® gel (Site 1 and 2) 
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5.2.2.4. Bioequivalence assessment 
The bioequivalence assessments of site 1 and site 2 in 18 subjects are summarised in Table 5.4 below. 
The 90% CI for AUCx/L and point estimate was outside the acceptance range of 80-125%. 
 
Table 5.4. Bioavailability comparison of application sites (n=18) 
PK 
parameter 
Units Arithmetic means 
(mean ± SD) 
%Ratio 
(T/R) 
90% CI 
(lower limit, upper limit) 
Power of 
ANOVA 
(%) 
ANOVA CV 
(%) 
Site 1 Site 2 
        
AUCx/L ngm/l 176.67 ± 228.15 134.58 ± 144.94 131.27 (100.71, 155.40) 99.97 41.15 
 
5.2.3. Discussion 
High variability associated with TS were observed with TEWL measurements (RSDs < 136.14%), 
tape strip weights (RSDs < 77.3%), the pharmacokinetic data (RSDs < 65.67%) and the 
bioequivalence assessment (ANOVA CV = 41.15%). The sources of variability have been indentified 
to be related to tape strips weight measurements, pressure application at sites, application procedure 
and the absence of formulation excipients effect with TEWL. 
 
The use of TEWL demonstrated the ability to normalise TS data, which was confirmed by the linear 
relationship obtained from all subjects. The determination of the SC thickness not only appeared to 
normalise the data but also provided insight into the exact position within the SC (Figure 5.2). This is 
an improvement over previously reported approaches where the sum of the AUC was used as an 
indicator of bioavailability (140). However, formulation excipients have been known to alter the 
integrity of the SC (212) and the TEWL as currently incorporated does not take formulation 
excipients into account since measurements are performed on the blank site and not on the application 
sites. This shortcoming may become apparent when formulations with different excipients are 
compared for bioequivalence assessments. 
 
Although a precision balance coupled with an electro-static source was used to weigh the tape strips, 
the time taken to achieve consistent weight measurements for each tape was relatively long with most 
determinations producing inconsistent readings after 1 min. The long duration allowed for possible 
desiccation of stripped SC on the tape strips as well as loss of volatile formulation excipients. The 
tapes were equally prone to adhesion of static matter from the ambient surroundings (i.e., within the 
clinic) which may have altered the weight of the strips. 
 
The pressure applied as well as the duration of the applied pressure at each application site prior to 
stripping was subject to variability between sites but more importantly between subjects. Although 
sufficient pressure duration (10 s) was employed during the study, it was difficult to qualify the 
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applied pressure prior to each strip and this may have also contributed to increased variability of the 
data. The pressure used at the blank sites may vary from that used at the application sites due to the 
presence of the formulation. Ideally, the pressure used for the determination of the SC thickness 
should be used during the stripping procedure. 
 
The use of the glass rod to spread the formulation within the application site may contribute to the 
variability by inconsistent removal of some of the dose. The use of a dose that would cover the 
application site similar to the DMD study to circumvent the use of the glass rod was not practical 
since excess formulation would remain even after several tape strips. Analysis of the first 3 tape strips 
showed high concentrations of ketoprofen which represented unabsorbed drug and hence discarding 
those strips served as a cleaning procedure. This cleaning procedure was chosen over previous 
methods which indicated the use of solvents or cotton swabs to remove excess formulation because 
the use of solvents are known to either increase of retard drug penetration and moreover, the physical 
rubbing with cotton swabs increases the possibility of mechanically pushing the drug into the SC 
hence producing higher concentrations than usual (24,213). 
 
The incorporation of TEWL with TS as currently used may be sufficient to provide adequate 
information for bioavailability studies for the in vivo differentiation of formulations. However, the 
high variability still associated with this technique is still a challenge for bioequivalence assessments. 
Increasing the number of stripping sites and the average of test and reference AUCx/L values used in 
the bioequivalence assessment may circumvent this issue. However, a possible limitation would be 
the need to use smaller tape strips sizes to accommodate a sufficient number of application sites on 
the volar aspect of the forearm of subjects. This further complicates tape strip weighing measurements 
since smaller tape strips may require a more sensitive weighing balance fitted with an anti-static 
component thus making a this procedure more time-consuming and laborious. 
 
5.2.4. Conclusions 
Although normalisation of data between subjects using TEWL has been proposed as a measure to 
reduce the variability of the TS technique, TS still remains a highly variable technique due to the 
number of variables, such as pressure application, removal of strips, weighing of tape strips and 
formulation applications that are yet to be standardised and validated. Tape strips are sensitive to 
desiccation and static matter. The incorporation of TEWL which determines the SC thickness of each 
subject negates the effect of formulation excipients which may alter the thickness of the SC. More 
sites are therefore necessary for bioequivalence studies however a more sensitive analytical balance 
fitted with an anti-static component may be required. 
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CHAPTER SIX 
CONCLUDING REMARKS 
 
Analytical methods were developed and validated for MD, TS and DMD samples in full compliance 
with all the required analytical method validation parameters. HPLC-UV methods were developed for 
MD and TS samples whereas a rapid UPLC-ESI-MS/MS method was developed for DMD samples. 
Normal saline did not affect HPLC-UV analysis however due to signal suppression with UPLC-ESI-
MS/MS analysis, DMD samples had to be extracted from normal saline into methanol to maintain 
sensitivity and column preservation. A step gradient elution was necessary for TS samples to reduce 
sample run time and flush out late eluting interfering peaks. Inclusion of methanol in both the mobile 
phase as well as in the sample reconstitution step following extraction was found to enhance 
sensitivity in NI ESI applications. Furthermore, system carryover and contamination from sample 
inserts which were detected were eliminated. 
 
In vitro MD provided valuable information for the development and optimisation of DMD studies. An 
equilibration period was necessary to obtain reproducible recovery, a membrane length of 3 cm was 
identified as practical and an appropriate perfusion rate was determined which generated sufficient 
dialysate volumes for analysis. 
 
The DMD studies demonstrated excellent potential for the determination of dermal bioavailability of 
topical formulations intended for local and/or regional activity although care must be taken to 
optimise the study design. Probe insertions were well tolerated by subjects with no residual 
inflammation or scarring after 4 weeks of post-experimental medical assessment. Limitations 
identified in the study design of the preliminary investigation were used to develop and optimise 
subsequent DMD investigations. Several necessary precautions were implemented which included the 
avoidance of any subject discomfort, care in the spreading of formulation, avoiding the widespread 
use of the volar aspect of the forearm by constraining product applications to specific sites and 
providing a controlled environment to result in an optimised study design with reduced variability. 
Although the 90% CI for AUC0-5 for a 10 subject study population was within the acceptable limits 
for bioequivalence for sequences A and B, the statistical power proved to be relatively low to 
conclude bioequivalence. The failure to show bioequivalence of sequence C was related to possible 
differences in vasculature at the sites being compared (i.e., 2 outer sites). An addition of 8 subjects 
resulted in the 90% CI for AUC0-5 for all sequences falling within the permissible limits describing 
bioequivalence. The statistical power for sequence C was however was still low whereas the statistical 
power of both sequences A and B were found to be excellent (> 90%) to conclude the declaration of 
bioequivalence. A study design modification to accommodate the low statistical power of sequence C 
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was proposed involving the use of 2 probes at sites 2 and 3 instead of the use of single probes within 
sites. Since Cmax was not obtained in most of the subjects, it was considered as an inappropriate 
parameter, hence AUC0-5 was used as the main bioequivalence parameter similar to the situation 
which has been found acceptable in the assessment of the bioequivalence of topical corticosteroid 
formulations. 
 
The relatively high variability obtained from TS studies is attributed to a number of variables and the 
optimisation and standardisation of these variables is essential to ensure that the method is optimised. 
  
Optimisation of the dose duration, i.e., the time for which the formulation is left on the application 
site, is essential to allow for sufficient drug diffusion into the SC prior to the stripping procedure. If an 
insufficient duration is used, possible analytical challenges may be encountered regarding the LOQ. 
The converse may show site saturation which may not provide a model capable of discriminating 
different formulations. 
 
The stripping technique has also been identified as a source of variability. Although the tape strips 
were removed in a sequential order (i.e., N, E, S and W) in order to ensure that approximately the 
same thickness of SC was consistently stripped, the pressure applied prior to the stripping procedure 
needs to be standardised and validated. An increased pressure would certainly increase the risk further 
by mechanically pushing the drug into the skin and beyond the SC. 
 
The careful removal of residual application prior to skin stripping allows for the exclusion of excess 
formulation being stripped thus generating extremely high concentration/amounts. Although tape 
strips were used in this study to remove residual application during the first 3 strippings where these 3 
tape strips were discarded, other “cleaning/removal methods” need to be investigated to ensure that 
the stripped skin contains drug that is present within the SC and not on the surface of the skin. For 
purposes of mass balance it will be useful to analyse the first 3 strips prior to discarding, for mass 
balance purposes. 
 
Careful control of the dose and application of doses to demarcated skin sites need to be addressed. 
The use of a finite amount of dose requires the need to spread the formulation over the application 
sites which could mechanically alter drug diffusion patterns throughout the adjacent demarcated site 
thereby contributing to increased variability. The use of infinite dose obviates the need to spread the 
formulation over the site and is thus a preferable approach which can be readily standardised and 
validated. A dose-response model should also be used in order to determine the number of subjects 
required to provide the necessary discriminatory power to distinguish between different formulations, 
if differences do in fact exist. 
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The control of temperature and humidity is essential to avoid the possibility of increased drug 
diffusion during warm days and vice versa during cold days and also to prevent possible tape strip 
desiccation due to variable humidity. The desiccation of tape strips generates inconsistent mass 
readings thus affecting the determination of subject SC thickness. 
 
The foregoing describes various issues and suggestions which could be pursued in order to further 
optimise the various methodologies. Resolution of these issues and implementation of these 
suggestions should allow the reduction of variability and provide better standardisation and facilitate 
the development of validation requirements to ensure consistent generation of reproducible data 
together with necessary quality control procedures.
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Grahamstown 
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Appendix I: RP Application for research protocol 
  
 
 
 
28 June 2007 
 
 
 
Professor Roy Jobson 
Chairman 
Rhodes University Ethical Standards Committee 
RHODES UNIVERSITY 
GRAHAMSTOWN 
 
Dear Professor Roy Jobson, 
 
APPLICATION TO UNDERTAKE A DERMAL MICRODIALYSIS AND TAPE STRIPPING 
STUDY 
 
The Biopharmaceutics Research Group (BRG) wishes to conduct a dermal microdialysis and tape 
stripping clinical study on healthy human volunteers for the assessment of the bioavailability of 
ketoprofen within the next 6 months. 
 
Microdialysis is a sampling technique used to study the concentration of endogenous and exogenous 
compounds in extracellular space. Tape stripping involves the sequential removal of microscopic 
layers of the stratum corneum. Both techniques will be applied within the dermal region on the volar 
aspect of the forearms of subjects. 
 
Healthy human volunteers will be drawn from Rhodes University for this study and as such the BRG 
requires approval from the Rhodes University Ethical Standards Committee. A research protocol 
outlining the study has been included in the application. 
 
Thank you. 
 
Sincerely, 
 
 
 
………………………………….. 
Ralph Nii Okai Tettey-Amlalo 
BPharm, MSc, PhD Candidate (Rhodes) 
Principal Investigator 
  
Rhodes University 
Faculty of Pharmacy 
Biopharmaceutics Research Group 
PO Box 94 
Grahamstown 6140 
South Africa 
Tel:  +27 82 831 5320 
Fax: +27 46 636 1205 
Appendix I: Research Protocol (RP) 
Biopharmaceutics Research Group, Rhodes University, Grahamstown, 6140, RSA. CONFIDENTIAL INFORMATION 
Tel: +27 (0) 46 603-8142 Fax: +27 (0) 46 636-1205 E-mail: r.tettey-amlalo@ru.ac.za 
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RESEARCH PROTOCOL 
 
 
APPLICATION OF DERMAL MICRODIALYSIS AND TAPE STRIPPING FOR THE 
ASSESSMENT OF THE BIOAVAILABILITY OF KETOPROFEN IN HEALTHY 
VOLUNTEERS 
 
 
 
STUDY NUMBER: RNO_01_2007 
PROTOCOL VERSION 1 
JULY 2007 
 
  
Test product Fastum® Gel 
(Ketoprofen 2.5%, m/m) 
Adcock Ingram Limited 
South Africa 
  
  
Principal Investigator Ralph Nii Okai Tettey-Amlalo 
BPharm, MSc, PhD Candidate (Rhodes) 
Biopharmaceutics Research Group (BRG) 
Faculty of Pharmacy 
Rhodes University 
Grahamstown 6140 
South Africa 
  
Supervisor Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
Rhodes University 
Grahamstown, 6140 
South Africa 
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FINAL APPROVAL OF PROTOCOL 
 
 
 
  
Study number 
 
RNO_01_2007 
  
Study title Application of dermal microdialysis and tape stripping for the assessment of the 
bioavailability of ketoprofen in healthy volunteers 
 
  
Test product Fastum® Gel 
(Ketoprofen 2.5%, m/m) 
Adcock Ingram, South Africa 
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1. BACKGROUND INFORMATION 
1.1. Ketoprofen 
1.1.1. Molecular structure 
Ketoprofen is an anionic non-steroidal anti-inflammatory drug (NSAID). It is a derivative of propionic acid and 
widely used in the management and treatment of patients with rheumatic disease (1). The molecular structure of 
ketoprofen is represented below. 
 
O
CH3H
CO2H
 
C16H14O3 MM 254.3 g/mol 
 
1.1.2. Mode of action and uses 
Ketoprofen is one of the most powerful inhibitors of cyclooxygenase (COX) at concentrations well within the 
range of therapeutic plasma concentrations (EC50 2 μg/l) (2). It produces reversible COX inhibition by 
competing with the substrate, arachidonic acid, for the active site of the enzyme (3). This inhibition results in a 
reduction in the tissue production of prostaglandins such as PGE2 and PGF2α (1). In addition to its effects on 
COX, ketoprofen inhibits the lipoxygenase pathway of the arachidonic acid cascade. This pathway produces 
non-cyclized monohydroxyl acids (HETE) and leukotrienes (LKT). Of these, only leukotrienes (B4, C4, and 
D4) are thought to increase vascular permeability, however, both HETE and LKT synthesised within leukocytes 
are active in promoting leukocyte migration and activation. It has been suggested that lipoxygenase inhibitors 
may attenuate cell-mediated inflammation and thus retard the progression of tissue destruction in inflamed 
joints. Ketoprofen is also a powerful inhibitor of bradykinin, an important chemical mediator of pain and 
inflammation. Furthermore, it stabilises lysosomal membranes against osmotic damage and prevents the release 
of lysosomal enzymes that mediate tissue destruction in inflammatory reactions (1,2,4-6). 
 
Ketoprofen has many applications: it is used for musculoskeletal and joint disorders, such as ankylosing 
spondylitis, osteoarthritis, and rheumatoid arthritis, and in peri-articular disorders such as bursitis and tendinitis. 
It is also used for postoperative pain, painful and inflammatory conditions such as acute gout or soft tissue 
disorders and to reduce fever (1,7,8). It is additionally indicated for the management of acute painful shoulder 
syndrome and juvenile rheumatoid arthritis (2). 
 
1.1.3. Pharmacokinetics 
The introduction of a topical formulation for ketoprofen raises the distinct possibility of achieving therapeutic 
benefit, without the risk of gastrointestinal or other side effects suffered by the oral route. To establish the 
validity of this hypothesis requires that:  
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i. percutaneous absorption occurs in sufficient amounts to achieve therapeutic concentrations in the 
target tissues, 
ii. clinical efficacy is demonstrable in suitably controlled clinical trials, 
iii. the safety profile of the topical agent is superior to that of the oral agent, particularly with regard to 
gastrointestinal side effects and  
iv. the topical agents are cost-effective (9). 
 
Pharmacokinetic data have demonstrated that, following percutaneous administration of ketoprofen gel, the anti-
inflammatory agent penetrates into the general circulation slowly (10,11) and reaches underlying tissues 
including the synovial fluid (6). This low systemic diffusion, combined with good local tolerance, would ensure 
an improved systemic tolerance for the local treatment of rheumatic conditions (6,10-16). 
 
Ketoprofen is extensively metabolised in the liver. Only 1% of the dose is excreted unchanged in the urine. The 
main pathway of metabolism is glucuronic acid conjugation, with hydroxylation as a minor pathway (1,6,7). The 
metabolites are excreted mainly in the urine with 80% of the dose as the glucuronide. 10-20% of the dose is 
excreted in the bile. Some enterohepatic circulation is probable. The metabolic products of ketoprofen appear to 
be pharmacologically inert (1). 
 
1.1.4. Adverse effects 
For topical preparations, delayed hypersensitivity dermatitis may occur at the site of the application, but this is 
uncommon (9,15). Cases of contact erythema and photocontact dermatitis have also been reported (14). It is 
advised that they should not be used on broken or inflamed skin (15). The skin reactions are reversible on 
discontinuation of therapy (6). Cross-sensitisation of topical ketoprofen and other propionic NSAIDs have been 
reported (9). 
 
1.1.5. Contraindications 
Administration should be avoided in persons who exhibit hypersensitivity to ketoprofen or to any other NSAID 
or to any ingredient in the preparation. 
 
A copy of the product information leaflet of the topical formulation to be used in this study is located in 
Appendix RP A. 
 
1.2. Dermal microdialysis sampling 
1.2.1. Rationale for dermal microdialysis sampling 
During recent decades the advantages of cutaneous and percutaneous drug delivery has gained increasing 
attraction for novel drug formulations. The percutaneous route may be an attractive solution for systemic 
delivery of very potent drugs with low oral bioavailability, low systemic clearance and narrow therapeutic 
window, due to the avoidance of hepatic first-pass metabolism and potential of long-term controlled release. 
However, the greatest potential for the topical administration route is targeted drug delivery to the skin itself, 
where dramatically higher skin-to-plasma ratios are attained compared to systemic drug delivery. This route of 
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administration can therefore maintain therapeutically effective drug concentrations in the target organ without 
the risk of inducing side-effects due to high systemic exposures (17).  
 
In the clinical setting, there are currently no sampling techniques which can be used to demonstrate dermal 
bioavailability or bioequivalence of topically applied agents which are both minimally invasive and which also 
give an indication of tissue concentration at a target site in the skin with time. Dermal microdialysis has the 
potential to address the gap in available sampling techniques due to its minimally invasive nature and its ability 
to generate concentration-time profiles at the target site with good resolution provided a sufficiently sensitive 
analytical method is available (18). 
 
1.2.2. Overview of microdialysis 
Microdialysis is a technique for sampling of endogenous and exogenous substances in the extracellular space in 
living tissue (19,20). The technique was originally developed in neuropharmacological sciences but has now 
been used extensively in other tissues in animal models and human studies (18,20). In human studies, this 
technique has been employed in adipose tissue, brain, heart, lung, solid tumours, skin etc (17,21,22). Initial 
clinical studies using microdialysis have demonstrated the suitability of this method for the measurement of 
drug concentrations in the interstitium of target tissues and allow for the description of relative changes of 
concentration-time courses of solutes against a baseline (22). The figure below shows a linear microdialysis 
probe inserted into the dermis prior to topical application (19). 
 
 
 
1.2.3. Principles of microdialysis 
A microdialysis fibre consists of a semipermeable membrane forming a thin hollow ‘tube’ (typically 0.22 mm 
ID), which functionally resembles a blood vessel. The fibre allows the passage of molecules with a volume 
smaller than the cut-off value of the membrane. The fibre has 1 end connected to an impermeable tube which 
leads to a micropump and the other end to an efferent sampling tube. For dermal microdialysis, the probe is 
implanted in the dermis of the skin via a guide cannula. The microdialysis fibre is slowly perfused with 
physiological solution, which equilibrates with extracellular fluid of the surrounding tissue exchanging 
substances smaller than the cut-off value of the membrane during the passage through the fibre. Entering the 
microdialysis fibre, the solution is termed perfusate and following dialysis of substances, the solution exiting the 
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fibre is termed dialysate (17). The diffusion of substances across the dialysis membrane will occur by passive 
diffusion, driven across the membrane by the concentration gradient; the speed of equilibrium is consequently 
proportional to the size of the gradient and diffusion rate of the medicine in the medium, in addition to the 
surface area of the fibre membrane. Using continuous flow through the probe, compounds will be recovered by 
the membrane and sampled for further analysis. As substances are able to diffuse in both directions through the 
membrane, microdialysis can principally be used to both extract and deliver substances in tissues (20). 
 
 
 
The figure above depicts the principle of microdialysis sampling by a linear probe (20). The perfusate is pumped 
through the probe at a preset, low flow rate. During the passage through the membrane, the diffusion of small 
molecules will take place. 
 
1.2.4. Insertion trauma and invasiveness of dermal microdialysis sampling 
Dermal microdialysis sampling has been described by authors as a minimally invasive technique (18,20). The 
insertion of microdialysis probes creates slight but reversible trauma which initially causes an acute 
inflammatory reaction characterised by increased blood flow, erythema and skin thickness. This is caused by the 
use of a 21G guide cannula/hypodermic needle for insertion of the linear microdialysis probe. An equilibration 
time of 60 min has been reported to be sufficient to allow the skin to normalise (20). Histological examination 
of skin biopsies showed no signs of an inflammatory reaction in the tissue around the probe 8-10 h after probe 
insertion. Ice induces anaesthesia during probe insertion to provide minimum discomfort to the human 
volunteer. No significant discomfort is observed when the cannulae have been removed. Hydrocortisone (0.1%, 
m/m) cream applied twice daily for 2 weeks is used to arrest any residual inflammation after the completion of 
the study. Sterile techniques will be employed during this study to ensure the minimum risk of skin infections. 
 
1.3. Tape stripping technique 
1.3.1. Overview of tape stripping 
Tape stripping is a non-invasive technique employed to study the penetration, the distribution and the 
dermatopharmacokinetics of topically applied drugs and cosmetics products (23-26) within the 
stratum corneum. It is commonly used to disrupt the epidermal barrier to enhance the delivery of 
drugs in vivo (27) and to obtain information about stratum corneum function (25). Tape stripping has 
been used extensively in dermatological and pharmaceutical fields to measure the stratum corneum 
mass and thickness, to collect stratum corneum lipids and protein samples, detect proteolytic activity 
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associated with the stratum corneum, quantitatively estimate enzyme levels and activities in the stratum 
corneum and allow the detection of metal in the stratum corneum (25). Although in use for over 5 decades there 
are no universally accepted protocols for tape stripping (28), however it has been identified to be of sufficient 
utility to have been proposed by the FDA as part of a standards method to evaluate the bioequivalence of topical 
dermatological dosage forms (29). 
 
1.3.2. Principles of tape stripping 
Tape stripping involves the sequential removal of microscopic layers (~ 0.5-1 μm) of the stratum corneum 
(24,30) by placing a strip of adhesive tape onto the skin surface with uniform pressure, which is then removed 
(23,24). Drug uptake into the stratum corneum in vivo can be measured by harvesting the stratum corneum 
previously exposed to a topical product with adhesive tapes, which are subsequently extracted and quantified for 
drug concentration by a validated analytical method (31). The number of tape strips needed to remove the 
stratum corneum varies with age, gender, anatomical site, skin condition and possibly ethnicity (25). Tape 
stripping is putatively simple, inexpensive and has been described as a minimally invasive technique (23). 
 
1.3.3. Invasiveness of tape stripping 
Although tape-stripping is considered to be essentially non-invasive, stripped sites in certain dark-skinned 
individuals may remain hyperpigmented for several months after healing. This effect will be communicated to 
the human volunteers before entering the study (24). 
 
2. STUDY PRODUCTS 
2.1. Description 
 Test product 
  
Commercial name Fastum® gel 
Generic name Ketoprofen gel 
Dosage form Gel 
Strength 2.5%, m/m 
Manufacturer Adcock Ingram, South Africa 
MCC registration details Z/3.1/165 
In-house batch # RNO1-01 
Expiry date 09/2010 
Description A mucilaginous, colourless almost transparent gel with an aromatic odour 
Dosage 90 μl (± 30 mg) per application site 
 
2.2. Supply, storage and use 
Sufficient test products will be timeously supplied to the clinic by the principal investigator prior to the study. 
On arrival the quantity, batch numbers and expiry dates of the test products will be recorded in the appropriate 
register and products stored in a secure cabinet. Dispensing and administration of test products will be recorded 
and administered only to subjects for the purpose of this study. Ketoprofen is available in gel, cream, ointment 
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and gel-spray preparations (32). However, only the gel preparations will be utilised in this study. It will be used 
externally. 
 
3. OBJECTIVES 
The objective of this study is to measure dermal concentrations of ketoprofen using both microdialysis and tape 
stripping to assess in vivo bioavailability from a topical gel formulation and therefore obtain valuable 
information which will lay the foundation in an attempt to determine bioequivalence of ketoprofen topical 
formulations using these 2 techniques. In addition, the 2 techniques will be compared for their effectiveness in 
the assessment of dermal bioavailability. 
 
4. STUDY POPULATION AND MEDICAL ASSESSMENT 
4.1. Number of subjects 
Similar studies have made use of 6-18 human subjects for this type of study (27,33-37) with equal numbers of 
male and female subjects. This study will make use of 10 human subjects and will make use of an equal number 
of male and female subjects. Four application sites on the left arm of each subject will be used for the 
microdialysis study whereas 2 application sites on the right arm of each subject will be used for the tape 
stripping studies. Preliminary statistical analysis (Section 8) will be performed on the subjects completing the 
study. If needed, an add-on study of up to 10 subjects will be conducted to obtain a degree of variability of less 
than 30% if possible. If no further study is required, preliminary statistical analysis will be finalised and 
presented in the final report. If an add-on study is conducted, data for all evaluable subjects from both Group 1 
and Group 2 will be used in preparation of the final report. Homogeneity testing will be conducted between the 
2 groups. 
 
4.2. Inclusion/Exclusion criteria 
Inclusion criteria 
Only those subjects meeting the following criteria will be included in the study: 
i. Female subjects who are using reliable contraception or abstaining. 
ii. Subjects who are aged between 18 and 50. 
iii. Subjects who are in general good health. 
iv. Subjects who will be available for the entire study period. 
 
Exclusion criteria 
Subjects meeting the following criteria will be excluded from the study. 
i. Female subjects who are breast feeding. 
ii. Female subjects who are contemplating becoming pregnant in the time immediately following the 
study. 
iii. Female subjects who are pregnant. 
iv. Subjects who have a known allergy/hypersensitivity to ketoprofen or any NSAID including 
aspirin. 
v. Subjects who have any history of drug or alcohol abuse. 
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vi. Subjects who have any mental deficiency or handicap. 
vii. Subjects who have hairy ventral forearm surfaces and/or abrasions on the underside of their 
forearms. 
viii. Subjects who have engaged in any sun-tanning or taken any sunny vacations within the last month. 
ix. Subjects who have participated in another NSAID dermal microdialysis or tape stripping study 
within 2 months of the study date. 
x. Subjects who have used any NSAIDs within the last 3 months. 
xi. Subjects who suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood 
eczema). 
xii. Subjects who suffer from any skin disorder such as psoriasis, eczema or other relevant skin 
disorder. 
xiii. Subjects who take regular medicine or tablets or used any creams within the last week 
(contraceptive pills excluded). 
xiv. Subjects who test positive for HIV and Hepatitis B. 
xv. Subjects with a history of any neurological, kidney or liver disorders. 
 
4.3. Subject restrictions 
i. No prescription medication and OTC medication (e.g. cold preparations, vitamins, natural products 
used for therapeutic benefits, antacids, herbal or traditional remedies) will be allowed for at least 1 
week prior to the study. 
ii. With the exception of study product no concomitant medication may be taken by subjects during 
the study. 
iii. No alcohol may be taken by subjects from 24 h prior to product application and during the study. 
iv. No strenuous physical activity may be undertaken by subjects from 12 h before product application 
and during the study. 
v. Subjects must not smoke more than 10 cigarettes per day and will not be allowed to smoke during 
the study. 
vi. Subjects must refrain from applying emollients, skin conditioning creams and/or tanning lotions to 
their forearms for a period of 24 h prior to the scheduled time of product application. 
 
Subjects will be informed of the above restrictions and each subject will be specifically questioned on these 
points prior to product application. Any deviations from the above restrictions which are made known to the 
investigators either voluntarily or on questioning will be recorded on the appropriate Case Report Form (CRF) 
(Appendix RP F). A decision as to whether the affected subject continues with the study will be taken by the 
principal investigator and the supervisor in consultation with the study nurse. 
 
4.4. Criteria for removal from the study 
Any subject may be withdrawn from the study at any time due to the following: 
i. Voluntary withdrawal by the subject due to any reason. 
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ii. Illness or injury during the study if regarded as clinically significant by the principal investigator 
and the supervisor in consultation with the study nurse. 
iii. Any adverse event or signs of toxicity if regarded as clinically significant by the principal 
investigator and the supervisor in consultation with the study nurse. 
iv. Failure of the subject to comply with or be uncooperative towards any study requirements or 
restrictions if regarded as clinically significant by the principal investigator and the supervisor in 
consultation with the study nurse.  
Subjects withdrawn or dropped out of the study will be fully documented and accounted for in the CRF. 
 
5. STUDY PROCEDURE 
5.1. Pre- and post-study medical screening 
Pre-study screening will be conducted not more than 30 days prior to the start of the study. Post-study follow-up 
will be conducted within 48 h after removal of the microdialysis probes from the forearm of the subject either at 
the end of the study or termination of the study or withdrawal from the study. Pre-study and post-study 
evaluations will be conducted as listed in the table below. 
 
Screening test Pre-study Post-study 
   
Medical tests √1 x 
Medical history √2 √5 
Dermatological assessment √3 √6 
Adhesive sensitivity √4 x 
 
1. Medical tests:  HIV, Hepatitis B and pregnancy test 
2. Medical history: Demographic data (date of birth, age, sex, origin), skin (dermatological), allergies, alcohol consumption, 
smoking habits, dietary habits and sporting commitments. 
3. Dermatological:  General assessment of the volar aspect of the forearm and any dermatological condition which may 
influence the barrier function of the skin and impact on the absorption of topically applied NSAIDs. 
4. Adhesive sensitivity:  Assessment of subject’s sensitivity to adhesive on application site demarcation tape. 
5. Medical history: Since start of study. 
6. Dermatological: Examination of forearms and application sites. 
 
If any study related abnormalities are observed at the post-study medical, appropriate follow-up action will be 
taken and re-examination and re-testing conducted until the abnormality returns to normal or until the study 
nurse considers the abnormality to be clinically insignificant. 
 
5.2. Medical tape sensitivity screening 
No less than 30 days prior to the start of the study, volunteers will undergo an assessment of their tolerance to 
the adhesive on medical tape used to demarcate application sites and for tape stripping procedures. 
The following screening protocol will be utilised. 
i. The forearm of the subject will be washed 1 h prior to the adhesion of the medical tape. 
ii. Adhesion of the medical tape will occur at 0700 h. 
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iii. Two different types of medical tapes to be employed as templates and for tape stripping will be 
used on each side of the arm. 
iv. Six h after application, the medical tapes will be removed. 
v. The forearm of the subject will be assessed for allergies to the adhesive medical tapes. 
  
Subjects who exhibit allergies will not be eligible as candidates for the study.  
 
5.3. Check-in and confinement 
Subjects will check-in at the clinic (Room T17) in the Faculty of Pharmacy building, Rhodes University, 
Grahamstown at 0700 h on the morning of the study day when they will undergo a brief medical examination, 
inclusion and exclusion criteria check and study restriction check. Subjects accepted into the study will then be 
prepared for product application. Subjects will remain in the study room for the entire duration of the study. 
 
5.4. Study design 
The study will comprise a single phase sequential design conducted on 10 subjects in the first instance, followed 
by another 10 subjects if necessary (see section 4.1). Only a single subject will be studied at any one time on any 
study day and the time between the first and the tenth subject is expected to be approximately 6 weeks. A total 
of 4 probes and application sites will be employed on the left arm for the microdialysis study whereas 2 
application sites will be employed on the right arm on each subject for the tape stripping study. The duration of 
the study for each subject will be approximately 10 h. 
 
Microdialysis probes prepared as described in section 5.6 will be inserted approximately 0.6 to 0.8 mm beneath 
the skin surface for a distance of 3 cm as described in section 5.7. Probes will be inserted parallel to each other 
across the volar aspect of the left forearm approximately 3 cm apart using 21G x 1½" hypodermic needles as 
guide cannulae. Application of an ice pack will anaesthetise the area of cannulation. No other anaesthetic will be 
necessary and the procedure during and after probe insertion is essentially pain-free (20). Probes will remain in 
place for no longer than 8 h. 
 
At the end of the microdialysis study, templates for use with the tape stripping study will be affixed on the right 
arm of the subjects with pieces of Micropore™ 1530 tapes. These will be used to demarcate (2 x 2 cm) the 
stratum corneum sampling site. The templates will be designed to have 2 sampling sites, 1 site for the 
application of the formulation and the other for use as control. The test formulation will be applied to 1 
application site and after a 30 min exposure period the excess drug will be removed by wiping with a cotton 
swab. Adhesive tapes (Transpore™ 1527 tapes) will be applied concurrently to both application sites with 
uniform pressure and then subsequently removed. Fifteen (15) successive strips will be made from both sites. 
Transepidermal water loss measurements will be recorded from the control application site. This procedure will 
take approximately 1 h. 
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5.5. Pre-study day activities and procedures 
This study is dependent on a number of preparations prior to the study. The following is a list of items that will 
be made available at least 24 h prior to the study. 
i. The linear microdialysis probes will be manufactured in-house no more than 24 h before the study 
(Section 5.6). 
ii. Microlitre glass (300 µl) inserts for use with the analytical procedure will be soaked overnight with 
chromic acid, rinsed thoroughly with double-distilled water and then soaked in methanol. This will 
be done no more than 48 h before the study. 
iii. Calibration standards and mobile phase for ketoprofen analysis will be prepared. 
iv. Pre-weighed sampling vials or centrifuge tubes will be labelled and ready for sample collection. 
v. Sterilisation solution (70%, v/v ethanol) will be prepared. 
vi. Microdialysis syringes, a pair of stainless steel scissors, a pair of tweezers, spatula, and a glass rod 
will be left overnight in sterilisation solution. 
vii. The checklist will be performed (Appendix RP B). 
viii. The general setup of the clinic will be ensured. 
 
5.6. Linear microdialysis probe manufacture 
The linear probes used for the study will be manufactured in-house by the principal investigator. The probes will 
be prepared no more than 24 h prior to each study day. The following manufacturing protocol will be used to 
prepare the linear probes for the study. 
i. The desired lengths of the Portex® tube (30 cm), Hemophane, (8 cm) and stainless steel wire (10 
cm) will be cut. 
ii. Stainless steel wire will be degreased with acetone. 
iii. Hemophane fibres will be carefully threaded with the stainless steel wire, which will provide 
mechanical strength to the probe assembly. 
iv. A length of Portex® tube will be glued with cyanoacrylate glue (Loctite®) to one end of the 
Hemophane fibre-stainless steel wire setup. This assembly will now be referred to as the probe. 
v. Probes will be left to dry for 2 h. 
vi. Preliminary leak tests will be performed with double-distilled water. 
vii. Blue tubing connectors will be attached to the Portex® end of the probes. 
viii. Probes will be stored in a clean glass petri dish with cover and conveyed to the clinic. 
ix. Six probes will be manufactured in the unlikely event that a probe fails the preliminary leak test. 
x. The probes will be sterilised by soaking in ethanol solution (70%, v/v) 20 min before use in 
subjects. 
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5.7. Study day activities and procedures 
5.7.1. Microdialysis study 
i. Study sessions will begin at approximately 0700 h each study day. 
ii. Verification by history of adequate washout of excluded drugs. 
iii. Checklist will be confirmed (Appendix RP B). 
iv. CMA microdialysis syringes pre-sterilised over night (Section 5.5) will be flushed and filled with 
sterile normal saline (perfusate). 
v. Probes will be connected to the syringes and a final 20 drop leak test will be manually performed 
using perfusate prior to installing the syringes into the CMA microdialysis pumps. 
vi. The syringes connected to the probes will be housed in the CMA microdialysis pump and aligned. 
vii. Subjects will be advised to take a bathroom visit. 
viii. The left forearm of the subject will be rinsed with mild soap and water and then blotted dry with a 
non-abrasive towel. 
ix. Subjects will be requested to either lie on a bed or sit in an arm chair. 
x. The wrist will be loosely restricted using a bandage to prevent any sudden jerk during and after the 
insertion of the probes. 
xi. Four parallel application sites aligned in a straight line from the elbow joint to the wrist will be 
demarcated on the ventral surface of the forearm of the subject using adhesive labels with a 1.0 cm 
x 3.0 cm application area cut out. 
xii. Entry and exit points through which the guide cannulae (21G x 1½") will be inserted will be 
marked on the forearm at the ends of each application site. 
xiii. Ice packs will be placed on each application site and, by employing sterile technique, guide 
cannulae will be inserted between 0.6 and 0.8 mm below the surface of the skin for a distance of 3 
cm transversally across the volar forearm in parallel at the 4 sites. The application of ice pack at 
each site on the forearm may have to be repeated during the insertion process. 
xiv. Care will be taken to maintain placement in the superficial dermis in order to minimise intra-probe 
depth variability. 
xv. Probes which have been sterilised by soaking into ethanol solution (70%, v/v) will be taken from 
the ethanol bath and the Hemophane portion introduced through the guide cannulae. 
xvi. The guide cannulae will then be removed leaving the Hemophane portion of the probe in the 
dermis with the Hemophane/Portex® junction abutting the dermal insertion point. 
xvii. Portex® tubing at the end of each probe will be secured on the arm with Micropore™ tape. 
xviii. Entry and exit points will be sealed with a drop of cyanoacrylate glue. 
xix. Adhesive labels (templates) will be placed over the probes to demarcate the product application 
area. 
xx. Perfusion of the probes will commence at 0.5µl/min for 15 min followed by 1.25 µl/min for 45 
min. 
xxi. Blank samples will be collected for 30 min. 
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xxii. Approximately 30 mg of the product will be applied to each site from a preloaded Eppendorf® 
pipette (Section 5.8). Individual doses of the product will be spread evenly over the application site 
using a glass rod. 
xxiii. Samples of perfusate will be collected continuously in 30 min aliquots in a period of 5 h, i.e. 10 
samples. 
xxiv. At the end of the last sampling period, the Portex® tubing will be severed from the pump setup and 
if necessary will be further secured on the forearm of the subject. 
xxv. Templates will be removed from the forearm of the subjects. 
xxvi. Ultrasound scanning will be conducted to determine the exact depth of each probe underneath the 
surface of the skin. 
xxvii. Probes will be carefully removed from the forearm of the subject ensuring that both the 
Hemophane fibre and the stainless steel wire are removed. 
xxviii. The application site area will be dressed with alcohol swabs and small adhesive plasters. 
xxix. Subjects will receive a tube of hydrocortisone cream (0.1%, m/m) to be used twice daily for 2 
weeks on the forearm to reduce any swelling caused by the insertion of the probes. 
xxx. The CMA microdialysis syringes, stainless steel scissors, tweezers, spatula, and glass rod will be 
sterilised overnight for use with the next subject. 
 
NB: There will no re-use of apparatus inserted into subjects. Such apparatus will be discarded as 
biological waste. 
 
5.7.2. Tape stripping study 
i. Adhesive tape strips (Transpore™ 1527) for the tape stripping study will be pre cut. 
ii. The template for use with tape stripping will be affixed onto the right forearm with Micropore™ 
(1530) tapes to delineate the application sites on the stratum corneum. 
iii. The test formulation will be applied to 1 of the 2 application sites while the other site will be used 
as control. 
iv. Excess test formulation will be removed from the application site after a 30 min exposure period 
using a cotton swab. 
v. Tape strips will be applied with uniform pressure to both sites and then subsequently removed. 
vi. Fifteen (15) successive strips will be removed from each site. 
vii. The removal of strips will be done in a clockwise manner (N, E, S, W) ensuring that equal amount 
of stratum corneum is removed in each of the 4 sides. 
viii. Transepidermal water loss measurements will be measured from the control site 
ix. The template will be removed from the subject. 
x. The forearm will rinsed to remove any residual drug. 
 
The actual time of study procedures and/or results/comments obtained during the study will be recorded on the 
‘Registration of Data during Microdialysis Form’ (Appendix RP C). The tape stripping procedure will 
commence after the microdialysis procedure is complete. 
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5.8. Product application 
Just prior to the product application, an Eppendorf® (0.5 ml) pipette will be filled with the test product. The 
setting will be adjusted (3 on the dial of the Eppendorf® dispenser) to ensure that the correct amount (30 µl) of 
the test product required for application on each site will be dispensed. The test product will be dispensed 3 
times at each application site to allow 90 µl (± 30 mg) of test product (corresponding to 0.75 mg of ketoprofen) 
to be applied at each site. The Eppendorf® dispenser will be used to ensure that an accurate amount of test 
product is dispensed to each application site for each subject. Application of the test product will be done by the 
principal investigator. 
 
5.9. Posture and physical activity 
Subjects will be expected to lie on a bed or sit in an arm chair for the duration of the microdialysis and tape 
stripping procedure with the forearm restricted loosely with a bandage. Subjects will not be able to walk around 
from the time of the first probe insertion until the disconnection of the probes from the microdialysis pump. This 
will be a period of approximately 8 h. Strenuous exercises will not be permitted as described in section 4.3. 
 
5.10. Food and fluids 
Subjects will not be restricted with respect to food and fluid intake. However subjects will be advised to keep 
fluid intake to a minimum, so as to not develop the urge to visit the bathroom during the study. 
 
5.11. Subject monitoring 
The principal investigator will be present at all times during the study. Subjects will be asked open-ended 
questions about their health at the time of each assessment and any discomfort observed during the experience 
will be recorded in the CRF (Appendix RP F). The study nurse will be contactable by phone for the duration of 
the study. 
 
6. SAMPLE ANALYSIS 
Samples will be analysed for ketoprofen using a validated extraction procedure and UPLC/MSMS analytical 
method. Analysis will be done within 24 h after sample collection. 
 
7. DATA ANALYSIS 
For the microdialysis study, concentration-time profiles will be generated and the AUC will be calculated using 
the trapezoidal rule. The Cmax and Tmax will also be calculated. The data used to estimate AUC will be reported. 
Normalised concentration-strip profiles will be generated for the tape stripping study. Deletion of data from 
analysis will be justified. All individual subject data will be documented and the individual dermal 
concentration-time and concentration-strip curves will be presented in linear/linear and log/linear scale. 
 
7.1. Statistical analysis 
Pharmacokinetic and statistical parameters to determine bioequivalence will be calculated with a statistical 
package SAS® (SAS Institute Inc., Cary, North Carolina, USA). AUC0-5 will be tested for comparative 
bioavailability using a 2 one-sided test procedure and bioequivalence concluded if the 90% CI of the log 
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transformed AUC0-5 data for pairs of test/reference application areas are within the acceptance range of 80-
125%.  
 
8. ETHICAL AND REGULATORY REQUIREMENTS 
8.1. Ethical and institutional review 
Approval by the Rhodes University Ethical Standards Committee (RUESC) will be obtained before the study 
commences. The original signed copy of the ethical approval will be retained by the principal investigator. 
 
The study will be conducted in accordance with the recommendations of the guidelines as set out in the 
Declaration of Helsinki (1964) and its amendments and carried out in compliance with the guidelines on the 
conduct of clinical trials in South Africa. 
 
8.2. Written informed consent 
Preceding the study, the nature, purpose and risk of participating in the study will be explained to all volunteers. 
If volunteers desire, they will be given time to consider the information and any questions that they might have 
will be answered. The nature of the insurance cover will also be explained. They will also be informed that they 
may withdraw from the study at any time without penalty to themselves (other than a reduced remuneration) but 
that they will be encouraged to be committed to completing the study prior to their enrolment. They will sign a 
consent form in the presence of a witness. Subjects will receive written, detailed instructions concerning the 
study performance and restrictions. 
 
8.3. Case report form 
The Case Report Form (CRF) for this study will be designed and supplied by the principal investigator 
(Appendix RP F). All case report forms will be quality assured and all major events such as final acceptance of a 
subject, adverse events and final release from the study will be signed by both the principal investigator and the 
study nurse. 
 
8.4. Record retention 
All source documents, study reports and other study documentation for which the principal investigator is 
responsible will be archived and retained by the Faculty of Pharmacy, Biopharmaceutics Research Group. 
Results will be published in the scientific journals and/or presented in a thesis submitted to Rhodes University in 
fulfilment of the requirement for the degree of Doctor of Philosophy (Pharmacy) after the completion of the 
study. 
 
8.5. Insurance 
Subjects will be insured against any permanent adverse effect on their health which may arise in connection 
with the conduct of the study. A copy of the certificate of insurance (Appendix RP G) will be provided to 
RUESC as part of the application to conduct this study. Adequate insurance cover in the event of negligence on 
the part of principal investigator, the supervisor and the study nurse will be ensured. 
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8.6. Termination of the study 
The principal investigator reserves the right to terminate the study in the interests of subject welfare following 
consultation with the supervisor and the study nurse. The supervisor may terminate the study at any time for 
scientific or safety reasons. If the study is prematurely terminated or suspended for any reason the principal 
investigator will promptly explain to the subjects, take appropriate steps as deemed necessary under the 
circumstances to assure the subjects and where applicable follow up with therapy and inform the RUESC. 
 
8.7. Adherence to protocol 
Excluding an emergency situation in which proper treatment is required for the protection, safety and well-being 
of study subjects, the study will be conducted as described in the approved protocol. Any deviation from the 
protocol will be recorded and explained. 
 
Should amendments to the protocol be required, the amendments will be documented and signed by the 
principal investigator and the supervisor. If the protocol amendment(s) has an impact on the safety of subjects, 
such as a change in dosing regimen or additional formulations, the amendment will be submitted to the RUESC 
for approval. 
 
8.8. Blinding 
Subjects will not be blinded and will be informed about the test product for use at the application sites. 
 
8.9. Adverse events/Adverse drug reactions 
Subjects will be questioned on their health status at check-in, during the course of the study and before leaving 
the clinic at the end of the study. During the study, open-ended questions will be asked. If any adverse events 
are reported, the principal investigator together with the study nurse will monitor the adverse event, initiate 
appropriate treatment if required and decide whether or not to withdraw the subject from the study. Signs and 
symptoms of any adverse events which occur during the study will be fully documented in the appropriate CRF 
(Appendix RP F). If necessary, adverse events will be referred to a suitably qualified medical practitioner for 
assessment and follow up. 
 
Adverse events (AEs) (which include illnesses, subjective and objective signs and symptoms that have appeared 
or worsened during the course of the study) will be assessed by the principal investigator and the supervisor in 
consultation with the study nurse during and after the study to determine whether or not they are adverse drug 
reactions (ADR) to the investigational test product, related to the study procedure or other. The outcome of this 
assessment will be recorded in the appropriate CRF (Appendix RP F). 
 
AEs classified as severe or serious will be reported to the supervisor/study nurse, Rhodes University Ethical 
Standards Committee within 24 h. 
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ADRs classified as serious and unexpected will be subject to expedited reporting as detailed in the ICH E2A and 
E2B guidelines on Clinical Safety Data Management and Data Elements for Transmission of Individual Case 
Report Forms respectively. 
 
 
9. REPORTS 
A full report on the study will be compiled by the principal investigator in the format requested by the 
supervisor and submitted to the supervisor. The analytical report will include results for all standard and quality 
control samples. A representative number of chromatograms or other raw data will be included covering the 
whole concentration range for all standards and quality control samples. The validation report will also be 
submitted. 
 
ABBREVIATIONS 
ADR Adverse Drug Reaction 
AE Adverse Effect/Event 
AUC Area Under the Curve 
BRG Biopharmaceutics Research Group 
Cmax Maximum Concentration 
CRF Case Report Form 
GCP Good Clinical Practice 
ICH International Conference of Harmonisation 
RUESC Rhodes University Ethical Standards Committee 
SOP Standard Operating Procedure 
Tmax Maximum Time 
UPLC/MSMS Ultra Pressure Liquid Chromatography Mass Spectroscopy 
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APPENDIX I: RP A 
PRODUCT INFORMATION LEAFLET 
 
 
 
 
 
SCHEDULING STATUS: S1 
PROPRIETARY NAME (and closage form): 
Fastum® gel 
COMPOSITION: 
Each 100 g contains 2,5 g ketoprofen i.e. 2,5 % mlm 
Preservatives: p-hydroxybenzoic acid esters 0,1 % m/m 
PHARMACOLOGICAL CLASSIFICATION: 
A 3.1 Antirheumatics (anti-inflammatory agents) 
PHARMACOLOGICAL ACTION: 
Ketoprofen is a non-steroidal anti-inflammatory agent. Since ketoprofen is an 
inhibitor of prostaglandin synthesis it provides for anti-inflammatory, analgesic 
effects. Fastum Gel is ketoprofen in an excipient suitable for allowing it to 
reach the site of inflammation by transcutaneous route, providing the local 
treatment of painful joints, tendons, ligaments and muscles. 
INDICATIONS: 
For the relief of localised pain and inflammation associated with acute musculo-
skeletal injuries. 
CONTRA-INDICATIONS: 
Known hypersensitivity to any of the ingredients. 
Safety of Fastum Gel during pregnancy and lactation has not been established. 
Safety in children has not been established. 
WARNINGS: 
The prolonged use of pwclucts for topical application may cause hypersensitivity 
phenomena. In such cases the treatment should be discontinued and a 
suitable alternate therapy instituted. 
Since the application of Fastum Gel may provoke photosensitisation, the 
treated skin area should not be exposed to the sun. 
DOSAGE AND DIRECTIONS FOR USE: 
Treatment should not exceed 7 days. 
Persons 12 years and older: Apply to the affected area once or twice daily by 
gently massaging in order to help absorption. Apply 5 to 15 cm of gel with 
each application (100 - 300 mg ketoprofen). 
SIDE EFFECTS AND SPECIAL PRECAUTIONS: 
ConSidering the very low systemic absorption by topical application, systemic 
side effects are not expected, but cannot be excluded. 
Side effects experienced with systemically absorbed ketoprofen include: 
111III1I1 
111111111 
Gastro-intestinal, peptic u!ceration, gastro-lntestinal bleeding, headache, 
diZZiness, nervousn!'lss, skin ra~~es, pruritus, tinnitus, oedema, depression, 
droWSiness, Insomma, blurred vIsion and other ocular reactions. 
Sensitivity reactions, abnormalities of liver function tests, impairment of renal 
function including interstitial nephritis or nephrotic syndrome, agranulocytosis 
and thrombocytopema may occur less frequently. 
Fastum Gel should be used with caution in patients with asthma or 
bronchospasm, bleeding disorders, cardiovascular disease, peptic ulceration 
or a history of such ulceration, renal failure and in those who are receiving 
coumarin anticoagulants. 
Fastum Gel should not be applied to open wounds or lesions of the skin, or 
near the eyes. 
Do not apply to mucous membranes. 
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS 
TREATMENT: 
Treatment is symptomatic and supportive. 
IDENTIFICATION: 
A mucilaginous, colourless almost transparent gel with an aromatic odour. 
PRESENTATION: 
50 g and 100 9 tubes. 
STORAGE INSTRUCTIONS: 
Store below 25°C. 
Keep out of reach of children. 
REGISTRATION NUMBER: 
Z/3.1/165 
NAME AND BUSINESS ADDRESS OF THE APPLICANT: 
MENARINI SA (PTY) LTD 
Epsom Downs Office Park, Sloane St., Bryanston, 2152 
Date of publication of this package Insert: 13.12.91 
Marketed by RESTAN LABORATORIES 
~ Zf3.1/165 
FASTUM®6.PJ 
NON - STEROIDAL ANTI - INFLAMMATORY ~~ 50 9 
Fast Topical Pain Relief j 
_.:...-- ...... -- -"--:~---. -~-.--~ ~---.:~-.--- ,: 
FOR EXTERNAL USE ONLY 
Each 100 9 contains KETOPROFEN 
2,5 g; p-hydroxybenzoic acid esters 0 ,1% nn1m 
(as preservative) . 
KETOPROFEN 
SLEGS VIR UITWENDIGE GEBRUIK 
Elke 100 9 bevat KETOPROFEN 
2,5 g ; esters p-hidroksie bensoesuur 0 ,1% nn1m 
(as preserveermiddel) . 
Store below 25 ·C out of reach of children 
Bewaar onder 25 ·C buite bereik van kinders 
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CHECKLIST 
SUBJECT NAME  SUBJECT INITIALS  DATE  
STUDY NUMBER RNO_01_2007 VOLUNTEER 
REFERENCE 
   
2.5 ml microdialysis syringes (labelled were necessary)  
21G 1½” intravenous needles  
3M Micropore™ tape (1530)  
3M Transpore™ tape (1527)  
Alcohol swabs  
Bandages  
Biological waste container (yellow)  
Calculator  
CMA 400 microdialysis pumps setup  
Cotton swabs  
Cyanoacrylate glue (Loctite® glue)  
Electrical cables and power supply  
Eppendorf® preparations  
Glass rod  
Glue remover-Bostix®  
Green cloth underlay  
Human subject under study  
Ice packs  
Pen/marker  
Perfusate solution-Normal saline  
Prepared probes attached to blue connectors (leaks pre-checked with water) in glass dish  
Pre-weighed and labelled sampling vials/centrifuge tubes  
Ruler  
Scissors  
Snack/Lunch/Supper  
Soap and towel  
Sterile gloves  
Sterilisation ethanolic solution (70%, v/v)  
Sterilisation trays  
Templates for sampling  
Thermometer  
Timer  
Tweezers  
Ultrasound scanner setup  
CHECKED BY: SIGNATURE: 
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REGISTRATION OF DATA DURING MICRODIALYSIS EXPERIMENTS 
Date  Subject initials  
Subject/Volunteer name  Volunteer Reference  
Age  Study number RNO_01_2007 
Sex  
Race  
Formulation  
Applied dose  
Site  
Principal Investigator  
Assistant principal 
investigator 
 
Room temperature  
Relative Humidity  
 
 
TIME SCHEDULE 
Task Time start Time stop Comments 
Confirm Inclusion and Exclusion criteria    
Confirm consent form    
Confirm checklist    
Fill syringes with perfusate    
Connect probes to syringes    
Preliminary leak check (20 drops)    
Flush and align syringes in CMA 400 pump    
Bathroom visit (volunteer!!)    
Forearm wash    
Wrist bandage to be placed    
Mark entry and exit points on arm    
Probes put in ethanol soak (20 min)    
Remove probes from ethanol soak    
Ice pack on arm    
Insertion 1    
Ice pack on arm    
Insertion 2    
Ice pack on arm    
Insertion 3    
Ice pack on arm    
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Insertion 4    
Probe insertion (4 probes)    
21G intravenous needle removal    
Seal entry and exit points (15 min)    
Place test area (templates) over probes    
Secure Portex® on the arm with Micropore™    
Stabilise flow at 0.50 µl/min (15 min)    
Stabilise flow at 1.25 µl/min (45 min)    
Collect blank solutions    
Application of test formulation and 
commence sampling every 30 min 
   
End of microdialysis sampling    
Cut the Portex® tubing to the pump    
Remove the templates from the arm    
Ultrasound scanning    
Probes out of arm    
Dress area with alcohol swabs and bandages    
Ethanol soak of equipment    
End of study    
 
 
ULTRASOUND SCANNING 
 Probe 1 (mm) Probe 2 (mm) Probe 3 (mm) Probe 4 (mm) 
 Skin Probe Skin Probe Skin Probe Skin Probe 
Scan 1(a)         
Scan 2(b)         
Scan 3(c)         
Mean         
Std Dev         
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APPENDIX I: RP D 
INFORMATION FOR VOLUNTEERS BROCHURE 
 
APPLICATION OF DERMAL MICRODIALYSIS AND TAPE STRIPPING FOR THE ASSESSMENT 
OF THE BIOAVAILABILITY OF KETOPROFEN IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: RNO_01_2007 
PROTOCOL VERSION 1 
BROCHURE VERSION 1 
JULY 2007 
 
1. Study objective 
The study involves research to assess the rate and extent to which ketoprofen diffuses into the skin from a 
generic product, using dermal microdialysis and tape stripping as a measure of efficacy. This study will provide 
valuable insight for use in the assessment of sameness of generic and proprietary ketoprofen formulations. 
  
Test product Fastum® Gel 
Drug Ketoprofen (2.5%, m/m) 
Company Adcock Ingram Limited 
 South Africa 
 
The study will involve 10 subjects. 
 
2. Ethical considerations and standards of practice 
Innovator drug companies who develop a new drug have patent protection for the drug for a number of years, 
typically 15-20. Once the patent has expired, generic drug companies are permitted to make and market their 
own products as competitors to the innovator's product, usually at a substantially reduced cost. However, a 
prerequisite for registration with national drug registration bodies (and subsequent marketing) is that the rate and 
extent to which the drug is absorbed from the generic product is shown to be equivalent to that from the 
innovator product. This is an indirect way of demonstrating that the generic product will be as effective 
clinically as the innovator and is demonstrated by what are known as ‘comparative bioavailability or 
bioequivalence studies’. 
 
2.1. Ethical and institutional review 
Approval by the Rhodes University Ethical Standards Committee (RUESC) is required before the study can 
commence. The study will be conducted in accordance with guidelines set out in the Declaration of Helsinki 
(1964) and its amendments of Tokyo (1975), Venice (1983), Hong Kong (1989), Somerset West (1996) and 
Edinburgh (2000). This Declaration sets out ethical principles, which protect your rights for participating in such 
studies. Guidelines on the conduct of clinical trials in South Africa will be adhered to. 
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The study will also be conducted according to the ICH (International Conference on Harmonisation) Guidelines 
for GCP (Good Clinical Practice), the Biopharmaceutics Research Group’s Standard Operating Procedures 
(SOP) and the requirements of RUESC. 
 
2.2. Written informed consent 
Preceding the study, the nature, purpose and risk of participating in the study will be explained to you. Should 
you wish, you will be given time overnight to consider the information and any questions that you might have 
will be answered. The nature of the insurance cover will also be explained. If you decide to participate in the 
study you will sign a consent form in the presence of a witness. You are encouraged to consult your parents or 
personal medical doctor for approval to partake in this study. 
 
3. Voluntary nature of participation 
Your participation in this study is entirely voluntary and you may withdraw from the study at any time, without 
prejudice. Should you decide to participate, we ask that you try to be committed to completing the study if at all 
possible. Should you encounter any problems along the way, please speak to me so that every effort can be 
made to assist you. 
 
4. Dates and duration of the study phases 
The study consists of 1 phase only which will run over a day. The study will be conducted from 0700 h until 
1800 h. 
 
5. Place of study 
The study will be conducted in the clinic (Room T17) in the Faculty of Pharmacy building at Rhodes University. 
Room T17 is on the top floor of the Pharmaceutical and Chemical Sciences building in Artillery Road on the 
Rhodes University campus. The principal investigator, supervisor and the study nurse will be suitably qualified, 
trained and experienced to perform the study procedures. 
 
6. Background information 
Ketoprofen is used in the management and treatment of patients with inflamed joints and muscles. In the 
treatment of adults, ketoprofen gel is usually applied to the affected area once or twice daily. 
 
Microdialysis is a technique for sampling of natural and foreign substances in the space surrounding cells in 
living tissue. The technique was originally developed for brain research but has now been used extensively in 
other tissues in animal models and human studies. In human studies, this technique has been employed in 
adipose tissue, brain, heart, lung, solid tumours, skin etc. A microdialysis fibre consists of a semipermeable 
membrane forming a thin hollow ‘tube’ (~ 0.22 mm i.d.), which acts like a capillary. The fibre has one end 
connected to a tube which leads to a micropump and the other end to sampling tube. The probe is implanted in 
the dermis or the middle layer of the skin via a needle. The microdialysis fibre is slowly perfused with normal 
saline and substance in the skin will diffuse across the membrane into the saline which is collected and analysed. 
Substances move across the dialysis membrane by passive diffusion. 
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Dermal microdialysis sampling is described as a minimally invasive technique. The insertion of the 
microdialysis probes creates acute inflammatory reaction characterised by increased blood flow, erythema and 
swelling demonstrated with the use of a linear microdialysis probe by a 21G needle. This procedure has been 
shown to be safe and no irritation with the probes has been noted to date. Ice is used as an anaesthetic to provide 
minimum discomfort. No more discomfort is observed when the needle has been removed. You will be supplied 
with a tube of hydrocortisone (0.1%, m/m) cream to apply twice daily for 2 weeks to arrest any residual 
inflammation after the completion of the study. Sterile techniques will be employed during the study to ensure 
the minimum risk of skin infections. 
 
Tape stripping is a technique also employed to study the penetration of drugs to the skin. Tape stripping 
involves the sequential removing of microscopic layers (typically 0.5-1 μm) of outer dead layers skin (stratum 
corneum) by placing an adhesive tape strip onto the skin surface with uniform pressure which is then 
subsequently removed. Tape stripping is simple and has been described as a minimal invasive technique. 
Although tape-stripping is considered to be essentially non-invasive, stripped sites in certain dark-skinned 
individuals may remain darker the usual for several months after healing. 
 
7. Study design 
On the left arm, 4 very thin microtubules which are 0.2 mm in diameter (microdialysis probes) will be inserted 
approximately between 0.6 and 0.8 mm beneath the skin and approximately 3 cm apart. Ice will be used as an 
anaesthetic to allow for minimum discomfort when the probes are inserted into the skin by means of a needle. 
Following this there will be no pain. Once the microdialysis probes are in place, you will not be able to move 
freely, but will have to remain lying on a bed or sitting in an arm chair with the opportunity to watch TV or read. 
During the study, the washout liquid which is pumped through the probes will be collected every 30 min. The 
microdialysis study will conclude at 1700 h, after the position of the probes under the skin has been ascertained 
by means of an ultrasound scanner. This is a quick pain free non-invasive technique which uses high frequency 
sound to measure the depth of the probe in the skin. Thereafter the probes will be removed from the skin and the 
area where the probes were inserted will be covered by small adhesive plaster strips.  
 
At the end of the microdialysis study, templates for use with the tape stripping study will be affixed on your 
right arm with pieces of Micropore™ 1530 tapes. These will be used to demarcate (2 cm x 2 cm) the stratum 
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corneum sampling site. The templates will be designed to have 2 sampling sites, 1 site for the application of the 
formulation and the other for use as control. The test formulation will be applied to 1 application site and after a 
30 min exposure period the excess drug will be removed by wiping with a cotton swab. Adhesive tapes 
(Transpore™ 1527 tapes) will be applied concurrently to both application sites with uniform pressure and then 
subsequently removed. 15 successive strips will be made from each site. The amount of moisture loss 
measurements will be recorded from the control application site using a small instrument which is placed on the 
skin. This is also entirely pain free. This procedure will take approximately 1 h. The entire study will conclude 
at 1800 h. 
 
8. Adverse effects 
For topical preparations, delayed hypersensitivity dermatitis may occur at the site of the application, but this is 
uncommon. Cases of reddening of the skin and inflammation of the skin have also been reported. It is advised 
that ketoprofen gel preparations should not be used on open wounds or lesions on the skin or near the eye. The 
skin reactions are however reversible on discontinuation of therapy. Ketoprofen must not be administered to 
healthy or ill individuals who have an allergy to this compound or to any of the ingredients in the formulation. 
In this study, a single application to a limited area is unlikely to invoke any adverse effects but procedures will 
be in place to address any discomfort noted during and after the study.  
 
Microdialysis and tape stripping techniques are safe and no adverse reactions such as irritation or allergic 
reactions to the probes have been reported so far. The insertion of microdialysis probes creates slight but 
reversible swelling. This is caused by the use of a 21G needle for insertion of the linear microdialysis probe. No 
reactions have been reported to date in tissue around the probe 8-10 h after probe insertion. Ice is used to induce 
anaesthesia during probe insertion to provide minimum discomfort. No significant discomfort is observed when 
the needles have been removed. Sterile techniques will be employed during the study to ensure the minimum 
risk of skin infections. Although tape-stripping is considered to be essentially non-invasive, stripped sites in 
certain dark-skinned individuals may remain hyperpigmented for several months after healing. 
 
9. Conditions of participation in the study  
To participate in this study you must:- 
i. Undergo and pass a medical assessment which includes giving a general medical history, recording 
of vital signs, body height and weight measurements and an assessment of your skin. 
ii. Undergo a skin test to assess any possible allergy or sensitivity to the adhesive in the medical tape 
that will be used. After 6 h the tape is removed, the forearm washed and the skin inspected for any 
signs of reaction to the tape adhesive. 
iii. Fulfil certain inclusion and exclusion criteria which have been set out in the protocol. 
iv. Agree to be fully committed to the study and conscientiously abide by the restrictions required of 
you as listed in section 11. 
 
NB: It is extremely important that you divulge any past medical history and abide by the rules for 
participation in this study. This is to protect you from unnecessary risks and to help ensure the reliability 
of the data gathered. 
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10. Volunteer inclusion/exclusion criteria 
You will be considered for this study if you are aged between 18 and 50, in general good health, available for 
the entire study period and, if female, be on reliable contraception or abstaining from sex. 
 
Please do not consider participating in this study if you 
i. are breast feeding. 
ii. are contemplating becoming pregnant in the time immediately following the study. 
iii. are pregnant. 
iv. have a known allergy/hypersensitivity to ketoprofen or any NSAID including aspirin. 
v. have any history of drug or alcohol abuse. 
vi. have any mental deficiency or handicap. 
vii. have hairy ventral forearm surfaces and/or abrasions on the underside of their forearms. 
viii. have engaged in any sun-tanning or taken any sunny vacations within the last month. 
ix. have participated in another NSAID dermal microdialysis or tape stripping study within 2 months 
of the study date. 
x. have used any NSAIDs within the last 3 months. 
xi. suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood eczema). 
xii. suffer from any skin disorder such as psoriasis, eczema or other relevant skin disorder. 
xiii. take regular medicine or tablets or used any creams within the last week (contraceptive pills 
excluded). 
xiv. test positive for HIV and Hepatitis B. 
xv. have a history of any neurological, kidney or liver disorders. 
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11. Study restrictions  
 
Restricted item 
 
Duration of restriction 
 
Examples of restriction 
 
Comments 
Prescription 
drugs 
From 1 week before the start of 
the study, until the end of the 
study. 
- all medication obtained 
on prescription 
- antibiotics, vaccinations 
- anti-inflammatories 
- anti-asthmatic drugs 
- anti-acne drugs etc. 
This includes all long 
term medication. 
Over-the-counter 
(OTC) drugs 
 
 
From 1 week before the start of 
the study, until the end of the 
study. 
- anti-flu drugs, sports 
supplements, antacids, 
paracetamol 
- vitamins, minerals 
-homeopathics 
This includes herbs, 
natural products & all 
medications that can be 
bought without a 
prescription. 
Alcohol From 24 h before the start of the 
study and during the study. 
 
No alcohol for a total of just 
over 2 days  
All alcoholic drinks and 
alcohol containing foods. 
It is important that this 
requirement is taken 
seriously and observed, 
as alcohol can 
significantly affect the 
liver. 
Strenuous 
Physical Exercise 
From 12 h before the start of the 
study. 
No strenuous exercise for a 
total of almost 2 days. 
Rugby 
Squash 
Rowing 
Gym 
Tennis etc. 
Light exercise such as 
walking is permitted. 
Smoking No smoking will be permitted 
during the study. 
Cigarettes No cigars or pipe 
smoking. 
Moisturising 
creams 
You must refrain from applying 
any type of skin conditioning 
creams to their forearms from 
24 h before the study until the 
end of the study 
All skin creams, e.g. 
moisturizers, Vaseline, 
medicated creams, 
aqueous cream and 
tanning lotions. 
This could interfere with 
the absorption of the 
study gel. 
 
NB: Random checks will be done to ascertain whether you have managed to adhere to the above 
restrictions. If you have not been able to adhere to the study restrictions please inform us immediately or 
else you may not be able to participate and remuneration will be reduced as detailed in section 15. 
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12. Procedures and duration of the study 
The study consists of a single phase. The procedures and duration of the study are detailed below. 
i. On the morning of the study you must check into the clinic (Room T17) in the Faculty of 
Pharmacy building at 0700 h. At check-in you will be:- 
a. questioned and undergo a brief medical examination to establish whether you still fulfil all the 
inclusion and exclusion criteria since your pre-study medical examination and that you have 
complied with the study restrictions. 
b. prepared for product application by having medical tape applied to your forearms. 
ii. You will be instructed to use the bathroom because when the study starts your wrist will be 
restricted and you will not be able to leave the bed or the chair for approximately 6 h. 
iii. The study will commence at 0800 h and you will be expected to remain in the clinic throughout the 
course of the study. 
iv. Entertainment and lunch will be provided. 
v. You are not restricted with regard to food and drink during the study period although minimum 
fluid intake will be advised so as not to develop an urge to visit the bathroom during the study. 
vi. Professional medical assistance (registered study nurse and/or a registered nurse) will be available 
throughout the course of the study. 
vii. Should any new and significant information about the study medication become available during 
the course of the study, this will be communicated to you. 
viii. A tube of hydrocortisone cream (0.1%, m/m) will be given to you to self medicate your arms twice 
daily for 2 weeks. 
 
13. Benefits 
Since you have been screened as healthy before the start of the study, there is no medical benefit to you from 
participating in this study. 
 
14. Financial compensation 
You will receive a gratuity of R 500.00 for full participation in the study. Payment following withdrawal from 
the study will be calculated on a pro-rated basis from the start of the study at 0700 h to the end of the study at 
1800 h. 
 
15. Adverse medical events 
You will be monitored prior to, during and after each study day for any adverse events whether or not they are 
thought to be related to the investigational products or procedures. If any adverse events are reported, the study 
nurse will decide whether or not to withdraw you from the study and what treatment is appropriate. In addition, 
the Rhodes University Ethical Standards Committee will be notified of any serious adverse events (SAEs). All 
adverse events will be monitored and treated until recovery to your pre-study status. You will be referred to a 
medical doctor if necessary and all medical costs will be covered by the BRG.  
 
 Biopharmaceutics Research Group 
Rhodes University 
Grahamstown 
6140, RSA  
 
Biopharmaceutics Research Group, Rhodes University, Grahamstown, 6140, RSA. CONFIDENTIAL INFORMATION 
Tel: +27 (0) 46 603-8142 Fax: +27 (0) 46 636-1205 E-mail: r.tettey-amlalo@ru.ac.za 
 
 
Ralph Tettey-Amlalo - 137 - Rhodes University, 2008 
Appendix I: RP D: Information for volunteers brochure 
16. Insurance 
You are covered by an insurance policy, taken out by the BRG, in case of claims arising from the medication or 
procedures as outlined in the protocol and in case of negligence on the part of the BRG. If you have personal 
insurance, e.g. life insurance/assurance, your participation in this study may affect your policy. You are advised 
to determine this prior to participating in the study. If you need any assistance in this regard please feel free to 
contact me. During the clinical study you are not entitled to participate in other studies and you should not 
participate in any other study/s for thirty (30) days after completion of this study to ensure that there are no 
interactions. Insurance policies will be available from the principal investigator for scrutiny. 
 
17. Confidentiality 
Your medical history and physical examination records and any other information or data generated during this 
study will be kept confidential. However, you must agree that all the above mentioned documentation and data 
can be released for any lawful purpose and released for publication in scientific journals and/or presentation in a 
thesis submitted to Rhodes University in fulfilment of the requirement for the degree of Doctor of Philosophy 
(Pharmacy) after the completion of the study. In such cases your name will be removed from all documentation 
to ensure your anonymity. In signing the consent form for the study, you agree to the granting of access to your 
medical data. Your medical data will be provided to you upon request and you will be informed of significant 
abnormalities identified before or after the study. 
 
Your consent is also required to permit the medical staff at the BRG to consult with any study nurse who is 
normally responsible for your care if the need arises. The onus, however, is on you to inform such a practitioner 
of your intention to participate in such a study, should you so wish. 
 
18. Amendments/Changes 
Should there be any changes made to the trial protocol these will be communicated to you verbally and in 
writing in time to enable you to reconsider your decision to participate in the study. 
 
19. Withdrawal  
You may withdraw from the study at any time due to the following: 
i. Voluntary withdrawal by yourself due to any reason. 
ii. Illness or injury during the study if regarded as clinically significant by the principal investigator 
and the supervisor in consultation with the study nurse. 
iii. Any adverse event or signs of toxicity if regarded as clinically significant by the principal 
investigator and the supervisor in consultation with the study nurse. 
iv. Failure to comply with or being uncooperative towards any study requirements or restrictions if 
regarded as clinically significant by the principal investigator and the supervisor in consultation 
with the study nurse.  
It is your right to withdraw from the study at any time. However, by signing the Informed Consent form and 
participating in the study, you agree to be committed to completing the study if at all possible. 
 
 Biopharmaceutics Research Group 
Rhodes University 
Grahamstown 
6140, RSA  
 
Biopharmaceutics Research Group, Rhodes University, Grahamstown, 6140, RSA. CONFIDENTIAL INFORMATION 
Tel: +27 (0) 46 603-8142 Fax: +27 (0) 46 636-1205 E-mail: r.tettey-amlalo@ru.ac.za 
 
 
Ralph Tettey-Amlalo - 138 - Rhodes University, 2008 
Appendix I: RP D: Information for volunteers brochure 
20. Termination of the study 
The BRG reserves the right to terminate the study prematurely in the interests of your welfare. 
 
21. Emergency contacts 
You are obliged to notify the principal investigator as soon as possible if you are unable to follow the 
procedures or if you suffer any adverse event we have not told you about. In particular, you should make every 
effort to contact me if you suffer a Serious Adverse Event (SAE) or need to take additional medication of any 
kind. This applies to out of h, as well as to normal work time. 
 
In such cases of medical emergencies during the study, or if you have any urgent questions relating to adverse 
effects or unrelated illness, please feel free to telephone the study nurse, Sr. Kay Wentworth, at any time at the 
following phone numbers: 
 
Work 046 603 8189 Home 046 622 6384 Cell 072 299 8230 
 
22. Contacts for additional information 
The following individuals are responsible for conducting this study and as such may be approached for more 
information: 
Portfolio Name Contact details 
    
Principal Investigator Ralph Nii Okai Tettey-Amlalo Work 046 603 8142 
 BPharm, MSc, PhD Candidate (Rhodes) Home 046 603 8041 
  Cell 082 831 5320 
  Email r.tettey-amlalo@ru.ac.za 
    
Supervisor Professor Isadore Kanfer Work 046 603 8381/8382 
 BSc (Pharm), BSc (Hons), PhD (Rhodes) Email i.kanfer@ru.ac.za 
 
If you have questions about this study which have not been answered adequately by the principal investigator, 
supervisor or the study nurse, you should first discuss them with your doctor. After you have consulted your 
doctor and still dissatisfied you may contact the Rhodes University Ethics Standards Committee at: 
 
Professor Roy Jobson 
Chairman: Rhodes University Ethics Standards Committee 
RHODES UNIVERSITY 
Tel: 046 603 8399 
Fax: 046 636 1205 
Email: r.jobson@ru.ac.za 
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APPENDIX I: RP E 
STUDY PARTICIPATION INFORMED CONSENT FORM 
 
APPLICATION OF DERMAL MICRODIALYSIS AND TAPE STRIPPING FOR THE ASSESSMENT 
OF THE BIOAVAILABILITY OF KETOPROFEN IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: RNO_01_2007 
PROTOCOL VERSION 1 
CONSENT VERSION 1 
JULY 2007 
 
I ........................................................................................... Born on............................. 
 
Present address ............................................................................................ 
............................................................................................ 
hereby give permission that the necessary probes may be inserted into the surface of my skin and the 
microdialysis and tape stripping procedure conducted as described to me by the principal investigator and that 
the formulation stated below be applied to my skin during the course of this study. 
 
Test product: Fastum® Gel (Ketoprofen 2.5%, m/m)-Adcock Ingram, South Africa  
 
My consent is given freely and I realise that it may be withdrawn at any time, without penalty to me. 
Furthermore, I understand that I do not give up any of my legal rights by signing this consent form. 
 
I have been fully informed by .................................................................................... regarding the possible 
adverse effects of the medication, procedures to be used in this study and the risks thereof, as detailed in the 
“Information for Volunteers Brochure”. I will receive a copy of the information brochure and signed consent 
form for my records. 
 
I undertake to comply with all the relevant conditions contained in the Information to Volunteers Brochure and 
confirm that I understand that it is important not to withhold or misrepresent any information asked of me. I 
agree to undergo the necessary pre- and post-study medical investigations as listed in the protocol. 
 
I undertake to inform the study nurse and the principal investigator immediately of any symptoms-expected or 
unexpected-which I might experience. 
 
I agree to my medical records being reviewed in the event of an audit, enquiry, monitoring and/or inspection on 
the understanding that my anonymity will be maintained. 
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I agree and consent that the BRG may consult with any study nurse who is normally responsible for 
care of study subjects. 
_____ 
Initial 
 
I have been informed that if I do not adhere to the protocol, it may result in my exclusion from the study and 
forfeiture of the agreed upon remuneration. I acknowledge that instructions relating to my participation in this 
study have been communicated to me both verbally and in writing, and that I understand them. 
 
I also declare that I have made the necessary arrangements regarding the attendance of lectures and other 
academic activities. 
 
I understand that a policy to cover volunteers in clinical studies against death or disablement arising as a direct 
result of participation in such clinical studies has been taken out by the Biopharmaceutics Research Group. I 
accept the conditions of the policy as set out in the insurance policies. 
 
I acknowledge that I will receive R 500.00 for full participation in this study and that I will receive a pro-rated 
amount if I withdraw from the study before it has been completed. 
 
 
 
 
__________________________ ___________________________ 
Signature of volunteer Date (yyyy-mm-dd) 
  
  
  
__________________________ ___________________________ 
Signature of a witness Date (yyyy-mm-dd) 
  
  
  
__________________________ ___________________________ 
Principal Investigator 
Ralph Nii Okai Tettey-Amlalo 
BPharm, MSc, PhD Candidate (Rhodes) 
Date (yyyy-mm-dd) 
 
 
 
Contact details of subject  
Telephone number  
Cell number  
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APPENDIX I: RP F 
CASE REPORT FORM 
 
APPLICATION OF DERMAL MICRODIALYSIS AND TAPE STRIPPING FOR THE ASSESSMENT 
OF THE BIOAVAILABILITY OF KETOPROFEN IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: RNO_01_2007 
PROTOCOL VERSION 1 
CASE REPORT FORM VERSION 1 
JULY 2007 
 
  
Test product Fastum® Gel (ketoprofen 2.5%, m/m)-Adcock Ingram, South Africa 
Principal Investigator Ralph Nii Okai Tettey-Amlalo  
BPharm, MSc, PhD Candidate (Rhodes) 
Supervisor Professor Isadore Kanfer 
BSc (Pharm), BSc (Hons), PhD (Rhodes) 
  
  
Subject initials  
Volunteer reference number  
Study subject number  
Date of screening medical  
 
 
Pre-study examiner: 
Name and initials  
Qualifications  
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MEDICAL HISTORY (to be completed by the examining study nurse) 
 
DEMOGRAPHIC DATA 
Birth Date  Age in Years Sex (M/F) Origin Other 
   White Black Oriental  Indian  
Height (m) 
 
 
Weight (kg) 
 
 
BMI (Body Mass Index) 
To be calculated by BRG 
Investigators 
Not required 
 
REVIEW OF PAST ILLNESS 
System/Site Illness? 
Y/N 
 Describe Abnormalities 
 
Skin -Connective Tissue    
Any other illness?    
    
 
PHYSICAL EXAMINATION (to be completed by the examining study nurse) 
 
VITAL SIGNS 
Blood Pressure-Supine (mmHg) Pulse (beats/min) Oral Temperature °C 
   
 
GENERAL SYSTEMS EXAMINATION 
System/Site Illness? 
Y/N 
 Describe Abnormalities 
 
Skin-General    
Skin-Forearms    
Medical tape allergy pass    
 
INCLUSION/EXCLUSION CRITERIA 
 
(NB: Unshaded areas-acceptable: Shaded areas-unacceptable) 
 YES NO 
Will you be available for the entire study period?   
Are you in general good health?   
Are you aged between 18 and 50?   
Do you have eczema or scratch marks on the underside of your forearms?   
Do you suffer from any skin disorder such as psoriasis or other relevant skin disorder?   
Do you suffer from any neurological, kidney or liver disorders?   
Do you suffer from any allergic conditions (hayfever, allergic rashes, asthma or childhood 
eczema)? 
  
Have you engaged in any sun-tanning or taken any sunny vacations within the last month?   
Do you take any regular medicine (prescription or OTC)?   
Have you taken any medicine or tablets or used any creams within the last week 
(contraceptive pills excluded)? 
  
Have you participated in another NSAID dermal microdialysis study within 2 months of the 
study date? 
  
Have you used any NSAIDs within the last 3 months?   
Do you have any mental deficiency or handicap?   
Are you pregnant?   
Have any history of drug or alcohol abuse?   
Are you contemplating becoming pregnant in the time immediately following the study?   
Are you breastfeeding?   
Are you using reliable contraception (The contraceptive pill, minipill, IUD or abstinence)?   
Do you have a known allergy/hypersensitivity to ketoprofen or any NSAIDs including aspirin?   
Have you ever had a reaction to a local anaesthetic injection at the dentist or in casualty?   
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VOLUNTEER ACCEPTABILITY /COMMENTS WITH REGARDEXAMINATION/INCLUSION/ 
EXCLUSION CRITERIA 
Acceptable   Not Acceptable  
Notes/Comments   
   
   
   
 
 
Sign Date ___________________________________  
Study nurse       (dd/mm/yy) 
 
 
Sign Date ___________________________________  
Principal investigator       (dd/mm/yy) 
 
 
POST-STUDY REPORT/MEDICAL 
 
SUBJECT/STUDY STATUS 
 
Study Completed   Study Not Completed  
Comments (If “no” give reasons and procedure/follow-up undertaken) 
   
   
 
Sign  Date _______________________  
Study nurse     (dd/mm/yy) 
 
 
CLINICAL EXAMINATION/SUBJECT RELEASE 
 
Test Status/Comments 
Medical Update 
 
 
Application Site 
Assessment 
 
 
Subject Released  Subject Retained for Further Investigation  
 
 
Sign  Date _______________________  
 Study nurse     (dd/mm/yy) 
 
 
Sign  Date _______________________  
 Principal investigator    (dd/mm/yy) 
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APPENDIX I: RP G 
CERTIFICATE OF INSURANCE 
 
 
A copy of the original certificate will be included in the application. 
BRG 
Q 
.' 
Biopharmaceuticals Research Institute 
e-mailed 
Attention: Mike Skinner 
Dcar Mr Skinner 
SUBJECT: Confirmation of Insurance 
TO WHOM IT MAY CONCERN 
Alexander Forbes 
RISK SERVICES 
31 July 2007 
This is to confIrm that clinical trial volunteers are insured for accidental bodily injury and I or 
illness as a direct result of participation in clinical study no RNO-Ol -Zoo7 subject to the terms and 
conditions of certificate 10/725/113 underwritten by Lloyds of I ,(mdon. This policy is renewable 
annually on the 1 January. The next renewal date is therefore 1 January 2008. 
The compensation limits are as follows (per volunteer but not exceeding RS,OOO,OOO in respect of 
all claims arising from one common tcst): 
Death 
P ermanent Disability 
Medical Expenses 
: R500,OOO 
: Such percentage of RSOO,OOO as is specified for the particular disability 
: Rl00,OOO (first amount payable R25D) 
If you have any queries, please call. 
Yours sincerely 
~ 
Debra Tuohy 
Direcf line: 041 ·3928514 
BP 0 BOle 27155.Green.cres. Port Elizabeth. 6057 
270 Cape ROad. Newton Park. Port Ellnbeth. 6045 
Tel : +27 (411 392 8300 Wbl 
A. OM ....... 01 Ale<ander fames Glow (Pry. Ud 
Co Reg. No 196910 1846710 7 
Fot )'OUT~. pk<Jse rete/ to _ l1;rea lines 
Websle: www.a\eleandertorbes.com 
M AulhorisM Fi-wnciaI Se<Y.cesProvidc:r. FS8IFSP lkmce No 9299 
O"~~"_F .. _ G._..".. L.n OOC -.......""--" >'f'MOyg-"'~()ucIofI ~8<_ lJ~ A! Conlon PI..-...... 1.1(; ...... N~_ M Mh' II£KN", G><N .... "'OB., IlM Vi.-HW_ .~ 
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APPENDIX I: RP H 
SCREENING MEDICAL AND HIV TESTING CONSENT FORM 
 
APPLICATION OF DERMAL MICRODIALYSIS AND TAPE STRIPPING FOR THE ASSESSMENT 
OF THE BIOAVAILABILITY OF KETOPROFEN IN HEALTHY VOLUNTEERS 
 
STUDY NUMBER: RNO_01_2007 
PROTOCOL VERSION 1 
HIV CONSENT FORM VERSION 1 
JULY 2007 
 
I ........................................................................................... Born on........................... 
 
Present address ............................................................................................ 
............................................................................................   
hereby: 
i. Confirm that my consent is given freely and I realise that it may be withdrawn at any time, without 
penalty to me. 
ii. Confirm that I have read the information contained in Appendix RP H.1 and have been informed of 
the tests to be undertaken. 
iii. Confirm that I have been informed of the general procedure for clinical studies undertaken by the 
BRG. 
iv. Confirm that I have attended an informed consent session specific to the clinical study for which I 
am volunteering at which the contents of the ‘Information for Volunteers’ Brochure, Version … 
were explained to me and a copy given to me to take home and read before making my decision. 
v. Recognise that undergoing a screening medical does not ensure automatic inclusion into the 
clinical study. 
vi. Agree to my medical records being reviewed in the event of an audit or enquiry on the 
understanding that my anonymity will be maintained. 
vii. Agree to be tested for Hepatitis B. 
viii. Agree to be tested for the Human Immunodeficiency Virus (HIV), which causes Acquired 
Immunodeficiency Syndrome (AIDS), and with respect to this test: 
a. I understand the information contained in the attached three-page HIV Informed Consent 
Document (Appendix RP H.1) 
b. I freely consent to the withdrawal of blood from me. 
c. I freely consent to the testing of that blood. 
d. I understand that the results will be kept confidential, except for the disclosure by the BRG of any 
reactive result to the doctor who performed the screening medical or a doctor of my choice. 
e. I have read the information in this document about what a test result means. 
f. I understand that the BRG will pay for 1 session of pre- and post-test counselling which will be 
conducted by a member of staff of the St Raphael Centre at 11 Donkin Street, Grahamstown 6139. 
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g. I understand that I should contact the study nurse who performed the screening medical or a doctor 
of my choice for further information and counselling concerning the HIV test if required. 
h. I understand that I have the right to request and receive a copy of this form. 
 
 
 
 
 
__________________________ ___________________________ 
Signature of volunteer Date (yyyy-mm-dd) 
  
  
__________________________ ___________________________ 
Principal Investigator 
Ralph Nii Okai Tettey-Amlalo 
BPharm, MSc, PhD Candidate (Rhodes) 
Date (yyyy-mm-dd) 
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Appendix I: RP H.1  HIV SCREENING TEST INFORMATION SHEET 
 
ALL CLINICAL STUDY VOLUNTEERS MUST READ THIS INFORMATION SHEET BEFORE THE TEST FOR HIV IS 
DONE 
 
INTRODUCTION 
This document contains the information that you have a right to be given before agreeing to be tested for HIV antibodies. The HIV antibody 
test (sometimes called the “AIDS test”) is a test that will tell you whether or not you have been infected with HIV, the “AIDS virus”. Below 
we set out your rights with respect to this test, information about HIV and AIDS and the AIDS test, any why the BRG wants to test you for 
HIV antibodies before it decides whether or not to include you in a clinical study. 
 
WHAT ARE MY RIGHTS? 
Your rights are: 
i. Not to be tested for the AIDS virus without your free and informed consent. 
ii. To be given all material information on the harms, risks and benefits of taking, or not taking, the AIDS test. 
iii. To refuse to take the test. If you do this, you will not be able to participate in a clinical study. 
iv. You will receive pre-test counselling which is private and confidential, and which will inform you more about the test and 
it’s implications before you consent to the test. Pre-test counselling will be at the expense of the BRG. 
v. To have your test result treated confidentially. The result will be made available to your doctor only with your prior 
consent. A test result will also be stored by the BRG. You have the right to access this information to check that it is 
correct. 
vi. To 1 session of post-test counselling at the expense of the BRG, whether the test is positive or negative. After this you will 
be referred to a healthcare provider who will provide you with further counselling and treatment if a positive result is 
obtained. 
 
WHAT IS HIV? 
HIV is the virus that causes AIDS, and is sometimes called “the AIDS virus”. While infected with HIV, and before a person develops AIDS, 
he or she will feel well or healthy. During this time, the person will be able to infect other people with the virus. 
 
WHAT IS AIDS? 
AIDS is the name for a number of illnesses that develop as a result of being infected with HIV. The AIDS virus attacks the immune system 
and leaves it unable to fight various illnesses. More than half of the people infected with the AIDS virus will get AIDS within 10 years of 
infection. 
 
When you are sick with AIDS, you can usually no longer work. AIDS is a serious disease that eventually leads to death. 
 
WHAT IS THE HIV TEST? 
The HIV test checks your blood for antibodies to the AIDS virus. The test cannot tell you the date you were infected, or by whom you were 
infected. A sample of blood will be drawn from you. It will be sent to a pathologist’s laboratory, where it will be tested. 
 
HOW DO I BECOME INFECTED WITH THE VIRUS THAT CAUSES AIDS? 
Almost all cases of infection result from sexual intercourse. The AIDS virus is transmitted in this way from one person to another through 
semen and vaginal fluids. The AIDS virus can also be passed on to babies through the mother’s blood or through breast-feeding. Although 
rare, the AIDS virus can be transmitted by contact with infected blood-for example, through blood transfusions, through sharing needles 
during drug-of-abuse use or by inadvertent needle-stick injuries or spillage, where health care workers are especially at risk. Most cases of 
infection are transmitted from women to men, or from men to women. Men and women of all ages, races and religious beliefs can be 
infected with the AIDS virus. Homosexual transmission also occurs. 
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IS THERE A CURE FOR HIV AND AIDS? 
There is no known cure for HIV or AIDS. Modern medical science as well as traditional healers have searched for cures for the AIDS virus. 
So far these efforts have been unsuccessful. 
 
However, should you be HIV positive, by adopting a healthy life-style and having your HIV managed properly by health care workers, you 
can greatly enhance your quality of life before AIDS sets in. It is therefore of the utmost importance that you keep yourself both mentally 
and physically healthy in spite of being HIV positive. It is also possible that a cure may be found over this time. 
 
WHY DOES THE BRG NEED TO TEST FOR THE AIDS VIRUS? 
The BRG conducts clinical tests (called bioequivalence tests) on pharmaceutical formulations. These tests involve administering 
medications to study subjects and taking blood samples from each subject at various intervals during the study. Blood samples are then 
centrifuged and prepared for analysis, when the concentration of medication in each sample is measured. During the clinical and analytical 
process numerous people handle each blood sample e.g. the nurse who takes the sample, the technician who prepares the sample 
immediately after it is taken and the analyst who prepares the sample for analysis. The BRG is duty bound to ensure that the individuals who 
handle these blood samples are not at risk from contracting the AIDS virus. The BRG must also ensure that subjects who participate in the 
study are not at risk from contracting the HIV virus through any possible accidental contact with any blood while participating in the study. 
In addition, the BRG must satisfy import/export authorities in South Africa and the receiving country that samples in any shipment across 
international borders are non-infectious. 
 
IS THE TEST ALWAYS CORRECT? CAN THERE BE MISTAKES? 
The tests are usually very accurate, and are performed by registered pathology laboratories. If your test result shows that you are infected 
with the AIDS virus, you can have this confirmed by having further tests done at your own expense, or by going to the nearest clinic or 
public hospital for a free HIV test. 
 
WHAT DOES IT MEAN IF THE TEST IS NEGATIVE? 
If your test result is negative, this does not mean that you may not become infected in the future. If you engage in unprotected sex, you may 
be infected at some time in the future. You should think very seriously about the ways in which you can ensure that you are not infected in 
the future. In particular, you should consider using safer sexual practices, for example, a condom. 
 
There is a time of approximately 6 weeks after infection when an HIV test will not detect the AIDS virus. This happens because the test for 
antibodies cannot detect them for a short while after infection. This time is called the “window period”. If you are in the “window period” 
your test results will be negative, although you are actually infected with the AIDS virus. 
 
The chance of being in the “window period” is very small. If you suspect that you may have become infected recently and are in the 
“window period”, you can arrange to be tested again in about 3 or more months’ time at your own expense, or go to the nearest clinic or 
public hospital for a free test and counselling. 
 
WHAT DOES IT MEAN IF THE TEST IS POSITIVE? 
If your test result is positive, this means that you have been infected with the AIDS virus. A positive test result will mean that you will not 
be able to participate in any clinical study conducted by the BRG. The implications of a positive test result should be discussed with your 
doctor or the doctor who conducted your screening medical. The BRG will pay for 1 session for you to discuss these implications with a 
doctor. 
 
WHAT ARE THE HARMS AND RISK OF THE AIDS TEST? 
Many people do not understand the facts about infection with the AIDS virus. This has led to people infected with the AIDS virus being 
stigmatised and isolated by their families and communities. Some people have committed suicide. A positive test can lead to difficulties in 
seeking housing bonds, employment, as well as medical and dental treatment. Psychological difficulties might also arise. For these reasons, 
the BRG will keep your test results confidential. 
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WHAT ARE THE BENEFITS OF THE AIDS TEST? 
If the test is negative, this can reassure you and help you make sure you do not become infected with the AIDS virus. A positive test result 
can offer an opportunity to get early treatment, to change life plans and to prevent infection of your sexual partners. 
 
NOTIFICATION OF TEST RESULTS 
If your test result is negative: You will be considered for inclusion into the clinical study. 
If your test is positive: Because a trained person should deliver that information so that you can understand clearly what the test result 
means, you are asked in Appendix RP H.2 of this document to designate the doctor who conducted the screening medical or a doctor or 
clinic of your choice to deliver the test result to you. 
 
Consequently it is of the utmost importance that you think carefully about the person who should receive the results. Should you not know 
who to name, please ask someone for assistance or suggestions. 
 
You will be advised to contact the designated doctor or clinic, so that they can discuss the meaning of the test result with you. Please note 
that if you are asked or receive a letter to contact the designated doctor, that this does not automatically mean that the AIDS test result is 
positive, as many other medical impairments may lead to you not being able to participate in the clinical study and which should require 
further medical follow-up for your benefit. 
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Appendix I: RP H.II 
   This page must be detached from the document and taken with you when you go for your HIV test. 
 
Section 1 must be completed by you, the clinical study volunteer. 
Sections 2 and 3 must be completed by the person drawing the blood sample. 
 
Section 1: To be completed by the clinical study volunteer. 
 
I designate: i. The doctor who conducted the screening medical as the person to deliver a positive test result to me. 
 
 
Signature of person being tested ____________________________________ Date ________________________________ 
 
OR 
 
I designate: ii The following doctor or clinic to deliver a positive test result to me. 
 
Name ______________________________________________________________________________________________________ 
  
Address ______________________________________________________________________________________________________ 
  
 ______________________________________________________________________________________________________ 
  
Signature of person being tested ____________________________________ Date ________________________________ 
 
 
To be completed by the person drawing the blood sample. 
(Please retain this document and forward to the BRG together with the HIV test results) 
 
Section 2: Identification of applicant for all pathological tests (must always be completed) 
 
Passport/Identity Number of person being tested:   
 
 
Name of person being tested __________________________________________________________________________________ 
  
Address __________________________________________________________________________________ 
  
 __________________________________________________________________________________ 
  
Signature of person being tested ____________________________________ Date ________________________________ 
 
Section 3:  Identification of and declaration by person drawing the sample. 
 
Name of person drawing the 
sample 
__________________________________________________________________________________ 
  
Practice number __________________________________________________________________________________ 
  
Address __________________________________________________________________________________ 
  
 __________________________________________________________________________________ 
  
Signature of person being tested ____________________________________ Date ________________________________ 
 
I have satisfied myself that the person being tested has received the Informed Consent Document, and I have verified the identity of the 
applicant and that he/she has freely consented to have the sample drawn and tested for HIV antibodies. 
 
I have inspected the following document to verify the identity of the volunteer: 
 
valid South African identity document 
 
valid South African passport 
 
valid temporary South African identity document 
 
foreign passport 
 
 
 
Signature of person drawing the sample ____________________________________ Date ________________________________ 
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APPENDIX I: RP I 
VERBAL DELIVERY OF INFORMATION TO STUDY VOLUNTEERS 
 
The announcement will be posted around campus. 
 
Students then contact the principal investigator directly and relay their interest in participating in the study. A 
short and factual explanation is given of the study and female participants are specifically asked whether they 
are using reliable contraception (the contraceptive pill, minipill or an IUD) and whether any participant suffers 
from eczema or psoriasis. 
 
The principal investigator then mails the participants information brochure to the participants at the place of 
residence of the study volunteer. As the announcement is made 1-2 weeks before the commencement of the 
study, ample time is allowed for the reading through of this information. 
 
At the first meeting in the Seminar Room in the Faculty of Pharmacy building 30 min are allocated to a verbal 
explanation of the study and any questions. This provides an undisturbed physical environment and the time 
allocation of 30 min is realistic. 
 
Study volunteers are then shown the clinic unit where the study will take place as well as the needles for the 
insertion of the probes etc. Thereafter questions from the study volunteers are answered. 
 
Study volunteers will be given approximately 7 days in which to consider the written information and formulate 
questions. Should there be any additional questions regarding the preceding verbal information, study volunteers 
have an opportunity to consider these answers before a final decision is made with regard to participation. 
 
Should the study volunteer continue to be interested in participating, the 2 days on which the study will be 
conducted are arranged. Thereafter the study volunteer signs the study participation informed consent form as 
well as the screening medical and HIV testing consent form which are also signed by the principal investigator 
and in the presence of a witness if required. Study volunteers are hereby included in the study and are given a 
copy of the Information for Volunteers Brochure and the signed consent forms as well as written instructions 
regarding the 2 pre-arranged study days. 
 
The study volunteers will then be contacted to see the study nurse for medical screening as outlined in the 
protocol. 
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04 December 2007 
 
 
Professor Roy Jobson 
Chairman 
Rhodes University Ethical Standards Committee 
RHODES UNIVERSITY 
GRAHAMSTOWN 
 
Dear Professor Roy Jobson, 
 
APPLICATION OF DERMAL MICRODIALYSIS AND TAPE STRIPPING FOR THE 
ASSESSMENT OF THE BIOAVAILABILITY OF KETOPROFEN IN HEALTHY 
VOLUNTEERS 
 
STUDY NUMBER: RNO_01_2007, APPROVAL DATE 22/08/2007 
 
PROPOSED AMENDMENTS TO THE PROTOCOL 
 
The outcome of the first study showed some degree of variability with respect to the diffusion pattern 
of ketoprofen through the skin. In an attempt to minimise variability, a number of key suggestions 
have been identified and discussed, one of which involves increasing the amount of formulation 
applied onto the skin during the study. 
 
We are of the opinion that the amount of formulation applied onto the skin is insufficient to generate 
reproducible results and the spreading of the formulation within the designated surface area may 
invariably cause alterations in diffusion pattern due to the rubbing effect of the principal investigator. 
Increasing the amount of applied formulation from 90 μl (± 30 mg) to 150 μl (± 50 mg) per 
application site will sufficiently occupy the surface area but more importantly will not require the 
principal investigator to spread the formulation over the application site with a glass rod. 
 
It is unlikely that an increase to 150 μl (± 50 mg) representing 1.25 mg of ketoprofen will cause any 
topical or systemic toxicity since this amount only represents 0.625% of an oral solid dosage form of 
ketoprofen (200 mg ketoprofen tablet). 
 
We are also of the opinion that the widespread use of the forearm may also contribute to variability. 
 
The following amendments to the protocol relating to study RNO_01_2007 are submitted herewith for 
your consideration.  
 
Section 2.1 Description 
  
Current Dosage: 90 μl (± 30 mg) per application site 
  
Proposal Dosage: 150 μl (± 50 mg) per application site 
 
Section 2.2 Supply, storage and use 
  
Current Approximately 30 mg of the product will be applied to each site from a preloaded 
Eppendorf® pipette (Section 5.8.). Individual doses of the product will be spread 
evenly over the application site using a glass rod. 
  
Proposal Approximately 50 mg of the product will be applied to each site from a preloaded 
Eppendorf® pipette (Section 5.8.). The product will be dispersed evenly across the 
entire surface area directly from the Eppendorf® dispenser  
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Section 5.4. Study design 
  
Current Probes will be inserted parallel to each other across the volar aspect of the left forearm 
approximately 3 cm apart using 21G x 1½" hypodermic needles as guide cannulae. 
  
Proposal Probes will be inserted parallel to each other across the volar aspect of the left forearm 
approximately 1.5 cm apart using 21G x 1½" hypodermic needles as guide cannulae. 
 
 
Section 5.8. Product application 
  
Current Just prior to the product application, an Eppendorf® (0.5 ml) pipette will be filled with 
the test product. The setting will be adjusted (3 on the dial of the Eppendorf® 
dispenser) to ensure that the correct amount (30 µl) of the test product required for 
application on each site will be dispensed. The test product will be dispensed 3 times at 
each application site to allow 90 µl (± 30 mg) of test product (corresponding to 0.75 
mg of ketoprofen) to be applied at each site. The Eppendorf® dispenser will be used to 
ensure that an accurate amount of test product is dispensed to each application site for 
each subject. Application of the test product will be done by the principal investigator. 
  
Proposal Just prior to the product application, an Eppendorf® (1.0 ml) pipette will be filled with 
the test product. The setting will be adjusted (5 on the dial of the Eppendorf® 
dispenser) to ensure that the correct amount (150 µl) of the test product required for 
application on each site will be dispensed. The test product will be dispensed 6 times at 
each application site to allow 150 µl (± 50 mg) of test product (corresponding to 1.25 
mg of ketoprofen) to be applied at each site. The Eppendorf® dispenser will be used to 
ensure that an accurate amount of test product is dispensed to each application site for 
each subject. Application of the test product will be done by the principal investigator. 
 
 
All these above changes are reflected in the relevant sections. 
 
Thank you. 
 
Yours sincerely, 
 
 
 
………………………………….. 
Ralph Nii Okai Tettey-Amlalo 
BPharm, MSc, PhD Candidate (Rhodes) 
Principal Investigator 
  
Rhodes University 
Faculty of Pharmacy 
Biopharmaceutics Research Group 
PO Box 94 
Grahamstown 6140 
South Africa 
Tel:  +27 82 831 5320 
Fax: +27 46 636 1205 
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06 August 2007 
 
 
 
Professor Roy Jobson 
Chairman 
Rhodes University Ethical Standards Committee 
RHODES UNIVERSITY 
GRAHAMSTOWN 
 
Dear Professor Roy Jobson, 
 
APPROVAL FOR ADVERTISEMENT 
 
The Biopharmaceutics Research Group (BRG) wishes to conduct a dermal microdialysis and tape 
stripping study on healthy human volunteers for the assessment of the bioavailability of ketoprofen 
within the next 6 months. We would like to post advertisements around Rhodes University campus in 
order to obtain volunteers for these studies. The BRG wishes to seek the approval from the Rhodes 
University Ethical Standards Committee. 
 
Attached is a copy of the advert. 
 
Thank you. 
 
Sincerely, 
 
 
………………………………….. 
Ralph Nii Okai Tettey-Amlalo 
BPharm, MSc, PhD Candidate (Rhodes) 
Principal Investigator 
  
Rhodes University 
Faculty of Pharmacy 
Biopharmaceutics Research Group 
PO Box 94 
Grahamstown 6140 
South Africa 
Tel:  +27 82 831 5320 
Fax:  +27 46 636 1205 
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BRG 
BRG ADVERTISEMENT Valid - 0 I July 2007 to 30 Dec 2007 
CLINICAL STUDY VOLUNTEERS 
The Biopharmaceutics Research Group is looking for 
HEAL THY FEMALE and MALE 
VOLUNTEERS 
to participate in clinical studies on a 
medicated gel applied to the skin 
using microdialysis and tape stripping 
If You Are: 
1. Over 18 years 
2. Generally healthy and currently medicine free 
3. Willing to spend a day in the clinic 
Then You May Be Eligible to Participate 
You Will Be Remunerated For Participating 
If You Are Interested Please Contact Ralph as soon as possible for 
More Information 
Preferably by E-mail at:r.tettey-amlalo@ru.ac.za 
Or by Phone at: 046 603 8412/8041 
This ad\'{'l't has orrn :l.ppl'on·d by tlit Rhodes Uniwl'slly Elhlcal Standards Committer 
Please take a tear-off slip below 
 
Appendix II 
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Dermal microdialysis (DMD) data 
 
 
Appendix II: DMD (HS I) 
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HUMAN STUDY I: RAW DATA 
SUBJECTS 1-10 
Subj. Probe Seq. 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 AUC Cmax Tmax
01 01 T 0.0000 4.2416 13.3215 2.8012 3.9082 21.5950 59.9007 55.9513 101.5902 57.6006 122.9518 191.1931 122.9518 5.0
01 02 T 0.0000 2.4882 4.5263 4.0683 3.3559 6.0308 3.6054 4.3639 8.3811 6.9381 9.4782 24.2485 9.4782 5.0
01 03 R 0.0000 2.4882 4.5263 4.0683 3.3559 6.0308 3.6054 4.3639 8.3811 6.9381 9.4782 24.2485 9.4782 5.0
01 04 R 0.0000 4.9653 4.5016 2.2994 1.9398 6.3765 4.6980 28.0982 5.3051 9.4794 13.2773 37.1510 28.0982 3.5
                 
02 01 T 0.0000 41.2054 47.8023 28.1066 25.3921 20.0423 27.5562 32.0817 57.0918 46.8488 50.1682 175.6056 57.0918 4.0
02 02 R 0.0000 65.5830 32.3122 16.9837 34.4546 33.7039 49.8111 39.7452 52.3429 49.8521 55.4569 201.2586 65.5830 0.5
02 03 T 0.0000 7.0033 7.1050 0.1083 13.9701 21.9657 24.1591 34.1787 31.5818 45.2110 43.5205 103.5216 45.2110 4.5
02 04 R 0.0000 13.2518 6.5506 43.7009 22.5465 26.8118 35.4272 28.1740 39.3617 44.2079 71.4772 147.8855 71.4772 5.0
                 
03 01 T 0.0000 4.9982 5.7805 2.8012 3.9082 4.4959 1.9811 3.5065 3.5053 2.7347 3.9681 17.8479 5.7805 1.0
03 02 R 0.0000 5.8953 3.9849 4.0683 3.3559 2.2909 2.6420 2.9999 3.4244 2.8935 3.7336 16.7110 5.8953 0.5
03 03 R 0.0000 7.5154 2.3574 2.2994 1.9398 2.9539 2.5893 2.2183 3.2060 2.3261 2.7979 14.4023 7.5154 0.5
03 04 T 0.0000 3.8554 4.0434 17.7612 3.9221 2.7423 3.1461 3.9326 3.2338 2.7422 2.7184 23.3692 17.7612 1.5
                 
04 01 R 0.0000 11.4475 7.3044 18.6599 9.2060 4.3332 3.4222 7.4222 6.9839 5.7292 6.0152 38.7580 18.6599 1.5
04 02 T 0.0000 9.0760 10.4612 58.7778 22.3461 4.9031 6.1848 7.8330 9.8994 10.9356 11.0619 72.9740 58.7778 1.5
04 03 T 0.0000 11.8058 22.8661 9.4412 6.6323 3.3578 5.3242 6.3950 5.0577 8.0104 7.4699 41.3127 22.8661 1.0
04 04 R 0.0000 5.8746 9.8954 5.1546 5.7921 2.6552 2.5166 3.1203 8.2365 7.2369 9.2156 27.5450 9.8954 1.0
                 
05 01 R 0.0000 5.1251 3.5658 5.2209 3.4340 2.5229 3.2698 4.7119 5.4670 8.6188 5.0276 22.2251 8.6188 4.5
05 02 T 0.0000 3.2392 2.9698 4.9668 3.5251 3.9158 3.0454 2.9094 5.7313 22.5646 4.7361 27.6177 22.5646 4.5
05 03 R 0.0000 4.4246 5.2554 4.6800 5.8964 5.5425 5.7572 6.7485 8.8779 8.1018 10.0665 30.1588 10.0665 5.0
05 04 T 0.0000 3.8297 3.7674 3.7802 6.1777 8.8891 9.4378 12.6351 36.2514 25.7147 27.3977 62.0910 36.2514 4.0
                 
06 01 R 0.0000 12.5534 11.2573 3.1873 15.4034 12.8707 17.2727 26.1776 22.8822 27.8161 37.6048 84.1117 37.6048 5.0
06 02 R 0.0000 13.2206 4.1903 10.3879 7.8645 5.2455 8.9168 9.6126 9.3852 11.1867 15.3221 43.8356 15.3221 5.0
06 03 T 0.0000 30.2682 10.5672 3.6304 13.1248 13.2086 15.6476 13.3737 14.1294 29.7661 29.6661 79.2745 30.2682 0.5
06 04 T 0.0000 7.7996 25.8956 23.1164 40.7211 54.2914 48.5452 41.6920 45.8549 43.5809 47.7053 177.6749 54.2914 2.5
                 
07 01 T 0.0000 2.7130 3.6225 3.8738 3.9097 4.8910 4.8431 2.3660 9.2589 15.1107 12.5857 28.4409 15.1107 4.5
07 02 T 0.0000 3.0937 6.0791 7.0871 6.1372 7.3391 7.4555 11.5846 13.2130 24.9413 21.7426 48.9010 24.9413 4.5
07 03 R 0.0000 3.6091 7.1515 3.9853 6.2581 5.2236 5.0512 7.0418 8.0920 12.2771 17.4810 33.7151 17.4810 5.0
07 04 R 0.0000 2.4260 7.4140 4.1320 6.4878 5.4155 5.2368 7.3002 8.3888 12.7269 18.1210 34.2942 18.1210 5.0
                 
08 01 T 0.0000 0.5835 1.2351 0.8501 0.5867 2.0193 0.5249 0.6510 2.0200 6.4042 3.9738 8.4309 6.4042 4.5
08 02 R 0.0000 0.6593 0.7751 0.3535 0.4084 1.3999 0.3258 1.6071 1.3831 5.6825 2.2207 6.8525 5.6825 4.5
08 03 T 0.0000 0.3144 2.6974 1.2695 0.4074 0.6612 0.3537 1.6727 1.5405 5.2612 4.5916 8.2369 5.2612 4.5
08 04 R 0.0000 0.9256 1.2360 0.4971 0.5472 0.8486 0.4685 0.5294 1.4085 3.9656 1.6116 5.6161 3.9656 4.5
                 
09 01 T 0.0000 0.1163 0.1389 0.2097 1.6435 1.0873 0.4034 0.9425 0.1779 0.2505 0.5871 2.6317 1.6435 2.0
09 02 R 0.0000 0.1086 0.0950 0.3882 1.5416 0.3970 0.4028 0.1980 0.2457 0.1518 0.3149 1.8430 1.5416 2.0
09 03 R 0.0000 0.0755 0.0913 0.1892 0.8485 0.3292 0.1181 0.0819 0.3128 0.2577 0.1988 1.2017 0.8485 2.0
09 04 T 0.0000 0.0962 0.2126 0.4266 2.0607 0.8293 0.9354 0.1206 0.6226 0.3688 0.2798 2.9064 2.0607 2.0
                 
10 01 R 0.0000 0.2418 0.8918 0.6961 0.3794 0.3666 0.3827 0.4274 0.3560 0.3123 0.4045 2.1281 0.8918 1.0
10 02 T 0.0000 0.3213 0.9078 0.6615 0.3830 0.2124 0.4355 0.2707 0.4469 0.4888 0.2696 2.1314 0.9078 1.0
10 03 T 0.0000 0.1815 0.7721 0.4554 0.2479 0.3763 0.1900 0.1517 0.1385 0.1135 0.2810 1.3836 0.7721 1.0
10 04 R 0.0000 0.3468 0.9384 0.3149 0.5317 0.1281 0.1766 0.1862 0.3205 0.1803 0.3278 1.6438 0.9384 1.0
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HUMAN STUDY I: DIALYSATE CONCENTRATION-TIME PROFILES 
SUBJECTS 1-10 
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HUMAN STUDY II: RAW DATA 
SUBJECTS 1-10 
Subj. Probe Seq. 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 AUC Cmax Tmax
1 01 T 0.0000 6.7276 10.4586 22.3493 10.9305 6.1350 15.0188 10.1972 12.3049 17.1054 1.7470 56.0504 22.3493 1.5
1 02 T 0.0000 9.7485 9.0833 34.4454 10.6966 5.9267 13.4572 17.4782 17.9788 8.2443 15.9143 67.5081 34.4454 1.5
1 03 R 0.0000 8.3261 13.0650 26.6472 6.7616 15.3397 14.3951 13.5278 20.6545 22.2416 9.5310 72.8621 26.6472 1.5
1 04 R 0.0000 5.1168 7.7864 20.3816 9.6006 11.5565 13.7572 14.0845 15.4197 16.3877 11.9878 60.0425 20.3816 1.5
                 
2 01 T 0.0000 19.7273 33.9988 13.0571 11.2770 6.8826 10.8528 6.7661 16.4792 10.3395 11.4770 67.5594 33.9988 1.0
2 02 R 0.0000 14.8239 38.7934 7.3047 8.2162 8.8179 8.4140 13.4556 8.4862 15.1435 13.2411 65.0380 38.7934 1.0
2 03 T 0.0000 7.9099 29.2352 4.3944 17.1835 7.9338 23.0997 23.4757 22.9498 24.4874 30.1433 87.8705 30.1433 5.0
2 04 R 0.0000 21.0471 54.3318 8.1127 13.0321 9.7274 15.1783 13.9299 13.6397 15.6432 29.4574 89.6854 54.3318 1.0
                 
3 01 T 0.0000 1.9458 6.5936 3.1815 5.6285 1.6081 3.4648 2.4885 2.6084 4.8664 3.7042 17.1189 6.5936 1.0
3 02 R 0.0000 3.5155 9.4307 3.7156 2.7562 3.9629 4.9623 2.7596 3.7114 4.5238 3.7817 20.6145 9.4307 1.0
3 03 R 0.0000 3.1409 9.0993 2.4181 2.0668 4.0135 2.6388 2.5761 4.7306 3.8777 4.9407 18.5161 9.0993 1.0
3 04 T 0.0000 3.9451 8.4003 3.6232 2.2024 5.2545 2.3682 1.7294 3.6272 3.3583 3.8417 18.2148 8.4003 1.0
                 
4 01 R 0.0000 2.5120 2.0746 3.1419 1.4367 1.0671 3.4195 7.0912 13.5946 15.2104 31.3607 32.6142 31.3607 5.0
4 02 T 0.0000 3.3111 0.6220 0.7561 1.7387 3.0389 6.2862 14.3329 18.6103 50.3687 89.0471 71.7943 89.0471 5.0
4 03 T 0.0000 1.5605 7.7509 2.2715 1.1075 2.8349 7.1236 5.9290 7.6118 17.6618 31.1881 34.7229 31.1881 5.0
4 04 R 0.0000 2.9655 6.1997 2.8731 2.1762 7.3537 3.4061 9.5004 20.7125 33.0971 46.4004 55.7423 46.4004 5.0
                 
5 01 R 0.0000 2.5878 2.6612 4.1436 18.2829 44.4740 16.5822 97.5562 53.7450 24.7688 66.9927 149.1491 97.5562 3.5
5 02 T 0.0000 3.1581 1.8326 4.6545 16.4457 7.5844 82.7465 113.2915 96.5684 89.2353 33.7471 216.1954 113.2915 3.5
5 03 R 0.0000 2.3332 2.7087 0.7356 13.6731 10.7012 11.0176 71.3438 78.1871 48.7607 25.4548 126.0942 78.1871 4.0
5 04 T 0.0000 3.7243 0.5770 1.8964 7.0309 21.4253 22.1799 27.5853 76.2709 20.4192 51.3912 103.4025 76.2709 4.0
                 
6 01 R 0.0000 3.9930 0.9097 2.0378 3.1720 6.6872 50.8585 42.3540 89.1891 99.0291 125.0330 180.3735 125.0330 5.0
6 02 R 0.0000 2.9800 0.5901 7.2347 35.1691 28.7840 67.7161 206.0861 140.1496 150.0479 106.5921 346.0268 206.0861 3.5
6 03 T 0.0000 1.9173 4.3615 8.8464 20.3191 139.4382 96.8757 227.4555 236.6054 163.9448 41.1038 460.1579 236.6054 4.0
6 04 T 0.0000 2.0412 2.8341 7.2560 28.3400 55.3103 176.5206 187.2228 197.4352 30.3264 30.2230 351.1991 197.4352 4.0
                 
7 01 T 0.0000 21.9967 3.3500 21.6660 11.6452 10.6278 12.6777 25.3603 30.9824 35.7411 41.5445 97.4097 41.5445 5.0
7 02 T 0.0000 2.4354 6.1485 28.1112 11.0024 6.6134 58.5008 22.9639 25.0788 28.8848 33.3987 103.2192 58.5008 3.0
7 03 R 0.0000 2.3648 1.5717 5.6320 4.8520 9.9087 50.2571 35.5165 42.9050 57.7418 54.7519 119.0628 57.7418 4.5
7 04 R 0.0000 1.9832 1.2916 1.0747 1.7686 7.3056 15.6421 17.1010 4.3453 21.5160 17.9565 40.5032 21.5160 4.5
                 
8 01 T 0.0000 4.3155 7.3875 4.8644 10.3280 15.3663 18.1394 27.8698 47.5847 64.0113 65.5789 116.3283 65.5789 5.0
8 02 R 0.0000 4.2991 4.6686 1.4536 7.1888 13.6949 21.3460 48.7009 56.1584 76.8715 67.3351 134.0247 76.8715 4.5
8 03 T 0.0000 8.9104 15.6116 4.3818 7.6764 20.2143 17.4092 32.3651 35.7410 54.7883 64.0000 114.5490 64.0000 5.0
8 04 R 0.0000 8.8031 8.7040 2.1417 2.8629 23.6611 27.1350 50.7068 56.4882 52.8060 57.1799 130.9494 57.1799 5.0
                 
9 01 T 0.0000 21.9803 3.2583 22.1567 31.7638 24.5229 47.7787 26.5781 34.2195 35.4851 45.1539 135.1602 47.7787 3.0
9 02 R 0.0000 2.9493 5.9844 23.2296 21.8831 17.2168 58.0215 23.8387 25.3814 30.0817 36.0519 113.3061 58.0215 3.0
9 03 R 0.0000 2.2377 1.4122 5.5760 12.9027 27.2437 50.1988 36.4921 44.3918 62.5535 56.9179 135.7337 62.5535 4.5
9 04 T 0.0000 1.5833 1.1011 1.0519 13.7456 18.4784 51.2317 18.3563 10.8117 22.3617 20.3914 74.4587 51.2317 3.0
                 
10 01 R 0.0000 5.5589 8.0602 5.1420 10.2798 15.3650 20.5945 29.5438 48.6304 151.5543 67.4964 164.2385 151.5543 4.5
10 02 T 0.0000 5.4741 5.3888 1.7199 7.9957 15.4752 21.4875 49.9931 58.2558 76.9537 79.1699 141.1643 79.1699 5.0
10 03 T 0.0000 10.9555 16.3444 5.3762 8.6144 20.1386 18.1768 33.2716 34.8640 56.9841 64.1825 118.4084 64.1825 5.0
10 04 R 0.0000 10.0651 10.3732 2.4990 3.0979 23.9031 28.0318 53.0289 81.6866 119.4402 144.2851 202.1342 144.2851 5.0
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HUMAN STUDY II: DIALYSATE CONCENTRATION-TIME PROFILES 
SUBJECTS 1-10 
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HUMAN STUDY III: RAW DATA 
SUBJECTS 11-18 
Subj. Probe Seq 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 AUC Cmax Tmax
11 01 T 0.0000 14.4310 54.0495 17.7209 11.2525 18.0000 15.0188 10.1972 12.3049 17.1054 1.7470 85.4768 54.0495 1.0 
11 02 R 0.0000 21.3363 58.0341 26.4813 20.4475 13.9641 13.4572 17.4782 17.9788 8.2443 8.0000 100.7109 58.0341 1.0 
11 03 R 0.0000 15.0805 41.0000 16.0000 20.5303 11.8565 14.3951 13.5278 20.6545 22.2416 9.5310 90.0260 41.0000 1.0 
11 04 T 0.0000 12.6682 43.4703 7.1019 19.0000 11.3750 13.7572 14.0845 15.4197 16.3877 11.9878 79.6292 43.4703 1.0 
                 
12 01 R 0.0000 15.4522 44.1218 29.9852 4.0592 14.4009 89.5496 77.7944 116.9299 102.1406 108.9380 274.4514 116.9299 4.0 
12 02 T 0.0000 13.2034 36.8828 4.4767 10.9855 14.4851 50.4903 123.7180 179.5443 203.6156 226.0511 375.2137 226.0511 5.0 
12 03 T 0.0000 9.4033 47.5746 36.4060 12.1246 21.1022 65.7159 84.1857 145.6124 172.2625 147.7076 334.1205 172.2625 4.5 
12 04 R 0.0000 1.8034 27.4433 18.6027 11.7935 18.6950 32.1461 107.6487 111.7778 132.5374 159.0367 270.9831 159.0367 5.0 
                 
13 01 R 0.0000 15.2369 54.0495 17.7209 11.2525 27.1768 45.6953 45.9393 77.8985 93.9606 137.6628 228.8808 137.6628 5.0 
13 02 T 0.0000 10.2568 58.0341 26.4813 20.4475 13.9641 28.7027 28.8543 79.0475 80.2690 110.2598 200.5936 110.2598 5.0 
13 03 R 0.0000 15.0805 49.2635 41.6252 43.9233 11.8565 17.3966 26.2769 38.7245 74.2339 87.0576 180.9549 87.0576 5.0 
13 04 T 0.0000 12.3695 52.0123 7.1019 30.2506 11.3750 10.1895 12.4199 33.9552 50.1609 84.6237 131.0733 84.6237 5.0 
                 
14 01 R 0.0000 5.2695 44.1218 29.9852 35.0256 70.2698 104.3034 90.2650 115.2360 102.1406 175.2369 342.1176 175.2369 5.0 
14 02 R 0.0000 13.2034 36.8828 4.4767 39.2654 66.0664 50.4903 123.7180 179.5443 203.6156 226.0511 415.1443 226.0511 5.0 
14 03 T 0.0000 9.4033 47.5746 36.4060 44.2657 90.1260 65.7159 84.1857 145.6124 172.2625 235.0125 406.5292 235.0125 5.0 
14 04 T 0.0000 1.8034 12.6044 18.6027 50.1260 110.2360 32.1461 55.1884 111.7778 132.5374 159.0367 302.2702 159.0367 5.0 
                 
15 01 T 0.0000 3.6812 3.5633 13.3667 8.0988 6.4356 10.0538 18.0588 54.3802 84.2468 78.6770 120.6119 84.2468 4.5 
15 02 T 0.0000 1.4946 1.2369 1.4740 8.3003 4.1675 11.9873 21.5909 46.9825 111.1997 78.3863 123.8134 111.1997 4.5 
15 03 R 0.0000 2.2771 1.8989 2.0341 18.6449 2.7904 8.0868 33.6313 70.3735 125.7261 133.3561 166.0705 133.3561 5.0 
15 04 R 0.0000 2.3608 9.7041 16.2343 11.4844 6.8756 8.6912 21.1018 50.2946 61.3612 52.6881 107.2260 61.3612 4.5 
                 
16 01 T 0.0000 0.6167 3.8177 14.7619 17.4697 20.1776 37.2315 82.0543 125.6404 138.6396 47.1296 231.9872 138.6396 4.5 
16 02 R 0.0000 1.1404 4.9341 13.5456 22.6711 27.6619 90.3323 108.2506 110.6190 120.9815 73.9598 268.5582 120.9815 4.5 
16 03 T 0.0000 3.3164 4.9368 12.8874 17.9032 30.2919 15.1921 78.0820 160.7158 64.3005 20.8619 199.0285 160.7158 4.0 
16 04 R 0.0000 11.8234 5.7665 50.4250 9.8400 22.4978 26.9038 88.2617 126.2654 79.9087 57.3235 225.1771 126.2654 4.0 
                 
17 01 T 0.0000 19.4579 65.9358 31.8152 56.2850 16.0814 34.6482 24.8855 26.0838 48.6645 37.0421 171.1892 65.9358 1.0 
17 02 R 0.0000 35.1551 94.3074 37.1559 27.5618 39.6294 49.6233 27.5960 37.1140 45.2377 37.8175 206.1447 94.3074 1.0 
17 03 R 0.0000 31.4087 90.9931 24.1812 20.6682 40.1351 26.3885 25.7613 47.3061 38.7770 49.4067 185.1612 90.9931 1.0 
17 04 T 0.0000 39.4512 84.0029 36.2323 22.0243 52.5454 23.6817 17.2936 36.2724 33.5832 38.4172 182.1478 84.0029 1.0 
                 
18 01 R 0.0000 5.8347 12.3512 8.5013 5.8672 20.1931 5.2489 6.5097 20.2004 64.0421 39.7381 84.3088 64.0421 4.5 
18 02 T 0.0000 3.1436 10.6987 12.6950 4.0738 6.6123 3.5366 16.7269 15.4051 52.6123 45.9159 74.2311 52.6123 4.5 
18 03 T 0.0000 6.5927 7.7508 3.5347 4.0839 13.9986 3.2576 16.0714 13.8315 56.8253 22.2070 68.5250 56.8253 4.5 
18 04 R 0.0000 9.2563 12.3600 4.9714 5.4718 8.4864 4.6850 5.2936 14.0846 39.6557 16.1161 56.1614 39.6557 4.5 
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HUMAN STUDY III: DIALYSATE CONCENTRATION-TIME PROFILES 
SUBJECTS 11-18 
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HUMAN STUDY IV: RAW DATA 
SUBJECTS 1-10 
Subj. Site 1 2 3 4 5 6 7 8 9 10 11 12 AUC 
1 1 42.3912 22.2378 20.2322 19.9153 17.5882 15.5646 12.3254 11.8592 8.2439 6.6036 4.8727 4.3852 131.2627
1 2 45.3275 28.1802 22.8971 16.0467 15.4081 14.1061 10.4792 10.1751 9.7598 7.9889 5.8869 0.4032 132.3731
       
2 1 42.2022 31.7573 19.7553 14.1761 9.2882 6.4688 5.5492 4.9958 4.8870 4.4387 3.1589 2.2188 91.5679
2 2 122.1778 73.4519 32.0932 22.8971 15.0465 12.6567 11.8129 11.5983 11.2316 8.4899 7.4075 6.7258 198.9422
       
3 1 140.9083 114.5712 112.7614 78.9718 76.5177 49.0711 32.1645 14.9009 7.2278 6.3471 3.8810 3.2837 203.0251
3 2 51.6552 48.5940 38.0230 32.0932 31.5500 29.9840 27.2041 25.7322 10.1344 5.3775 3.8936 3.4743 99.0895
       
4 1 59.4629 46.5917 15.9614 8.3744 6.5541 4.6055 4.1700 3.4347 2.3641 2.1332 1.9022 1.4475 88.9335
4 2 28.2395 21.4225 11.0227 9.7269 8.3412 6.8537 3.8331 2.8203 2.2024 1.7856 1.4017 1.3803 56.7731
       
5 1 69.4183 55.2788 45.3756 35.8250 34.0491 31.4760 13.1795 12.9820 6.7086 4.8072 4.5904 3.6875 271.3461
5 2 32.3637 20.0972 15.8519 13.3936 11.2729 10.0381 4.6313 3.6579 2.5552 1.8645 1.3807 1.1263 98.8002
       
6 1 105.9720 93.3092 46.1362 32.8487 21.9377 17.1670 11.0729 10.7796 6.8727 4.9146 3.1869 2.6728 205.2040
6 2 86.8081 39.9175 26.2624 16.0280 14.4263 10.3056 8.4425 6.4182 2.9986 2.5535 1.9930 1.9906 117.9588
       
7 1 59.6675 31.6140 20.0465 13.5737 9.8199 5.2165 2.9667 1.7894 1.3643 0.8533 0.6778 0.6659 110.2500
7 2 34.3950 29.0770 16.9121 7.3560 5.9262 5.1185 3.2219 2.6415 2.3676 1.6971 1.0435 1.0254 84.5746
       
8 1 33.6617 18.1776 12.2061 10.2937 8.9318 6.9893 5.9556 2.7128 2.5626 2.2555 2.0350 1.0389 75.8011
8 2 30.1484 20.1330 10.9333 10.1908 5.6715 5.4660 3.9538 3.2340 3.0054 2.1852 1.7169 1.1699 68.4090
       
9 1 49.0579 27.7417 17.9987 14.6675 12.2302 6.8619 5.5389 4.6327 3.6138 3.2054 2.1959 1.7833 138.0394
9 2 42.2077 29.2921 23.2276 16.8906 10.9904 7.8001 5.7957 4.7277 4.0990 3.4220 2.2141 2.1177 145.7501
       
10 1 22.0920 12.8668 8.4156 4.3085 4.2487 3.3625 2.7241 1.3610 1.2644 0.6856 0.6602 0.4665 33.8621
10 2 17.5629 9.8697 5.4628 4.0396 2.8176 2.3594 1.6464 1.5618 1.0546 0.7616 0.6618 0.3366 25.8316
       
  Cummulative SC depth (µm) 
1  4.0000 5.0000 5.8750 6.6250 7.3750 8.3750 9.3750 10.1250 10.7500 11.1250 11.3750 11.6250 
2  2.7500 3.6250 4.3750 5.1250 5.7500 6.3750 7.0000 7.5000 8.0000 8.5000 9.1250 9.6250 
3  1.5000 1.7500 2.2500 2.6250 2.8750 3.2500 3.7500 4.1250 4.3750 4.6250 4.8750 5.0000 
4  2.3750 3.1250 3.8750 4.6250 5.3750 5.8750 6.2500 6.7500 7.3750 8.0000 8.5000 8.7500 
5  3.8750 5.0000 6.2500 7.0000 7.6250 8.7500 10.0000 10.6250 11.2500 11.8750 12.2500 12.6250 
6  3.8750 4.6250 5.3750 6.0000 6.6250 7.2500 7.8750 8.5000 8.8750 9.2500 9.6250 10.1250 
7  3.7500 4.8750 5.8750 6.6250 7.3750 8.2500 8.7500 9.0000 9.8750 10.6250 10.7500 11.0000 
8  3.7500 4.6250 5.1250 5.7500 6.7500 7.7500 8.8750 9.8750 10.8750 11.8750 12.8750 14.2500 
9  4.3750 5.5000 6.7500 7.8750 8.8750 9.7500 11.1250 12.3750 13.2500 14.1250 15.0000 16.1250 
10  1.5000 2.0000 2.5000 3.0000 3.8750 5.1250 6.1250 7.2500 8.2500 8.8750 9.6250 10.2500 
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HUMAN STUDY IV: CONCENTRATION-CUMULATIVE SC DEPTH PROFILES 
SUBJECTS 1-10 
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HUMAN STUDY IV: RAW DATA 
SUBJECTS 11-18 
 
Subj. Site 1 2 3 4 5 6 7 8 9 10 11 12 AUC 
11 1 62.7730 31.4381 55.8472 18.9890 6.7054 0.4217 10.7004 5.2171 3.7641 3.4089 4.4799 8.1498 103.3381
11 2 30.7047 46.9034 23.8961 15.4773 10.8756 16.5818 17.1667 6.8353 14.3680 13.2615 4.9188 10.7576 107.7423
       
12 1 131.0436 87.2089 95.3867 82.9926 48.7392 36.3891 16.9528 15.5088 9.1806 31.9967 11.1789 7.4538 367.0119
12 2 133.6703 75.6023 44.2009 56.5078 68.4375 35.1663 14.4826 8.6967 5.3538 61.0152 5.2183 4.6798 321.0700
       
13 1 67.2966 37.8960 18.6483 11.4733 8.2789 9.4231 4.4584 6.8066 5.9758 7.6001 8.4742 6.3691 80.6341
13 2 79.7733 46.1193 22.2166 19.8708 13.3266 11.3126 3.5773 4.5303 4.6273 2.8860 2.7146 2.4775 86.0027
       
14 1 24.7770 32.5169 24.0181 8.6038 7.2995 4.5179 5.0678 5.3162 2.2581 1.8154 2.4669 1.0513 57.7974
14 2 23.8071 15.2052 7.9046 5.4723 4.6951 2.8913 2.1379 2.7807 2.9257 1.4080 0.9770 1.0029 32.5623
       
15 1 111.4051 44.2826 22.8765 11.2939 5.2808 3.5288 3.5407 2.5191 3.0675 3.1025 1.4495 1.0125 79.4227
15 2 22.6535 9.9890 5.6583 5.6237 4.8352 2.5328 2.5955 1.8582 1.4093 1.4201 1.0625 1.0459 24.4455
       
16 1 65.3988 48.6410 54.0851 26.7441 38.3166 12.7369 28.2692 5.9002 6.9254 9.1722 23.1058 3.3504 153.1223
16 2 69.8760 40.3289 26.4994 12.1203 9.5975 8.2887 7.9250 4.2797 3.6014 5.2646 6.0068 6.7095 84.2191
       
17 1 32.6484 17.7581 10.7503 8.3699 7.5381 4.0714 4.7087 3.4558 3.1986 2.7664 1.4136 1.3101 47.8668
17 2 136.8702 53.8567 27.2024 14.8591 18.7783 15.7288 8.7271 3.9700 4.0382 2.9155 3.9233 3.7792 127.0460
       
18 1 69.8760 40.3289 26.4994 12.1203 9.5975 8.2887 7.9250 4.2797 3.6014 5.2646 6.0068 6.7095 84.2191
18 2 65.3988 48.6410 54.0851 26.7441 38.3166 12.7369 28.2692 5.9002 6.9254 9.1722 23.1058 3.3504 153.1223
       
       
       
       
  Cummulative SC depth (µm) 
11  2.2500 2.8750 3.5000 4.0000 5.0000 5.8750 6.2500 6.6250 7.0000 7.3750 7.7500 8.1250 
12  1.7500 2.2500 3.0000 3.7500 4.5000 5.7500 7.0000 7.7500 8.1250 8.5000 9.0000 9.6250 
13  5.1250 5.6250 6.2500 6.7500 7.1250 7.5000 7.8125 8.1250 8.6250 9.1250 9.8750 10.6250 
14  1.7500 2.3750 2.8750 3.2500 3.7500 4.2500 4.8750 5.6250 6.2500 6.7500 7.3750 8.0000 
15  2.0000 2.3750 3.1250 3.8750 4.2500 4.7500 5.1250 5.5000 6.0000 6.3750 6.8750 7.5000 
16  2.7500 3.2500 3.7500 4.2500 4.7500 5.2500 6.1250 6.8750 7.1250 7.5000 7.8750 8.5000 
17  4.0000 4.5000 5.0000 5.6250 6.2500 6.8750 7.7500 8.5000 9.2500 10.1250 10.6250 11.0000 
18  2.7500 3.2500 3.7500 4.2500 4.7500 5.2500 6.1250 6.8750 7.1250 7.5000 7.8750 8.5000 
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HUMAN STUDY IV: CONCENTRATION-CUMULATIVE SC DEPTH PROFILES 
SUBJECTS 11-18 
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